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ABSTRACT 
Promoter hypermethylation mediated gene silencing is a frequent epigenetic 
finding in many cancers that affects genes known to have important roles in several 
aspects of cell biology.  Hematological malignancies have been reported to harbor 
multiple genes aberrantly silenced by promoter hypermethylation and as a result, 
cytosine analogs known to inhibit the DNA methylation machinery are currently 
being evaluated in clinical trials.  As such, the general goal of this thesis was to 
identify genes silenced by promoter hypermethylation in human acute myeloid 
leukemia (AML) and to study the mechanism of promoter hypermethylation 
mediated gene silencing.  Interestingly, the cyclin dependent kinase inhibitor p15 
was found to be methylated at a high frequency in AML patients and cell lines in 
association with a lack of detectable p15 mRNA.  Treatment with the cytosine 
analog 5-Aza-2’-deoxycytidine (5-Aza-dC) in vitro resulted in promoter 
demethylation and p15 mRNA re-expression, which was associated with a release 
of a transcriptionally repressive complex at the p15 promoter.  Importantly, 5-Aza-
dC treatment also reversed specific histone amino-terminal modifications at the p15 
promoter which are normally associated with transcriptionally inactive chromatin 
regions, implicating chromatin remodeling in promoter hypermethylation mediated 
gene silencing.  The recently discovered DNA methylation inhibitor, zebularine – 
considered more stable than 5-Aza-dC – was also able to reconstitute p15 mRNA in 
vitro in association with promoter demethylation, regional enrichment of histone 
acetylation, and growth inhibition.   
To identify novel genes silenced by promoter hypermethylation in AML, 
cDNA microarray analysis was employed following in vitro pharmacological 
inhibition of DNA methylation and histone deacetylation.  Of note, four genes from 
the metallothionein family of cysteine rich small molecules were consistently 
upregulated following drug treatment and further evaluation identified the gene 
MT1H to be hypermethylated at a high frequency in AML patients and cell lines.  
Taken together, the data suggests that aberrant promoter hypermethylation 
mediated gene silencing occurs in multiple genes from different gene families 
during the molecular pathogenesis of human AML.  Furthermore, the mechanism 
of promoter methylation mediated transcriptional silencing acts in concert with 
specific histone modifications which, importantly, can be reversed by treatment 
with pharmacological inhibitors of DNA methylation.  
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1. REVIEW OF THE LITERATURE 
 
1.1. INTRODUCTION 
Cancer has been historically considered a genetic disease and human 
leukemia, which is primarily associated with hallmark chromosomal translocations, 
is no exception.  However, although much is known about many of the underlying 
genetic abnormalities in cancer, aside from the discovery of imatinib mesylate for 
the treatment of chronic myeloid leukemia (CML), little progress has been made in 
exploiting cancer genetics for clinical gain.    
The field of molecular biology known as ‘epigenetics’ involves the study of 
heritable changes in gene expression that occur without any alteration in DNA 
sequence and, importantly, deregulation of this process has been implicated in 
many diseases and inherited syndromes, including cancer.  The recent expansion of 
knowledge regarding cancer epigenetics has influenced the cancer research 
community twofold: 1) it has modified the previous cancer paradigm, whereby 
cancer is now viewed as a genetic and epigenetic disease (Feinberg, 2001), and 2) it 
has exposed a new direction for experimental therapy (Egger et al., 2004).  
The general goal of this thesis is to investigate the presence of aberrant 
epigenetics in human acute myeloid leukemia (AML) and to study the mechanisms 
that are involved in epigenetic gene silencing.  As such, the following review of the 
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literature aims to familiarize the reader with AML, the molecular basis of human 
cancer, and the general concepts of epigenetics.  Emphasis will be placed on cell 
cycle regulation and its role in cancer, DNA methylation mediated transcriptional 
silencing, and the exciting prospect of pharmacologic inhibition of aberrant 
epigenetic gene silencing. 
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1.2. ACUTE MYELOID LEUKEMIA 
 
1.2.1. Epidemiology and Etiology 
AML is a malignant neoplasm of hematopoietic stem cells originating in 
and infiltrating the bone marrow.  The clonal accumulation of leukocyte precursors 
known as leukemic blasts that are characteristic of AML often results in 
pancytopenia.  In most cases the disease involves the peripheral blood but it can 
involve any organ including the spleen, liver, and lymph nodes.  The disease 
primarily occurs in adults, shows an equal frequency in males and females, and like 
many cancers, the incidence rises steeply with increasing age (Alderson, 1980; 
Clark and Macmahon, 1956).  The median age of AML diagnosis is 64 years and it 
is the most common adult leukemia, accounting for roughly half of all leukemias 
(Alderson, 1980; Appelbaum et al., 2001). 
The etiology of leukemia is unknown; however, environmental factors such 
as ionizing radiation and chemical exposure have been associated with the disease.  
Hereditary factors are implicated in leukemia etiology as evidenced by a tendency 
for the disease to cluster within some families and an association with 
constitutional chromosomal abnormalities (Zuelzer and Cox, 1969).  Furthermore, 
clinical observations have identified unusual AML susceptibility in monozygotic 
twins and in children with certain genetic diseases and congenital disorders 
(Fraumeni and Miller, 1967; Jackson et al., 1969), most notably Down syndrome 
(Rosner and Lee, 1972).  However, like other leukemias and solid tumor 
malignancies, the etiology of AML likely involves an intricate combination of 
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hereditary and genetic factors as well as environmental exposures.  Given that the 
precise mechanism by which these potential etiologic factors produce leukemia are 
as yet unknown, the bulk of knowledge regarding AML etiology remains indirect.  
To this end, a great deal of effort and research is continually expended with the 
goal of identifying causative factors of leukemia. 
 
1.2.2. Acute Leukemia Classification 
 The diagnosis of AML entails a stepwise approach that requires 
differentiating it from reactive disorders and other neoplastic diseases, such as 
acute lymphoblastic leukemia (ALL), and then classifying the disease into 
subcategories that define treatment and prognostic groups.  Morphologic 
assessment of blood and bone marrow smears and marrow biopsy sections 
accompanied by cytochemical stains such as myeloperoxidase and non-specific 
esterase can often accurately discriminate between AML and ALL (McKenna, 
2000).  However, leukemias that are poorly differentiated or whose lineage cannot 
be discerned using standard morphologic and cytochemical techniques require 
immunophenotyping to assist in their diagnosis and accurate classification (Griffin 
et al., 1983).  To this end, the lineage of hematopoietic cells is defined both by 
antigen expression and the absence of antigen expression associated with a unique 
lineage.  In AML, immunophenotyping is most important in distinguishing poorly 
differentiated cases from ALL and in characterizing AML subsets (McKenna, 
2000).    
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 Clonal cytogenetic abnormalities are identified in 60 - 80% of AMLs 
(Mrozek et al., 1997), and can frequently be of clinical value.  This is particularly 
true of cases with the t(15;17) translocation that is consistently associated with 
acute promyelocytic leukemia (APL) and often has distinct clinical and 
morphologic features (Bitter et al., 1987).  The reciprocal translocation involves the 
PML gene on chromosome 15 and the retinoic acid receptor-alpha (RARα) gene on 
chromosome 17 (Grimwade, 1999), and the resulting fusion mRNA product 
inhibits maturation of the affected cells leading to a proliferation of atypical 
promyelocytes.  In most cases of APL, treatment with all-trans-retinoic acid 
(ATRA) overcomes the maturation block and induces a temporary complete 
remission of the disease (Degos et al., 1995).  However, standard chemotherapy 
administered after or with ATRA is often required to sustain remission. 
 Although immunophenotyping, cytogenetics, and molecular analysis are 
important in the diagnosis of acute leukemia, the widely used classification scheme 
proposed by the French-American-British (FAB) Cooperative Group primarily 
utilizes morphologic assessment to classify acute leukemias (Bennett et al., 1976; 
Bennett et al., 1985a; Bennett et al., 1985b; Bennett et al., 1991).  The FAB 
classification of AML is a lineage-based morphologic classification that categorizes 
cases according to the degree of maturation of the leukemic cells and their lineage 
differentiation (Table 1.1).  Although the system is widely accepted internationally, 
an exclusively cytogenetic/molecular analysis-based classification of acute 
leukemias, believed to better define biologic and prognostic groupings, is currently 
being evaluated (Harris et al., 2000; Vardiman et al., 2002).   
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Table 1.1 FAB Classification and Incidence of AML 
AML Classification Incidencea
Myeloblastic leukemia minimally differentiated M0 <10% 
Myeloblastic leukemia without maturation M1 20% 
Myeloblastic leukemia with maturation M2 30% 
Hypergranular promyelocytic leukemia M3 10% 
Myelomonocytic leukemia M4 25% 
Myelomonocytic leukemia with eosinophilia M4Eo <5% 
Monocytic leukemia – poorly differentiated M5A <10% 
Monocytic leukemia – differentiated M5B ≤5% 
Erythroleukemia M6 ≤5% 
Megakaryoblastic leukemia M7 ≤5% 
 
a Based on Tuzuner and Bennett, 1995. 
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1.2.3. Pathology  
As mentioned, AML is diagnosed primarily in adults, although it can occur 
at any age.  An elevated white blood cell (WBC) count is found in approximately 
one-third of patients with AML at diagnosis, and an equal number of patients have 
a normal WBC count or leukopenia.  Blasts are only present in the peripheral blood 
of 85% of patients with AML.  Thrombocytopenia and a reduced absolute 
neutrophil count are observed in almost all AML patients at diagnosis.  The 
majority of patients present with a hypercellular bone marrow due to the 
proliferation of malignant blasts or promyelocytes.  According to the original FAB 
classification scheme, a diagnosis of acute leukemia is made when immature blasts 
count for at least 30% of all nucleated marrow elements.  The more recent World 
Health Organization (WHO) Classification system requires that blasts account for 
greater than 20% of all nucleated marrow elements to render a diagnosis of acute 
leukemia (Jaffe et al., 2001).  A marrow containing increased blasts, but accounting 
for less than 30% of all nucleated marrow elements (or less than 20% in the WHO 
Classification), usually indicates the presence of a myelodysplastic syndrome 
(MDS), a diverse group of related disorders characterized by clonal stem cell 
proliferation, ineffective hematopoiesis, and increased risk to evolve into AML.  
 
1.2.4. The Molecular Basis of AML  
1.2.4.1. Impairment of Differentiation 
Cloning of translocation breakpoints associated with human leukemias has 
provided important insights into disease pathogenesis as well as targeted 
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therapeutics.  For example, CML is caused by constitutively activated tyrosine 
kinases, such as BCR/ABL, that confer a proliferative and survival advantage to 
hematopoietic progenitors with minimal effects on differentiation.  In contrast, the 
chromosomal translocations commonly associated with AML frequently result in 
loss-of-function of transcription factors that are required for differentiation and 
normal hematopoietic development (Tenen, 2003).  Hematopoietic development, or 
hematopoiesis, takes place in the bone marrow and refers to the production of all 
functioning blood cell types from a pool of pluripotent self-renewing stem cells 
(Figure 1.1).  Some examples of transcription factors involved in hematopoiesis 
that are often translocated in AML include core binding factor (CBF), the 
aforementioned RARα, and members of the HOX family of transcription factors 
(Kelly and Gilliland, 2002).   
CBF is a heterodimeric transcription factor composed of a DNA binding 
component AML1, and CBFβ, a subunit that increases AML1 transcriptional 
activity without contacting DNA (Coustry et al., 1995).  The CBF heterodimer 
induces expression of a broad spectrum of genes that are critical for hematopoietic 
development (Speck et al., 1999), as mice deficient in either AML1 or CBFβ are 
incapable of normal hematopoiesis (Castilla et al., 1996; Okuda et al., 1996).  
Common translocations that involve CBF are the t(8;21), inv(16), and t(12;21) that 
result in aberrant expression of the AML1/ETO (Erickson et al., 1992), 
CBFβ/SMMHC (Liu et al., 1993), and TEL/AML1 (Golub et al., 1995) fusion 
proteins, respectively.  In most cases, expression of the fusion gene dominantly 
interferes with the function of the residual normal allele, resulting in complete CBF 
 9
 
  
 
 
    
 
   
  
 
Figure 1.1 Mammalian Hematopoiesis.  Illustrated are the various differentiation pathways 
of the major types of blood cells.  Normal hematopoiesis involves the formation of all blood 
cells originating from a common pluripotent stem cell.   
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loss-of-function.  Interestingly, transcriptional repression of CBF target genes by 
CBF-related fusion proteins, as well as the aforementioned t(15;17) PML/RARα 
fusion protein, is frequently mediated in part through abnormal recruitment of a 
nuclear corepressor complex harboring histone deacetylase (HDAC) activity 
(Gelmetti et al., 1998; Grignani et al., 1998; Wang and Hiebert, 2001).  The 
concept of histone modification and subsequent chromatin remodeling mediated 
transcriptional repression is of key interest to the work defined within this thesis 
and will be expanded upon in subsequent sections.  
Although not nearly as prevalent as chromosomal translocations, loss-of-
function point mutations in hematopoietic transcription factors also play a role in 
AML pathogenesis.  For example, evidence for mutation of AML1 resulting in both 
dominant negative activity (Michaud et al., 2002) and haploinsufficiency (Song et 
al., 1999) exists in association with familial platelet disorder, a disease similar to 
MDS that often develops into AML.  In contrast, mutations in CBFβ have not been 
found in patients with AML (Leroy et al., 2002), although, as mentioned, the gene 
is disrupted by inv(16) in some leukemias (Liu et al., 1993).  Other loss-of-function 
mutations associated with AML include the hematopoietic transcription factor 
CCAAT/enhancer binding protein-alpha (C/EBPα) (Pabst et al., 2001).  In some 
AML patients, point mutations result in a dominant negative C/EBPα allele that is 
believed to impair normal hematopoiesis, specifically granulocyte differentiation. 
Although the hypothesis that inactivating gene rearrangements and 
transcription factor mutations are causative for AML is attractive, murine models 
with similar genotypes fail to fully develop comparable leukemic phenotypes 
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(Higuchi et al., 2002).  This suggests that the aforementioned abnormalities alone 
are insufficient to cause AML.  In many of the mouse models there is a long 
latency of disease, incomplete penetrance, and an acquisition of karyotypic 
irregularities during progression to AML (Grisolano et al., 1997; Pollock et al., 
2001), all indicative of a requirement for secondary genetic and/or epigenetic 
abnormalities.  
 
1.2.4.2. Activation of Proliferation 
Most acute leukemias appear to result from collaboration between 
abnormalities associated with the impairment of differentiation, and a second class 
of mutations that confer a proliferative and/or survival advantage to hematopoietic 
progenitor cells.  An example of activating mutations in AML and MDS that confer 
proliferative advantage are the mutations found in codons 12, 13 and 61 of N-RAS, 
and codons 12 and 13 of K-RAS (Nakagawa et al., 1992).  Given their incidence in 
preleukemic conditions such as MDS, it is possible that these mutations play a role 
in the early phases of carcinogenesis.  However, the reported incidence of these 
mutations (25 - 44%) varies greatly between studies (Beaupre and Kurzrock, 1999) 
and the prognostic value data is conflicting (Neubauer et al., 1994; Ritter et al., 
2004).  Despite the inconsistent clinical data on RAS mutations, a considerable 
effort has been devoted to the development of small molecule inhibitors of RAS 
activation, with a focus on farnesyl transferase and geranylgeranyl transferase 
(prenyl transferase) inhibitors that prevent targeting of activated RAS to the plasma 
membrane (Karp, 2001; Sebti and Hamilton, 1997).   
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Another genetic abnormality associated with leukemic transformation and 
proliferation is the internal tandem duplication (ITD) of the juxtamembrane domain 
of the FLT3 gene (Nakao et al., 1996).  The ITD is generally monallelic, resulting 
in a heterozygous increase in FLT3 message length, and is specific for AML and 
MDS, not being detected in a spectrum of other hematological malignancies and 
normal hematopoietic cells (Ishii et al., 1999; Yokota et al., 1997).  The overall 
frequency of FLT3-ITD in AML is approximately 24% (Kelly and Gilliland, 2002), 
occurring in all FAB subtypes, with an incidence that increases with age (Stirewalt 
et al., 2001).  Additionally, mutations in the activation-loop domain of FLT3 have 
been reported in a small percentage of AML patients with D825Y being the most 
common amino acid substitution (Yamamoto et al., 2001), making FLT3 the single 
most commonly mutated gene in AML. 
Wild-type FLT3 is a membrane-bound receptor tyrosine kinase and 
mutations in the juxtamembrane and activation-loop domains are predicted to 
abolish autoinhibitory activity, resulting in constitutive activation of the FLT3 
kinase.  ITD mutations of FLT3 result in ligand independent dimerization and 
tyrosine autophosphorylation (Kiyoi et al., 1998) as well as activation of multiple 
pathways including STAT5, RAS/MAPK, and PI3K (Hayakawa et al., 2000; 
Mizuki et al., 2000).  Not surprisingly, the recognition of FLT3 mutations has led 
to the development of several small molecule FLT3 tyrosine kinase inhibitors 
(Levis and Small, 2004), and although in vivo inhibition of FLT3 phosphorylation 
has been observed (O'Farrell et al., 2003), clinical utility is still under evaluation 
(Smith et al., 2004).   
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AML is an aggressive, heterogeneous disease with various cytogenetic 
abnormalities.  As such, the response rates and efficacy of novel FLT3 inhibitors in 
the treatment of AML patients will most likely not reach those of imatinib mesylate 
treatment of CML, as the latter disease is uniformly associated with the presence of 
the BCR/ABL producing t(9;22) translocation.  Moreover, in contrast to 
BCR/ABL, expression of the FLT3-ITD in primary murine hematopoietic 
progenitors is not sufficient to cause AML (Kelly et al., 2002a), again suggesting 
that secondary mutations are required for AML development.  This hypothesis is 
supported by the fact that FLT3-ITDs occur concurrently with other previously 
discussed gene rearrangements and point mutations, which, as mentioned, alone are 
also insufficient to cause AML.  Thus, it is attractive to envision the AML 
phenotype as a disease that requires collaboration between genetic abnormalities in 
proliferation and hematopoietic differentiation pathways.  This model is likely 
oversimplified as additional mutations, and epigenetic abnormalities, may play an 
important role in disease pathogenesis.   
Although there are more target genes to be identified, those currently under 
investigation have provided great insight into the molecular basis of leukemia.  
Like other cancers, the elucidation of the molecular pathogenesis of AML will 
undoubtedly improve the design of molecularly targeted therapies for patients with 
well defined subtypes of disease.  Genes involved in important aspects of cell 
biology that are often targets of deregulation in other cancers will be expanded 
upon in the following section. 
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1.3 THE MOLECULAR BASIS OF CANCER 
A vast body of research has uncovered many molecular irregularities 
associated with cancer and as a result, a clear model now exists of how two sets of 
genes, oncogenes and tumor suppressor genes, participate in cellular 
transformation.  These types of genes have proven to play specific roles in all steps 
of carcinogenesis and have afforded a foundation for diagnostic and therapeutic 
development (Weinberg, 1994).    
 
1.3.1. Oncogenes 
The first oncogene, a gene that has the potential to cause a normal cell to 
become cancerous, was identified in 1976 through pioneering work on the Rous 
sarcoma virus (Stehelin et al., 1976).  This gene, identified as SRC, is a proto-
oncogene in the human genome whereby retroviral transduction or other in situ 
influence is required to convert it to an oncogene with transforming activity.  
Examples of in situ influence on a proto-oncogene can be categorized into two 
types of molecular irregularities, changes in the structure of a gene that results in 
the synthesis of an abnormal oncoprotein, and changes in the expression of a gene 
that results in the inappropriate production of the normal growth-promoting protein. 
 A proto-oncogene structure altering mechanism commonly associated with 
cancer is the introduction of a point mutation that alters the amino acid sequence of 
the resulting protein.  One of the most documented mutational activations 
associated with a spectrum of human tumors are point mutations within the 
aforementioned RAS proto-oncogene family (Rodenhuis, 1992).  For example, 
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nearly half of all colon cancers harbor an activating mutation in the K-RAS proto-
oncogene, which gives the K-RAS protein potent transforming ability (Bos et al., 
1987; Kinzler and Vogelstein, 1996).   
Another molecular event that can result in the activation of a proto-
oncogene is the chromosomal translocation.  As stated earlier, a classic example of 
a translocation resulting in the formation of a novel oncoprotein is the Philadelphia 
chromosome, characteristic of CML, which involves the reciprocal genetic 
exchange between chromosomes 9 and 22 (de Klein et al., 1982; Rowley, 1973).  
The resulting chimeric protein, BCR/ABL, has potent tyrosine kinase activity and 
is an effective therapeutic target in myeloid leukemias (Druker, 2004). 
 Translocation induced overexpression of a proto-oncogene is also 
demonstrated in Burkitt’s lymphoma, where the gene c-MYC, located at 8q24, is 
juxtaposed to 14q32.  This translocation places c-MYC very close to the enhancer 
elements of the immunoglobulin heavy chain gene, a region with exceptionally 
high transcriptional activity, and ultimately drives the irregular production of the c-
MYC protein product (Gauwerky and Croce, 1993).  Interestingly, another member 
of the MYC family, N-MYC, is an example of increased proto-oncogene 
expression through a separate mechanism known as gene amplification (Schwab, 
1993).  This process results from reduplication and amplification of a gene’s DNA 
sequence that can be detected cytogenetically or by fluorescence in situ 
hybridization.  In the case of neuroblastoma, an amplified N-MYC gene results in 
elevated expression of both N-MYC mRNA and protein and is significantly 
associated with poor prognosis (Schwab, 1993). 
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 However, these types of in situ influences on genes throughout the human 
genome do not always result in the formation of an oncogene.  Ultimately, the 
genetic insults within a cancer cell will often affect a gene whose function is not 
amenable to assisting cellular transformation and as a result, a formal operational 
definition of an oncogene was established (Bishop, 1985).  If a candidate gene 
causes the cell to adopt the attributes of a cancer cell (cellular transformation) upon 
introduction into a normal cell, then the introduced gene can be considered a true 
oncogene.  Functionally, many such oncogene proteins induce cellular 
transformation by activating growth promoting signaling pathways within the cell 
in the absence of normal exogenous growth factor stimulation. 
 
1.3.2. Tumor Suppressor Genes 
Equally as important as the growth promoting oncogene is the recognition 
of the growth suppressive, or tumor suppressor gene.  The protein products of 
tumor suppressor genes inhibit the proliferation of a cell and are therefore very 
important to neoplastic transformation.  The retinoblastoma (RB) gene, named after 
the rare childhood eye tumor in which it was discovered, provides a model for 
many of these genes (Hollingsworth et al., 1993).  Like almost all genes, it is 
present in two copies per cell.  When one of these copies becomes inactivated, cell 
growth is still normal, in part by relying on the remaining gene copy.  Yet, when 
the second copy is also lost, the growth constraint redundancy is lost and 
unregulated cellular proliferation proceeds.  Importantly, inactivated versions of the 
RB gene can be passed through the germline from parent to offspring, leaving the 
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child with a higher probability of accidental loss of the functional RB copy.  This 
concept forms the foundation for the ‘two hit’ hypothesis postulated by Alfred 
Knudson in 1971 (Knudson, 1971).  As such, through Mendelian laws of 
inheritance, when particular genetic changes involved in the initiation or 
progression of a tumor occur in the germ line, all somatic cells of the individual 
whom inherits this particular change will already carry one of the steps required for 
malignant change.  This results in an increased chance for tumor development and 
an inherited susceptibility to that particular cancer. 
 Yet, this dogma is incomplete as tumor suppressor gene function can also 
be lost by a mechanism distinct from that described for the RB gene.  In the case of 
the p53 tumor suppressor gene, which is mutated in over half of all human cancers 
(Szymanska and Hainaut, 2003), the initially mutated gene copy loses its growth 
suppressive function and simultaneously acquires the ability to interfere with the 
function of the remaining intact copy.  This is considered a dominant negative 
mode of action as the mutant p53 protein compromises the ongoing function of its 
normal counterpart in the same cell (Blagosklonny, 2000). 
 With respect to the functional mechanism employed by tumor suppressor 
genes, the signals and signal transducing pathways are less understood than for 
those involved in growth promotion.  However, analogous to an oncogenes 
involvement in a growth promoting pathway, tumor suppressor gene proteins are 
often involved in the receiving or processing of growth inhibitory signals.  As such, 
having lost a tumor suppressor gene and its encoded protein, a cell may then lose 
its ability to respond to external growth antagonizing signals, such as those 
 18
conveyed by the naturally occurring growth suppressive transforming growth 
factor-β1 (TGF-β1) (Massague, 1990).  When certain cells lose RB function, they 
lose responsiveness to TGF-β1 and continue to grow even when the growth factor 
is present at relatively high concentrations (Pietenpol et al., 1990), functionally 
implicating RB in the TGF-β1 pathway.  Downstream mediators of the TGF-β1 
pathway will be discussed in a subsequent section regarding cell cycle regulation. 
 
1.3.3. Apoptosis Regulation 
Cellular transformation may result from activation of oncogenes or 
inactivation of tumor suppressor genes that are involved in the regulation of 
apoptosis, or programmed cell death.  Dysregulation of apoptosis has been 
implicated in numerous other pathological conditions, including neurodegenerative 
diseases and autoimmunity, and in the resistance to cancer therapy (Yu and Zhang, 
2004).  Studies have revealed that the apoptotic machinery in humans consists of a 
molecular network of proteins that regulate a cascade of events throughout all the 
various stages of apoptosis.  As such, apoptotic defects can therefore allow 
neoplastic cells to live beyond their normal lifespan, accumulate genetic mutations, 
sustain growth under hypoxic conditions, and promote tumor angiogenesis 
(Hanahan and Weinberg, 2000).   
 The variety of apoptotic stimuli affecting a cell often signal through the 
many members of the BCL-2 family of proteins found within the core apoptotic 
machinery (Yu and Zhang, 2004).  Deregulation of this process is observed in 
follicular B-cell lymphoma where overexpression of the anti-apoptotic BCL-2 
 19
occurs at a high frequency due to the gene, located at 18q21, being translocated to 
the immunoglobulin heavy chain gene on chromosome 14 (Bagg and Cossman, 
1992).  This process is analogous to the previously mentioned t(8;14) translocation 
activating the c-MYC oncogene in Burkitt’s lymphoma.  Conversely, related genes, 
such as BAX and BAK antagonize the anti-apoptotic BCL-2 and BCL-XL proteins, 
and therefore act by initiating or accelerating cell death (Letai et al., 2002).  
Ultimately, the decision to undergo programmed cell death appears to be based on 
the relative amounts of pro-apoptotic and anti-apoptotic signals within a given cell, 
and therefore any gene activating or inactivating irregularity within either pathway 
will significantly affect the lifespan of that cell. 
 
1.3.4. DNA Repair Regulation 
The primary function of the mismatch repair (MMR) system is to eliminate 
spontaneous single-base mismatches and insertion-deletion loops that arise during 
DNA replication.  These types of errors, if not repaired promptly, can contribute to 
neoplastic transformation and are therefore vigorously addressed by a family of at 
least six different eukaryotic MMR proteins (Jiricny and Nystrom-Lahti, 2000).  
Owing to their importance in maintaining genomic stability, germline alterations in 
any one of the five human MMR genes, MSH2, MLH1, MSH6, PMS2 and PMS1, 
gives rise to hereditary nonpolyposis colon cancer (HNPCC) that accounts for 1-
5% of all colon cancer cases (Peltomaki, 2001).  Predisposed individuals from 
HNPCC families have a high lifetime risk of developing a range of carcinomas, 
collectively referred to as the HNPCC tumor spectrum (Aarnio et al., 1999). 
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 Tumors from HNPCC patients often show acquired variation in the number 
of short repeat units contained within microsatellite sequences, deemed 
microsatellite instability (MSI), and is the result of a failure to correct repeat errors 
following DNA replication.  Not surprisingly, the mutation rates in tumor cells with 
MMR deficiency are 100 - 1000 fold greater as compared to normal cells 
(Bhattacharyya et al., 1994), and can affect important growth regulatory genes 
including the coding region containing repeats of the TGF-β1 receptor type-II 
(TGFβRII) gene and the previously mentioned pro-apoptotic BAX gene (Samowitz 
et al., 2002).  Thus, cells lacking a functional MMR system are associated with 
decreased genomic stability, and if the mutational activity occurs in critical genes 
involved in growth suppression, apoptosis or signal transduction, a growth 
advantage may be acquired.   
 
1.3.5. Cell Cycle Regulation 
Passage through the eukaryotic cell cycle requires a replication of the 
genome, doubling of cell mass, a precise segregation of chromosomes and a 
distribution of other cell components to the daughter cells (Prescott, 1976).  The 
execution of these events divides the cycle into four phases: chromosomes are 
replicated during the S (synthetic) phase; cellular constituents are divided into 
daughter cells during the M (mitotic) phase; and two G (gap) phases, G1 and G2, 
intervene between S and M (Fig. 1.2).  In addition, cells can also exit the cell cycle 
by becoming latent, or quiescent, a period known as G0.  Cell growth occurs 
continuously in G1, S, G2, and M; however it is during G1 and G2 that cells  
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Figure 1.2 Regulation of the Eukaryotic Cell Cycle.  Illustrated is the life cycle of a 
eukaryotic cell that highlights some of the major regulatory features.  Progression through the 
cycle is marked by oscillating levels of a family of proteins known as cyclins, which are 
regulated, in part, by CDKs.  G1 cyclin-CDK complexes are inhibited by two families of listed 
CDKIs, altogether regulating the phosphorylation status of the RB protein.  Unphosphorylated 
RB binds the E2F transcription factor family and inhibits the transcription of E2F target genes 
by targeting histone deacetylase activity (Luo et al., 1998), yet when phosphorylated, releases 
E2F and allows the transcription of multiple E2F target genes.  E2F target genes are essential 
for S phase DNA replication and the G1/S checkpoint is commonly deregulated in cancer.   
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typically respond to proliferative and antiproliferative signals that determine if the 
cell cycle ought to proceed.  Importantly, the cell cycle has the option of stopping 
within G1 and G2 without interrupting the critical and precarious events of 
chromosome replication and chromosome segregation. 
Much of what is known about the regulated transition of cells through the 
cell cycle has come from genetic and biochemical studies carried out in lower 
organisms.  One of the first genes to be recognized as being an important regulator 
of the cell cycle in yeast was cdc2/cdc28 and, importantly, a regulatory subunit 
referred to as a ‘cyclin’ was also identified which is required for cdc2/cdc28 kinase 
activation (Hartwell, 1978).  Cyclins were first identified in marine invertebrates as 
proteins whose accumulation and degradation oscillated during the cell cycle 
(Rosenthal et al., 1980).  It is the sequential activation and inactivation of cyclin-
dependent kinases (CDKs), through the periodic synthesis and destruction of the 
cyclins, which provide the primary means of cell cycle regulation (Johnson and 
Walker, 1999).  Cyclin expression is rate-limiting for CDK activation, and control 
of cyclin expression is a fundamental mechanism underlying CDK periodicity.  In 
general, cyclin levels are determined by both transcriptional control and regulated 
proteolysis by the ubiquitin-proteasome system (Johnson and Walker, 1999).  
 The primary mammalian cyclins in G1 are the D- and E-type, which 
associate with the CDK4/6 and CDK2 subunits, respectively.  Of note, inhibition of 
cyclin D1 function blocks the cell cycle in G1, demonstrating the necessity of 
cyclin D for the cell cycle (Baldin et al., 1993).  Progression through the eukaryotic 
cell cycle, however, is promoted by CDK mediated phosphorylation of protein 
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substrates, most notably RB (Weinberg, 1995).  The RB protein is crucial for 
control of the G1/S checkpoint within the cell cycle and, as mentioned, the RB 
gene is frequently inactivated in cancer cells.  Normal passage through G1/S of the 
cell cycle occurs when the RB protein undergoes cell cycle-dependent 
phosphorylation during G1, disrupting its interaction with the essential E2F family 
of transcription factors (Buchkovich et al., 1989).  E2F factors regulate the 
expression of many genes that encode proteins involved in cell cycle progression 
and DNA synthesis but when complexed with an unphosphorylated RB, E2F is 
inactive and the cell cycle arrests in the absence of these much needed gene 
products.  However, as cycling cells progress through G1, RB is progressively 
phosphorylated by CDKs at multiple sites, ultimately releasing E2F and allowing 
transcription of essential S phase genes.  
 
1.3.6. Cyclin Dependent Kinase Inhibitors 
All organisms express proteins that directly bind to and inhibit CDK 
activity (Sherr and Roberts, 1995) (Fig. 1.2).  These cyclin dependent kinase 
inhibitors (CDKIs) provide another important mechanism by which CDK activity is 
regulated in response to diverse stimuli.  Mammalian cells express two classes of 
CDKIs that are distinguished by their CDK targets: the CIP/KIP family of CDKIs, 
which are universal CDK inhibitors, and the INK4 CDKIs, which are specific for 
CDK4/6 inhibition (Sherr and Roberts, 1995).   
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1.3.6.1. The CIP/KIP CDKI Family 
The CIP/KIP family of CDKIs consists of three members: p21CIP1/WAF1 
(p21), p27KIP1 (p27), and p57KIP2 (p57).  Overexpression of these molecules 
causes a G1 arrest in cultured cells and they are able to inhibit most cyclin-CDK 
complexes in proliferating cells in vitro (Sherr and Roberts, 1995).  The first of this 
family to be isolated was p21 which was identified by several independent 
laboratories employing a variety of strategies (el-Deiry et al., 1993; Harper et al., 
1993; Xiong et al., 1993).  As illustrated in Figure 1.3, the p21 protein contains two 
functional domains, an amino-terminal CDK interaction region that is sufficient for 
CDK inhibition, and a carboxy-terminal region that binds proliferating cell nuclear 
antigen (PCNA), a processivity factor associated with DNA polymerase-δ (Waga et 
al., 1994).  Thus, induction of p21, which can occur in response to DNA damage 
through a p53-dependent mechanism (el-Deiry et al., 1993), contributes to cell 
cycle arrest in two ways: by inhibiting cyclin-CDK complexes, and by inhibiting 
DNA synthesis through PCNA binding. 
 The CDKIs p27 and p57 are structurally related to p21 as they share 
significant amino-terminal homology within the CDK inhibitory domain, but p27 
and p57 do not contain the PCNA interaction region (Lee et al., 1995; Polyak et al., 
1994) (Fig. 1.3).  Both p27 and p57 bind to a variety of cyclin-CDK complexes, yet 
only p27 has been implicated in modulation of contact inhibition (Polyak et al., 
1994).  Furthermore, like p21, p27 also mediates several growth inhibitory signals 
including the aforementioned growth factor TGF-β1 (Robson et al., 1999).  In 
contrast to the ubiquitous expression of p21 and p27, p57 displays a tissue-specific  
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Figure 1.3 CIP/KIP CDKI Proteins.  Illustrated are the amino acid alignments of CDKIs 
p21, p27, and p57 revealing the common cyclin and CDK binding domains (represented by 
black bars above sequence).  The carboxy-terminal PCNA interaction region of p21 is not 
shown and numbers represent amino acid position.  Alignments were generated using the 
‘ClustalW’ amino acid sequence alignment algorithm and the ‘prettyplot’ diagram tool 
available from the European Molecular Biology Open Software Suite (EMBOSS).   
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expression pattern suggesting a specialized role in cell cycle control.  A role for 
p57 in carcinogenesis is evidenced by the fact that the p57 gene locus is subject to 
imprinting, with preferential expression of the maternal allele that is associated 
with various cancers (Kondo et al., 1996).  Taken together, as essential inhibitory 
mediators of the G1/S cell cycle checkpoint, and therefore cellular proliferation, all 
three members of the CIP/KIP family of CDKIs are associated with cellular 
transformation by unique mechanisms  (Lee and Yang, 2001).   
 
1.3.6.2. The INK4 CDKI Family 
The second family of CDKIs is the INK4 family, consisting of p16INK4a 
(p16), p15INK4b (p15), p18INK4c (p18), and p19INK4d (p19).  The majority of 
the INK4 proteins, when bound to CDKs, prevents the association of CDK4 and 
CDK6 with the D-type cyclins and can also inhibit the activity of preassembled 
cyclin D-CDK4/6 complexes.  This activity is accomplished through homologous 
tandem ankyrin repeats (Sherr and Roberts, 1995), which are motifs of about 34 
amino acids and are often involved in protein-protein interaction (Bork, 1993). As 
illustrated in Figure 1.4, p16 and p15 contain four ankyrin repeats (ankyrin I-IV), 
while p18 and p19 contain five (ankyrin I-V). 
Like RB, the p16 gene is altered in a high percentage of human tumors by a 
variety of mechanisms including deletion, point mutation, and promoter 
hypermethylation, an epigenetic mechanism (Kamb et al., 1994; Okamoto et al., 
1994).  Interestingly, analysis of p16 is complicated in the fact that its 9p21 locus 
encodes a second protein in an overlapping alternative reading frame (ARF) 
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Figure 1.4 INK4 CDKI Proteins.  Illustrated are the amino acid alignments of CDKIs p16, 
p15, p18, and p19 revealing the common ankyrin repeat protein binding domains (represented 
by black bars above sequence).  Numbers represent amino acid position.  Alignments were 
generated using the ‘ClustalW’ amino acid sequence alignment algorithm and the ‘prettyplot’ 
diagram tool available from EMBOSS.   
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(Quelle et al., 1995) (Fig. 1.5).  This non-INK4 family alternative reading frame 
protein (p14ARF) has been shown to assist in the regulation of p53 stability by 
counteracting the MDM2-mediated destruction of p53 (Bothner et al., 2001; Zhang 
et al., 1998).  Furthermore, in many tumors and cell lines with p16 deletion, the 
related and closely linked p15 gene is also affected (Sherr, 1996).  However, unlike 
p16, p15 is unaffected by RB status but can, like p21 and p27, be induced by TGF-
β1 (Hannon and Beach, 1994).  The frequent deletions of p15 and p16 in primary 
tumors and the high spontaneous tumor rate in p16-deficient mice indicate that 
these proteins play a critical role in maintaining normal growth control (Serrano et 
al., 1996).   
Of note, the INK4 family member p18, located at 1p32, which has largely 
been considered to be unaffected in human tumors (Otsuki et al., 1996), has 
recently been shown to be silenced by promoter hypermethylation in Hodgkin 
lymphomas (Sanchez-Aguilera et al., 2004).  Similarly, the INK4 family member 
p19, located at 19p13, has recently been associated with aberrant epigenetic 
transcriptional silencing.  The gene, previously reported to lack inactivating 
mutations in cell lines and primary tumors (Zariwala and Xiong, 1996), has been 
shown to be upregulated following treatment with the HDAC inhibitor trichostatin 
A (TSA), implicating epigenetic silencing at this locus in the human T-cell 
leukemia cell line Jurkat (Yokota et al., 2004).  
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Figure 1.5 INK4 Genomic Locus at 9p21.  The genomic organization at 9p21 houses two 
members of the INK4 family of CDKIs, p15 and p16, and an unrelated gene p14ARF. 
Interestingly, p14ARF utilizes two of the same exons as p16 but is translated in an alternative 
reading frame.  Boxes represent exons and CpG islands (described in Section 1.4.1.) are 
represented by asterisks.   
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1.3.7. Multistep Molecular Carcinogenesis 
In 1990, Fearon and Vogelstein proposed a highly publicized genetic model 
of a multistep pathway for colorectal tumorigenesis (Fearon and Vogelstein, 1990).  
The model illustrates the concept that as a cell evolves through the steps of 
transformation, including hyperplasia, metaplasia, neoplasia, and metastasis, that 
multiple genetic ‘hits’ are acquired affecting genes in several pathways.  As such, 
genetic abnormalities are reflected histologically by precursor lesions that progress 
to common features of malignancy.  Specifically, the model predicts inactivation of 
the adenomatous polyposis coli (APC) gene, a common mutation in both sporadic 
and familial colorectal cancer (Tomlinson et al., 1997), as an early event in the 
formation of a small benign adenoma.  Other genetic insults purported to be 
important in cell transformation include RAS proto-oncogene activation and loss of 
the deleted in colorectal cancer (DCC) gene.  Loss of p53 is predicted as a late 
adenoma evolves into a malignant cancer, or carcinoma, at which point the model 
recognizes other, as yet unidentified, alterations during the final progression to an 
invasive and metastatic tumor.  
 Although the multistep model of carcinogenesis is widely accepted for 
colorectal cancer and other common human tumors, it has since been modified to 
account for novel genes and recently described mechanisms of molecular 
aberrancy, including epigenetic mechanisms (Bellacosa, 2003; Ilyas et al., 1999; 
Issa, 2000; Kinzler and Vogelstein, 1996).  As such, the basic model is admittedly 
oversimplified, most likely underestimating the number of genes involved in clonal 
transformation, yet it has provided a resilient framework for the continued 
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understanding of the molecular basis of cancer, specifically that of colorectal 
cancer.  Identifying all the molecular irregularities, both genetic and epigenetic, and 
the interactions of the genes involved therein will undoubtedly assist in further 
understanding how a tumor evolves, potential points of intervention, and prognostic 
implications of the molecular abnormalities.  Furthermore, transposing this model 
to leukemia and identifying novel genes involved in proliferation and impaired 
differentiation could assist the development of targeted therapies.  The concept of 
epigenetics and its involvement in cancer biology is expanded upon further in the 
subsequent section. 
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1.4 EPIGENETICS 
The term ‘epigenetics’ was originally defined in the 1940s by the 
developmental biologist Conrad H. Waddington and, since then, has been used in a 
variety of forms.  In its original definition it was a manifestation of two concepts, 
‘epigenesis’ and ‘genetics’ (Van Speybroeck, 2002), and has since been the topic of 
much philosophical debate over its precise meaning (Jablonka and Lamb, 2002).  
Regardless of its many forms, the term ‘epigenetics’ largely involves two major 
concepts: 1) the study of heritable developmental processes within an organism, 
and 2) the study of heritable changes in gene expression that occur without a 
change in the genomic DNA sequence.  In both instances the major focus is how 
gene regulatory information that is not encoded in the DNA sequence is transmitted 
from one generation, either of cells or organisms, to the next.  Studies on DNA 
methylation and chromatin structure, which became increasingly prominent in the 
1960s and 1970s, identified molecular systems that account for epigenetic variation 
and have since become the focal point of contemporary epigenetic theory (Henikoff 
and Matzke, 1997). 
 
1.4.1. DNA Methylation 
 DNA methylation in higher eukaryotes affects only the pyrimidine base 
cytosine which becomes covalently modified at the carbon atom five position (Fig. 
1.6).  This modification only takes place when a cytosine is followed by a guanine 
base, and therefore only the dinucleotide CpG is methylated throughout the 
mammalian genome.  Interestingly, methylated cytosine is a target for point 
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Figure 1.6 Pyrimidine Nucleoside and 5-Methyl-Cytidine Chemical Structures.  Illustrated 
are the chemical structures and names of the common pyrimidine nucleosides, thymidine and 
cytidine, and the modified 5-methyl-cytidine.  The grey box highlights the methyl group 
attached to the carbon-5 of cytidine.  Structures were constructed using ChemSketch Version 
5.12 software (Advanced Chemistry Development Inc., Toronto, ON, Canada). 
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mutation as deamination of 5-methyl-cytidine leads to the formation of the 
naturally occurring DNA base thymidine, which is not recognized as mutated by 
the DNA repair machinery (Rideout et al., 1990).  As deamination is constantly 
taking place under physiological conditions, there is a resulting selective pressure 
that reduces the number of methylated cytosine bases within the genome.  In the 
mammalian genome, this has led to a progressive depletion of the CpG dinucleotide 
throughout evolution (Cooper and Krawczak, 1989). 
Only the physiologically unmethylated CpG sites in the promoter region 
and first exons of transcribed genes remain unaltered in part because active 
transcription seems to protect CpG sites against methylation (Clark and Melki, 
2002).  These typically unmethylated CpG-rich stretches of DNA form ‘CpG 
islands’ throughout the vast CpG depleted genome.  CpG islands comprise 1 - 2% 
of the genome and were originally arbitrarily characterized by an overall GC 
content of greater than 50% and an approximately five times more frequent 
occurrence of the dinucleotide CpG (Gardiner-Garden and Frommer, 1987).  In 
order to avoid many of the recently identified GC-rich sequences not associated 
with promoter regions, such as Alu-repetitive elements (approximately 0.3 kb in 
size) and intragenomic parasites, the CpG island definition has recently been 
modified with slightly more stringent criteria (Takai and Jones, 2002).  Notable 
exceptions to the unmethylated CpG island dogma are the constitutively methylated 
CpG islands found within imprinted genes (Reik and Walter, 2001) and those found 
on the inactive X-chromosome in females (Heard, 2004).  These concepts will be 
discussed in more detail in subsequent sections. 
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1.4.1.1. Global Hypomethylation 
 A global loss of DNA methylation at CpG dinucleotides was the first 
epigenetic abnormality to be identified in cancer cells (Feinberg and Vogelstein, 
1983a).  In this study, utilizing methylation sensitive restriction enzymes and 
southern blotting, the authors found that a substantial proportion of CpGs that were 
methylated in normal tissues were unmethylated in cancer cells, which was later 
confirmed that same year using high-performance liquid chromatography (Gama-
Sosa et al., 1983).  Since then, global deficiencies in methylated cytosine content 
have been observed in prostatic tumors (Bedford and van Helden, 1987), leukemias 
(Wahlfors et al., 1992), hepatocellular carcinomas (Lin et al., 2001), cervical 
cancers (Kim et al., 1994), and breast ductal carcinomas (Bernardino et al., 1997), 
despite the frequent finding of localized hypermethylation.  The biological 
significance of DNA hypomethylation in cancer is still not fully understood, 
however the high frequency of cancer-associated DNA hypomethylation, the nature 
of the affected sequences, and the absence of any association with regional DNA 
hypermethylation are consistent with an independent role in assisting cancer 
formation and tumor progression. 
 Hypomethylation observed in cancer is often found in DNA repeats, most 
notably endogenous retrotransposons, which tend to be highly methylated in 
somatic tissues (Ehrlich, 2002).  For example, in vivo hypomethylation dependent 
transcriptional upregulation of the repetitive retrotransposon LINE-1 has been 
shown to interfere with karyotypic stability and the transcriptional activity of 
neighboring genes, ultimately affecting phenotype and disease risk (Whitelaw and 
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Martin, 2001).  Furthermore, the normally methylated small Alu-repetitive 
elements, which constitute approximately 10% of the genome, can be transcribed 
and mobilized by tumor associated DNA hypomethylation, occasionally leading to 
cancer-associated gene insertions (Liu et al., 1994).  Another class of methylated 
human retrotransposons that become hypomethylated in association with 
oncogenesis are endogenous retroviruses, especially those from the HERV-K 
family (Florl et al., 1999).  It is speculated that decreased methylation of the 
HERV-K retroelement, like that of Alu-repeats and LINE-1, may contribute to 
genomic instability in specific human tumors by rendering these normally 
repressed sequences competent for transcription and recombination. 
 Interestingly, it has been reported that a limited number of proto-oncogene 
associated CpG islands are methylated in somatic tissues and that cancer associated 
hypomethylation can actually lead to gene activation (Feinberg and Vogelstein, 
1983b; Strichman-Almashanu et al., 2002).  Strong support for hypomethylation 
leading to activation of cancer related genes comes from reports linking the 
overexpression of cyclin D2 in gastric carcinoma (Oshimo et al., 2003), the 
S100A4 metastasis-associated gene in colon cancer (Nakamura and Takenaga, 
1998), and the 14-3-3σ proliferation-associated gene in pancreatic cancer (Sato et 
al., 2003b).  Moreover, hypomethylation of the multidrug-resistance gene (MDR1) 
has been identified in AML and is strongly associated with increased aberrant 
MDR1 expression, the acquisition of drug resistance, and adverse clinical outcome 
(Nakayama et al., 1998). 
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Taken together, while there is only a limited understanding of the pathways 
that lead to cancer-associated hypomethylation of some sequences and 
hypermethylation of others, there are some clues as to the types of sequences 
generally affected.  As mentioned, hypomethylation in repetitive DNA sequences 
may play a special role in carcinogenesis, such as increasing karyotypic instability 
or indirectly affecting gene expression, and evidence does exist for direct 
expression linked hypomethylation of cancer related genes.  For some types of 
cancer, DNA hypomethylation is seen as an early indicator of tumorigenesis 
(Feinberg et al., 1988) and therefore may have the potential to become a clinically 
useful diagnostic aid.  Although DNA hypomethylation is often overlooked when 
studying the relationship between methylation and carcinogenesis, its contribution 
to cell transformation may in the future be considered equivalent to that of the 
phenomenon of DNA hypermethylation. 
 
1.4.1.2. CpG Island Hypermethylation 
 Site specific DNA hypermethylation was first reported in 1986 by Stephen 
Baylin and colleagues who described 5’-promoter region CpG methylation of the 
calcitonin gene in association with transcriptional silencing in human lung cancers 
and lymphomas (Baylin et al., 1986).  Although the function of the calcitonin gene 
has yet to be directly related to carcinogenesis, it was the first study to show cancer 
associated site specific DNA hypermethylation as compared to that of normal adult 
tissue.  It was not until 1989 when hypermethylation associated transcriptional 
silencing of a bona fide tumor suppressor gene was reported in cancer, that of the 
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RB gene in retinoblastoma (Greger et al., 1989).  This important finding was the 
first to establish aberrant epigenetics, as opposed to loss-of-function mutations, as a 
novel mechanism behind disease associated gene silencing.  This finding was later 
confirmed by the identification of allele specific hypermethylation associated 
inactivation of the gene in primary retinoblastomas (Sakai et al., 1991).  
Mechanistic analysis of the RB promoter came in 1993 when Ohtani-Fujita et al. 
reported that hypermethylation of the RB promoter in vitro reduced the gene’s level 
of expression to 8% of the unmethylated control and that essential transcription 
factors could not bind their RB promoter recognition sequences when the CpGs 
within were methylated (Ohtani-Fujita et al., 1993).  Based on these observations, 
the mechanism behind promoter hypermethylation mediated gene silencing was 
long considered to be solely based on the steric blockage of transcription factor 
binding.  
 The subsequent few years following the discovery of RB promoter 
hypermethylation resulted in a marked increase in research that identified numerous 
loci in cancer cells which are targets for hypermethylation associated 
transcriptional silencing.  Key tumor suppressor genes, including p16 (Gonzalez-
Zulueta et al., 1995), MLH1 (Kane et al., 1997), the von Huppel-Lindau (VHL) 
gene (Herman et al., 1994), and E-cadherin (Graff et al., 1995), have all been 
shown to be repressed both in cell lines and in primary cancers by an epigenetic 
mechanism that correlates with dense promoter associated CpG island 
hypermethylation.  As such, evidence has accumulated implicating CpG island 
hypermethylation as a novel mechanism of transcriptional silencing that can affect 
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multiple pathways involved in various components of cellular biology, including 
cell cycle regulation, apoptosis, mismatch repair, and contact inhibition.   
   
1.4.1.3. Genomic Imprinting in Human Cancer 
 Genomic imprinting is the epigenetic marking of a gene or genes based on 
its parental origin that results in monoallelic expression, despite both parents 
contributing equally to the genetic content of their progeny.  The mechanism of 
imprinting is complex and not fully understood, yet prevailing evidence implicates 
parental-specific methylation of CpG-rich domains which are likely established 
during gametogenesis (Ferguson-Smith et al., 1993).  Imprinted genes are involved 
in many aspects of development including fetal and placental growth, cell 
proliferation, and adult behavior.  It is therefore not surprising to presuppose that, 
when altered, imprinted genes are often involved in numerous human diseases 
including cancer (Falls et al., 1999). 
 Imprinted genes can be involved in carcinogenesis in several ways.  For 
example, loss of heterozygosity (LOH) at an imprinted region may result in the 
deletion of the only functional copy of a tumor suppressor gene and conversely, 
loss of imprinting (LOI) of an imprinted proto-oncogene may allow for 
inappropriate increases in gene expression (Feinberg, 1993).  The most common 
example of aberrant genomic imprinting associated with cancer involves the 
childhood Wilms’ tumor and the reported high frequency of irregular biallelic 
insulin-like growth factor 2 (IGF2) expression (Ogawa et al., 1993).  Interestingly, 
LOI of IGF2, located at 11p15.5, has been linked to LOH of the neighboring H19 
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gene in this disease, resulting in a complex enhancer competition model for the 
reciprocal control of expression between the two genes (Webber et al., 1998).  The 
model involves a 2.4 kb imprinting control region regulating the somatic 
monoallelic expression of IGF2 and H19, which is achieved through a DNA 
methylation dependent chromatin insulator (known as CTCF) and promoter 
silencing activities on the maternal and paternal alleles, respectively (Webber et al., 
1998).  Of note, many adult tumors have since showed LOI at the IGF2 locus, 
indicating aberrant IGF2 imprinting in the pathogenesis of a variety of cancers. 
 As previously mentioned, the p57 gene, also located at 11p15.5, is a 
maternally expressed and paternally imprinted CDKI and, owing to its location, 
biochemical functions and imprinting status, is considered a candidate tumor 
suppressor gene (Kondo et al., 1996).  As a candidate tumor suppressor gene, LOH 
of the remaining expressed p57 copy, through either genetic or epigenetic means, 
could hypothetically assist cellular transformation and its reduced expression in 
human Wilms’ tumors and Beckwith-Wiedemann syndrome (BWS) supports this 
notion (Thompson et al., 1996).  Genetic analysis in BWS, a prenatal cancer-
predisposing disorder, has revealed missense and frameshift mutations of the 
maternal p57 allele in a significant number of cases resulting in little or no active 
p57 protein (Hatada et al., 1996).  Yet, the role of DNA methylation in the control 
of p57 imprinting has been questioned as evidence has shown that p57 is expressed 
in nonneoplastic tissues in the absence of promoter hypermethylation.   
The methylation status of the p57 promoter associated CpG island has been 
recently evaluated in many tumor cell lines and primary cancers and a high 
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frequency of cases harbored promoter hypermethylation in association with 
decreased p57 mRNA expression (Kikuchi et al., 2002; Li et al., 2002b; Shen et al., 
2003).  Importantly, treatment of methylated ALL cell lines with 5-Aza-2’-
deoxycytidine (5-Aza-dC), a DNA methyltransferase inhibitor, restored p57 
expression in association with CpG island demethylation.  Moreover, in one of 
these studies deacetylated histones H3 (H3) and H4 (H4) were found to be 
associated with methylated p57 promoter alleles (Kikuchi et al., 2002), implicating 
a functional role for histone modifications and chromatin conformation in promoter 
hypermethylation mediated gene silencing.  Although the role of DNA 
hypermethylation in p57 genomic imprinting is as yet unresolved, evidence is 
accumulating implicating p57 promoter specific hypermethylation in many 
hematological malignancies.   
 
1.4.1.4. Mammalian DNA Methyltransferases  
 Cytosine methylation, as stated, is known to be involved in transposon and 
other repetitive element silencing, gene specific transcriptional regulation, and 
genomic imprinting.  In addition, recent evidence supports a role for DNA 
methylation, as well as unique RNA coating and chromatin remodeling, in the 
developmental silencing of multiple genes located on one of the two X-
chromosomes in XX female mammals (Heard, 2004).  Although it is still unknown 
what signals or triggers mammalian methylation, what is consistent throughout 
these processes is the DNA methyltransferase (DNMT) enzyme family involved 
therein. 
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 The methyl donor for cytosine methylation is the cofactor S-adenosyl-L-
methionine and the catalytic reaction involves the target cytosine to become 
completely everted from the DNA helix and inserted deep into the active site of the 
DNMT enzyme (Bestor, 2000).  In mammals, three families of DNA cytosine-5 
methyltransferase enzymes, DNMT1, DNMT2, DNMT3a, and DNMT3b, have 
been identified.  DNMT1 is the largest methyltransferase with a molecular mass of 
184 kDa (Smith et al., 1992).  The amino-terminal two-thirds of the protein is 
considered to be the regulatory domain and the carboxy-terminal region contains 
the catalytic domain (Yen et al., 1992), which is homologous with all the known 
DNMTs (Kumar et al., 1994).  In proliferating cells, DNMT1 is found to be 
associated with replication foci (Leonhardt et al., 1992), ensuring reciprocal 
methylation of the newly synthesized daughter strand during replication, a process 
known as maintenance methylation.  Importantly, disruption of DNMT1 in mice 
results in abnormal imprinting (Li et al., 1993), embryonic lethality, greatly 
reduced levels of DNA methylation (Li et al., 1992) and derepression of 
endogenous retroviruses (Walsh et al., 1998), further supporting the important role 
epigenetics plays in cell biology and development.  In comparison with DNMT1, 
DNMT2 is much smaller, with a predicted molecular mass of 45 kDa, lacking the 
large amino-terminal, but containing all the conserved methyltransferase motifs.  
Biological activity for this protein has yet to be demonstrated and is as yet 
unknown. 
 The discovery of the third family of methyltransferases, DNMT3a and 
DNMT3b, confirmed the presence of de novo methylation in mammals (Okano et 
 43
al., 1998).  Both of these enzymes are crucial for embryonic development and are 
responsible for the de novo methylation during embryogenesis that establishes the 
somatic methylation pattern of the organism (Okano et al., 1999).  DNMT3a and 
DNMT3b are intermediate in size (100 - 130 kDa) in comparison with DNMT1 and 
DNMT2, and possess a smaller amino-terminal region.  Mutation within the 
carboxy-terminal of human DNMT3b has been shown to be associated with ICF 
(immunodeficiency, centromeric instability and facial anomalies) syndrome, 
characterized by abnormally hypomethylated centromeric satellite sequences and 
genomic instability (Xu et al., 1999).   
 It is commonly hypothesized that maintenance and de novo methylation 
must be performed by separate enzymes.  As such, sequence specific de novo 
methyltransferases act at specific stages of gametogenesis and early development to 
establish the methylation patterns, which are then maintained during cell division 
by sequence independent DNMTs that methylate only hemimethylated substrates 
(Bestor, 2000).  In this model DNMT3a and DNMT3b act as the de novo enzymes 
and DNMT1 is responsible for methylation maintenance (Okano et al., 1999).  
However, many facets of this paradigm have yet to be fully proven; for example, 
no mammalian DNMT has been shown to be sequence specific and recent evidence 
actually supports a role for cooperation between DNMT1 and DNMT3b in the 
methylation dependent silencing of genes in cancer cells (Rhee et al., 2002).  
Although the exact responsibilities, either independent or redundant, of mammalian 
DNMTs have yet to be fully elucidated, there is no question regarding their 
important roles in development, imprinting and transcriptional regulation, and their 
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association with various disease states.  Furthermore, it should be noted that novel 
as yet undiscovered mammalian DNMTs may still exist. 
 
1.4.1.5. Mammalian Methyl-CpG Binding Domain Proteins 
 Once established, the DNA methylation profile of tumor cells is unlikely to 
be the primary event in gene inactivation.  Rather, DNA hypermethylation is 
thought to provide a long term and robust memory for ‘locking in’ a 
transcriptionally inactive state established, in part, by other mechanisms (Bird, 
2002).  Part of the machinery involved in hypermethylation mediated gene 
silencing involves a family of proteins that contain a conserved methyl-CpG 
binding domain (MBD) (Hendrich and Bird, 1998).  There are presently five 
known mammalian MBD proteins in which four, MeCP2, MBD1, MBD2, and 
MBD4, have the capacity to specifically target methylated CpG dinucleotides 
through the MBD motif.  Like these four proteins, the related MBD3 protein 
contains this highly conserved MBD motif but, despite having over 70% amino 
acid similarity to the MBD2 protein, has lost the ability to specifically bind 
methylated DNA (Hendrich and Bird, 1998).  The fifth MBD protein that targets 
methylated CpG dinucleotides, KAISO, is different from the others in that it binds 
methylated DNA through a zinc finger motif (Prokhortchouk et al., 2001).  
Interestingly, unlike the other family members, MBD4 appears to not be involved 
in hypermethylation mediated transcriptional repression but rather DNA repair by 
interacting with the previously mentioned MMR protein MLH1 (Bellacosa et al., 
1999).  Due to the preference for MBD4 to bind 5-methyl-CpG-to-TpG 
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mismatches, the previously mentioned product of 5-methyl-cytidine deamination, it 
has been proposed that the role of MBD4 is to minimize mutation at 5-methyl-CpG 
(Hendrich et al., 1999b), and of note, when removed from mice, is associated with 
significantly increased CpG mutability and tumorigenesis (Millar et al., 2002). 
 The first MBD protein to be cloned was the second methyl-CpG binding 
activity to be discovered, accordingly named MeCP2 (Lewis et al., 1992), and was 
the protein in which the MBD was defined (Nan et al., 1993).  Located at Xq28, it 
is a highly abundant chromosomal protein that colocalizes in the nucleus with 
methylated DNA, suggesting a role as a global transcriptional repressor in 
vertebrate genomes (Nan et al., 1997).  Mutations in the MeCP2 gene cause human 
Rett syndrome, which is a progressive neurologic developmental disorder primarily 
affecting females (Amir et al., 1999).  Those suffering from Rett syndrome, one of 
the most common causes of mental retardation in females, are actually 
heterozygous for MeCP2 inactivating mutations.  In this instance, aberrant 
inactivation of the single wild-type MeCP2 allele, located on the X chromosome, 
abrogates MeCP2 protein function and contributes to neuronal degeneration. 
 MBD1 is unique among the MBD proteins in that it is capable of repressing 
transcription from both methylated and unmethylated promoters in cell transfection 
experiments (Fujita et al., 1999).  MBD1 is also unique among the methyl-CpG 
binding repressors in that it contains within it multiple copies of a cysteine-rich 
motif (CXXC) with unknown function that is also found in DNMT1, the histone 
methyltransferase (HMT) MLL, and numerous other uncharacterized expressed 
sequence tags (ESTs) (Fujita et al., 1999).  Similar to MeCP2, MBD1 is an 
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abundant chromosomal protein (Ng et al., 2000), which contains a powerful 
transcriptional repression domain (Fujita et al., 2000; Ng et al., 2000), yet a 
proportion of its repressional activity appears to rely upon the recruitment of 
HDAC activity (Patra et al., 2003), a concept that will be elaborated on in 
subsequent sections.  
 MBD2 and MBD3 are the only vertebrate MBD proteins for which 
homologues can be identified in invertebrate genomes or EST collections, and thus, 
MBD2/3 is predicted to represent the original MBD protein (Hendrich et al., 
1999a), likely divided into two genes by an evolutionary gene duplication event.  
Although MBD3 does not have methyl-CpG binding capacity, it is part of an 
abundant nucleosome remodeling and histone deacetylation (NuRD) co-repressor 
complex in humans (Zhang et al., 1999), which can be recruited to DNA by several 
different repressor proteins and is important in embryonic development (Ahringer, 
2000).  MBD2 is a component of the methyl-CpG binding protein 1 (MeCP1) 
complex (Ng et al., 1999), which was the first methyl-CpG binding activity to be 
described, repressing transcription in a methylation density-dependent fashion 
(Bird and Wolffe, 1999).  Interestingly, biochemical purification in HeLa cells has 
revealed that MeCP1 actually consists of the NuRD complex in association with 
MBD2 (Feng and Zhang, 2001), substantiating the close relationship between 
MBD2 and MBD3. 
 Molecular evidence for the importance of MBD proteins in control of gene 
transcription in vivo has been illustrated by chromatin immunoprecipitation assays 
in hepatocellular carcinoma (Bakker et al., 2002), colon cancer (Magdinier and 
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Wolffe, 2001), bladder cancer (Nguyen et al., 2002), and T-cell leukemia cell lines 
(El-Osta et al., 2002).  These studies demonstrate the physical presence of MBD 
proteins, most often MeCP2 and/or MBD2, at several hypermethylated tumor 
suppressor gene promoters and further confirm the association between DNA 
hypermethylation and histone deacetylation.  Importantly, treatment with 5-Aza-dC 
results in predicted promoter demethylation and the release of MBD proteins at p16 
(Magdinier and Wolffe, 2001; Nguyen et al., 2002) and MDR1 promoter loci (El-
Osta et al., 2002) in association with local enrichment of H3 and H4 acetylation.  
Thus, the recruitment of MBD proteins to hypermethylated tumor suppressor gene 
promoters supports a model that involves another epigenetic process, that of 
chromatin remodeling and post-translational histone modification, which directs 
transcriptional silencing by means of a repressive chromatin conformation. 
 
1.4.2. Post-translational Histone Modification 
 Eukaryotic chromosomes, which consist of a highly ordered and condensed 
protein:DNA complex known as chromatin, are dynamic entities whose appearance 
varies with the stage of the cell cycle.  Individual chromosomes assume their 
familiar condensed forms only during M phase of the cell cycle, yet during the 
remainder of the cell cycle, when the chromosomal DNA is transcribed and 
replicated, the chromosomes of most cells become highly dispersed and 
indistinguishable.  As a result, two different forms of chromatin have been defined: 
‘heterochromatin’, which is tightly compacted and associated with transcriptionally 
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silent genomic regions, and ‘euchromatin’, which has a more open or relaxed 
conformation that tends to support transcription (Wolffe and Kurumizaka, 1998). 
 
1.4.2.1. Nucleosomes and Chromatin Organization 
The protein component of chromatin, which comprises over half of the total 
chromatin mass, consists primarily of histones.  All histone proteins have a large 
proportion of positively charged arginine and lysine residues (Smith, 1991) and 
consist of five families: histone H1 (H1), H2A (H2A) and H2B (H2B), and the 
aforementioned H3 and H4.  The fundamental unit of the chromatin polymer is the 
nucleosome, identified in 1974, which consists of approximately 146 base pairs of 
DNA wrapped around an octamer of core histones, comprised of two copies each of 
H2A, H2B, H3 and H4 (Kornberg, 1974).  Core histones are evolutionarily 
conserved and consist of flexible amino-terminal ‘tails’ protruding outward from 
the nucleosome, and globular carboxy-terminal domains making up the nucleosome 
scaffold.  These positively charged proteins ionically bind DNA’s negatively 
charged phosphate groups, allowing the DNA to form two complete left-handed 
superhelical turns around the octamer.  The linker H1 is responsible for binding the 
nucleosomal DNA in a cavity of the core particle where DNA both enters and exits 
the nucleosome, which creates a slightly larger histone:DNA structure known as 
the chromatosome (Allan et al., 1980).   
Nucleosomes form in vivo at physiological salt concentrations with the 
assistance of molecular chaperones such as nucleoplasmin and DNA topoisomerase 
I, which assist in bringing histones and DNA together in a controlled fashion 
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(Lilley and Pardon, 1979).  The next level of chromosomal organization is achieved 
through contacts between multiple nucleosomal H1 proteins forming a 300Å-thick 
filament (Allan et al., 1980).  Although little is known how the filaments undergo 
higher order organization to form functional metaphase chromosomes, it is believed 
that multiple filaments are packaged along a scaffolding fibrous protein forming a 
solenoid, and eventually a comprehensive chromosome.  
As mentioned, following cell division chromosomes unravel into long thin 
extended microfibrils of euchromatin or condensed coiled masses of 
heterochromatin.  In order to successfully regulate gene transcription, euchromatic 
regions require several proteins and multisubunit complexes to act directly on 
chromatin structure.  Aside from transcription, other processes such as 
chromosomal segregation, replication, recombination and repair also require 
chromatin manipulation and it has recently become clear that covalent modification 
of regional histones facilitates this process.  Evidence for this stems from the many 
reports correlating chromatin activity with specific post-translational modifications 
of the 25 - 40 amino acid residues within the flexible histone amino-terminal tails 
(Luo and Dean, 1999; Strahl et al., 1999).   
By interacting with other chromatin remodeling factors the histone tails 
themselves therefore provide additional gene regulatory information that 
contributes to chromatin conformation and is the foundation for the recently 
hypothesized ‘histone code’ (Jenuwein and Allis, 2001; Strahl and Allis, 2000).  
This popular hypothesis predicts that distinct histone modifications act sequentially 
or in combination to form a code that is read by other proteins to bring about 
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distinct downstream events.  These downstream events include modulation of 
transcription and the post-translational modifications at the center of this paradigm 
include histone acetylation, phosphorylation, methylation, ubiquitination, and 
ADP-ribosylation (van Holde, 1988). 
 
1.4.2.2. Histone Acetylation  
 Acetylation and deacetylation of the ε-amino groups of conserved lysine 
residues present in histone tails have long been linked to transcriptional activity 
(Allfrey et al., 1964) and has been the most intensively studied histone 
modification.  Acetylated histones are typically associated with transcriptionally 
active chromatin and deacetylated histones with inactive chromatin.  In addition to 
the relationship between histone acetylation and the transcriptional capacity of 
chromatin, acetylation is also involved in processes such as replication and 
nucleosome assembly, higher-order chromatin packaging and the interactions of 
non-histone proteins with nucleosomes (Grant and Berger, 1999).  In particular, the 
highly conserved H3 lysines at amino acid positions 9, 14, 18 and 23, and H4 
lysines 5, 8, 12 and 16, are frequently targeted for acetylation (Roth et al., 2001) 
(Fig. 1.7).  The neutralization of the histone tail basic charge by acetylation is 
thought to reduce the affinity for DNA and to alter histone:histone interactions 
between adjacent nucleosomes as well as the interactions of histones with other 
regulatory proteins (Grant and Berger, 1999; Roth et al., 2001).  These changes 
contribute to a ‘relaxed’ chromatin environment believed to be permissive for 
transcription. 
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Figure 1.7 Known Post-Translational Histone Modifications.  Illustrated are the amino acid 
sequences of the major areas of currently known post-translational modification in H3, the H3 
amino-terminal (N) variant CENP-A, H4, H2B, H2A, and the H2A carboxy-terminal (C) 
variant H2A.X.  As noted in the legend, common modifications include acetylation, 
methylation, phosphorylation and ubiquitination, and numbers represent amino acid position. 
Black boxes represent the alpha helices in the structured domains of the histone proteins. 
Adapted from Upstate Biotechnology, Inc. ‘Histone Modification Map’, 2004. 
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Molecular evidence for a direct link between acetylation and transcription 
was provided when the conserved transcriptional regulator GCN5 was found to 
harbor histone acetyltransferase (HAT) activity (Brownell et al., 1996).  Since the 
identification of GCN5 as the archetypal nuclear HAT, numerous other coactivator 
proteins have been found to possess HAT activity and have frequently been 
identified as components of high molecular weight complexes composed of 
proteins with homology to transcriptional regulators (Grant and Berger, 1999).  
There are now several reported families of HATs which generate specific patterns 
of free and/or nucleosome associated histone acetylation.  Importantly, many HATs 
have also been reported to modify other transcription factors, such as p53 (Gu and 
Roeder, 1997) and the basal transcription factors TFIIE and TFIIF (Imhof et al., 
1997), suggesting a role for acetylation in gene and/or protein regulation beyond 
the modification of histones.  This concept of HATs having non-histone protein 
substrates is becoming increasingly more popular and will undoubtedly be of great 
interest to many research areas of molecular biology. 
 The activity of HATs within a cell is balanced by the activity of the 
previously mentioned HDACs, which catalyze the removal of acetyl moieties from 
specific histone lysine residues, uncovering the lysine positive charge.  The 
interaction between the positively charged lysines with DNA presumably restricts 
nucleosome mobility on the DNA, rendering a promoter region, for example, 
inaccessible to the transcription machinery (Ura et al., 1997).  The HDAC 
superfamily is divided into three known classes: class I is similar to yeast RPD3, 
class II is similar to yeast HDAC1, and class III is similar to yeast Sir2.  Class III 
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was discovered very recently and as a result, little is known regarding their 
expression, location, and specific activity (Thiagalingam et al., 2003).  The 
numerous members of classes I and II, however, share a region of about 390 amino 
acids that contains the catalytic site and is conserved in eukaryotic cells.  HDACs 
are targeted to histone tails by protein or protein complexes and, not surprisingly, 
both class I and II enzymes are found in the nucleus (Villar-Garea and Esteller, 
2004).   
An example of mislocalized HDAC activity in cancer is seen in the 
aforementioned AML associated t(8;21) translocation (Wang et al., 1999).  This 
chromosomal abnormality fuses the DNA-binding domain of AML1, a 
transcriptional activator and repressor, with ETO, a nuclear phosphoprotein that is 
expressed in hematopoietic progenitors and which interacts with multiple HDACs, 
Sin3, and other co-repressors.  The AML1/ETO fusion protein localizes to AML1 
target genes, where it, in contrast to the wild-type AML1 protein, actively 
suppresses transcription via a co-repressor complex made up of N-
CoR/Sin3/HDAC1.  Since AML1 is required for differentiation of hematopoietic 
cells, AML1/ETO expression leads to a block in myeloid development and 
therefore assists leukemic transformation (Jones and Saha, 2002).  Not surprisingly, 
since the detection of HDACs at inappropriately silenced tumor suppressor genes in 
human cancer, considerable effort has been put forward to identify inhibitors of this 
type of activity, which will be discussed in a subsequent section. 
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1.4.2.3. Histone Phosphorylation 
 In contrast to the relative wealth of information about the large number of 
HATs and HDACs, relatively little is known about the enzymes that generate other 
histone modifications.  For example, specific histone kinases and phosphatases 
have largely remained elusive, yet progress has been made towards understanding 
the role of histone phosphorylation in processes such as transcription, DNA repair, 
apoptosis, and chromosome condensation (Cheung et al., 2000a).  Although the 
mechanism by which phosphorylation contributes to transcriptional activation is 
not well understood, phosphorylation of H3 serine 10 (Fig. 1.7) has been reported 
to correlate with gene activation in mammalian cells (Thomson et al., 1999) and 
heat shock transcriptional induction in the Drosophila melanogaster fruit fly 
(Nowak and Corces, 2000).  One possible mechanism behind this, analogous to 
acetylation, is that the addition of negatively charged phosphate groups to histone 
tails neutralizes the basic charge, reducing the affinity of histones for DNA.  
Furthermore, it has been reported that several acetyltransferases have increased 
HAT activity on H3 serine 10 phosphorylated substrates, and that mutation of 
serine 10 decreases activation of GCN5-regulated genes (Cheung et al., 2000b; Lo 
et al., 2000).  Thus, it is possible that histone phosphorylation may contribute to 
transcriptional activation through the stimulation of HAT activity on the same 
histone tail. 
 Interestingly, phosphorylation of H3 at serine 10 has also been correlated 
with mitotic chromosome condensation, which is dephosphorylated at the 
completion of mitosis (Hendzel et al., 1997), and recent work suggests that the 
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kinase responsible for this modification is necessary for cells to pass through the 
G2/M transition (Van Hooser et al., 1998).  Furthermore, as the induction of 
apoptosis also involves chromosome condensation, toxic agents have been shown 
to induce H3 serine 10 phosphorylation in association with apoptotic chromosome 
condensation (Waring et al., 1997).  Serine 139 of the mammalian histone H2A 
variant, histone H2A.X (H2A.X) (Fig. 1.7), is also rapidly phosphorylated upon 
exposure to DNA damaging agents, which may play a role in facilitating end-
joining repair of DNA (Rogakou et al., 1999).  Recent work has also established a 
correlation between apoptosis and rapid phosphorylation of H2B serine 14 at sites 
of DNA double-strand breaks (Cheung et al., 2003; Fernandez-Capetillo et al., 
2004).  Although the functional roles that histone phosphorylation play in 
transcriptional activation and chromosome condensation are not fully actualized, 
the available data supports a role in the histone code hypothesis. 
 
1.4.2.4. Histone Methylation 
 Methylation of histones was first described in 1964 (Murray, 1964), but the 
linkage of histone methylation and transcription was not evident until the H3 
arginine specific HMT CARM1 was shown to interact and cooperate with the 
steroid hormone receptor coactivator GRIP-1 during transcriptional activation 
(Chen et al., 1999).  Aside from arginine residues, multiple lysine residues residing 
within H3 (4, 9, and 27) and H4 (20) have been identified as substrates for 
preferential methylation (Fig. 1.7), and adding to the potential complexity, can be 
mono-, di-, or tri-methylated (Lachner and Jenuwein, 2002; Strahl et al., 1999).  
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The first lysine specific HMT to be discovered was the SUV39h1 protein, which 
has a catalytic site residing in a highly conserved SET domain which is directed 
against H3 lysine 9 (Rea et al., 2000).  Since its identification, numerous other 
mammalian proteins have been characterized that contain SET domains, together 
comprising the SUV39, SET1, SET2, and RIZ families of lysine 9 HMTs 
(Kouzarides, 2002).   
 Mammalian SUV39h1 is a transcriptional repressor and localizes to 
transcriptionally silent heterochromatic sites, co-localizing with the transcriptional 
repressor heterochromatic protein 1 (HP1) (Aagaard et al., 1999).  The HP1 protein 
is able to bind to H3 methylated at lysine 9 through interaction with its conserved 
chromodomain, yet how HP1 generates a highly compact chromatin structure is not 
known.  It may link up several nucleosomes and/or may bring in other enzymatic 
activities necessary for compaction.  Evidence that the SUV39h1/HP1 complex is 
involved in transcriptional repression at euchromatic loci comes from the finding 
that the RB protein recruits SUV39h1/HP1 to cell cycle controlling genes such as 
cyclin E (Nielsen et al., 2001).  These results emphasize that histone lysine 
methylation and subsequent HP1 binding do not occur ubiquitously but rather are 
targeted events.  Importantly, as H3 lysine 9 methylation can not take place if H3 
lysine 9 is acetylated, the aforementioned HDAC activity of the RB repressor 
complex must first remove the acetyl moiety in order for lysine 9 methylation to 
proceed.  This interaction has been documented in Drosophila melanogaster where 
specific HMT and HDAC proteins were identified in the same physical complex 
(Czermin et al., 2001), yet the exact mechanism behind HP1 in transcriptional 
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silencing at specific promoters, like that of its role at heterochromatic regions, is 
still unclear. 
Other examples of genes potentially repressed by lysine methyltransferase 
activity are those regulated by IKAROS, a protein required for lymphoid 
development.  In addition to recruiting HDAC activity, IKAROS also co-localizes 
with the HP1β isoform, suggesting that lysine 9 methyltransferase activity may be 
involved in its repressive mode of action (Brown et al., 1997). 
 Conversely, H3 lysine 4 methylation in mammalian cells and in yeast 
correlates with an active state of transcription (Strahl et al., 1999).  Studies at the 
mating type loci in fission yeast have shown that there are large stretches of silent 
heterochromatin that contain histones methylated at H3 lysine 9 but that are devoid 
of H3 lysine 4 methylation.  In contrast, the surrounding actively transcribed 
regions harbor H3 lysine 4 methylation but not that of H3 lysine 9.  Importantly, 
removal of a boundary element in this model causes spreading of H3 lysine 9 
methylation into the active domain resulting in depletion of H3 lysine 4 
methylation (Noma et al., 2001).  To add to the complexity, a recent yeast study 
using antibodies that distinguish between di- and tri-methylated H3 lysine 4 
revealed that tri-methylation of H3 lysine 4 is specific for the active state of 
transcription, whereas di-methylated H3 lysine 4 exists in both active and repressed 
genes (Santos-Rosa et al., 2002).  Thus, the number of methyl groups in a histone 
modification, and not just the targeted amino acid residue, appears to play a 
significant role in the functional consequences of histone methylation. 
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1.4.2.5. Histone Ubiquitination and ADP-ribosylation 
 A potentially vast number of other histone modifications within the 
unstructured amino-terminal tails and structured carboxyl-termini of histones may 
await discovery or warrant further investigation, including ubiquitination and ADP-
ribosylation.  Although very little is currently known about these histone 
modifications, early reports indicate that ubiquitination of H2B in yeast may play a 
role in mitosis and meiosis (Robzyk et al., 2000), and work in Drosophila 
melanogaster indicates potential roles for histone ubiquitination in transcriptional 
activation (Pham and Sauer, 2000).   
ADP-ribosylation, which is the transfer of an ADP-ribose unit from 
nicotinamide adenine dinucleotide to a histone protein, has very recently been 
implicated in the enzymatic process involved in determining and/or maintaining the 
methylation pattern on genomic DNA (Zardo et al., 2003).  Functional 
consequences of histone ADP-ribosylation, the enzymes responsible, and the 
specific histone substrates and amino acid targets are not well understood and are 
still very much in the early stages of exploration.  However, the proposed 
relationship between histone ADP-ribosylation and DNA hypermethylation is very 
interesting and warrants further investigation.  Other connections between histone 
modifications and DNA methylation have been established and will be further 
discussed in the subsequent section. 
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1.4.3. DNA Hypermethylation and Chromatin Remodeling 
One of the major questions regarding DNA methylation is the identity of 
initial targeting mechanisms.  In other words, how do patterns of DNA methylation 
originate?  A seminal observation in the filamentous fungus Neurospora crassa has 
lead to the proposal that a specific chromatin structure involving methylated 
histones may be necessary for DNA methylation to take place (Tamaru and Selker, 
2001).  Specifically, the study showed that the Neurospora crassa gene dim-5, a 
histone H3 lysine 9 HMT, precedes and is a requirement for DNA methylation.  
This suggests a dependence on lysine 9 methylation for local DNA methylation to 
occur.  Although dim-5 lacks a chromodomain, a model consistent with the 
SUV39h1/HP1 system suggests that H3 lysine 9 methylation could recruit a 
DNMT, either directly or through an intermediary factor, that has affinity for the 
H3 methylated lysine 9 position.  Indeed, such a link has been described recently 
by the functional analysis of KRYPTONITE mutants in Arabidopsis thaliana.  
KRYPTONITE encodes a SET domain containing H3 lysine 9 specific HMT, 
which generates a substrate for a HP1-like protein that is known to interact with a 
DNMT, thereby recruiting DNA methylation activity to H3 lysine 9 methylated 
chromatin (Jackson et al., 2002).  These results indicate an attractive hierarchy in 
epigenetic pathways where histone methylation functionally directs DNA 
methylation (Fig. 1.8). 
However, a caveat of these two reports is that DNA methylation in fungi 
and plants is distinct from DNA methylation in mammalian cells.  For example, 
Fuks et al. have shown that the mammalian MBD protein, MeCP2, in addition to  
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Figure 1.8 Model of DNA Hypermethylation Mediated Gene Silencing.  The diagram 
illustrates a current model for epigenetic gene silencing involving promoter associated CpG 
island hypermethylation and post-translational modification of local histones.  Black filled
circles represent methyl-cytosines located within CpG dinucleotides (black vertical lines) and 
the bent arrow represents the major transcriptional start site.  ChRF: chromatin remodeling 
factor.  
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interacting with a HDAC complex, associates with a HMT specific for H3 lysine 9 
(Fuks et al., 2003b).  This important study shows that the presence of MeCP2 on 
nucleosomes within the repressor region of the H19 gene coincides with an 
increase in H3 lysine 9 methylation and provides evidence for MeCP2 
reinforcement of a repressive chromatin state by acting as a bridge between DNA 
methylation and histone methylation.  Moreover, in a recent study involving the 
GSTP1 gene in prostate cancer, promoter hypermethylation was associated with the 
presence of MBD2 and local histone deacetylation (Stirzaker et al., 2004).  The 
authors postulate a chronological model that includes promoter hypermethylation, 
MBD2 binding, H3 lysine 9 histone deacetylation, recruitment of more DNMTs 
and spreading of DNA hypermethylation, binding of MeCP2, and eventual H3 
lysine 9 methylation.  Again, it is an attractive hypothesis to envisage MBD 
proteins as co-repressors which target HDAC and HMT activities to 
hypermethylated promoters, (Fig. 1.8), yet the model fails to address the question 
of initial DNA methylation targeting mechanisms. 
Although the exact targeting mechanism of aberrant epigenetic silencing in 
mammalian cells is as yet still unknown and the specific direction of modifications 
– either from DNA to histones or from histones to DNA – is still uncertain, it is 
clear that a strong correlation exists between DNA hypermethylation and histone 
deacetylation.  Interestingly, between DNA hypermethylation and histone 
deacetylation, DNA hypermethylation appears to play a dominant role in the 
silencing of genes in cancer cells.  Evidence for this comes from the fact that 
pharmacological inhibition of HDAC fails to induce transcription of 
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hypermethylated genes (Cameron et al., 1999a; Suzuki et al., 2002).  In contrast, 
genes silenced by promoter hypermethylation are routinely reactivated when 
exposed to pharmacological inhibition or genetic knock out of DNMT activity.  
Moreover, synergistic reactivation of hypermethylated genes occurs in vitro when 
cells are treated with a combination of demethylating drugs and HDAC inhibitors, 
reinforcing the hypothesis that DNA methylation is involved in transcription 
modulation by ‘locking’ in a repressive chromatin conformation. 
 
1.4.4. Inhibitors of DNA Methylation and Histone Deacetylation 
 The fact that many human diseases, including cancer, have a significant 
epigenetic etiology has encouraged the development of novel therapeutic options.  
Many agents have been discovered that alter methylation patterns on DNA or the 
modification of histones, and several of these agents are currently being evaluated 
in clinical trials.  
 
1.4.4.1. DNA Methyltransferase Inhibition 
 Inhibitors of DNA methylation rapidly reactivate the expression of genes 
that have undergone promoter methylation dependent gene silencing, particularly if 
this silencing has occurred in a pathological situation.  The first described inhibitors 
of methylation, 5-azacytidine (5-Aza) and its deoxy analog 5-Aza-dC, were initially 
developed as chemotherapeutic cytotoxic agents (Sorm et al., 1964) (Fig. 1.9), but 
it was subsequently discovered that they were also powerful inhibitors of DNA 
methylation and could induce gene expression and differentiation in cultured cells 
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Figure 1.9 Chemical Structures of Common DNMT Inhibitors.  Illustrated are the chemical 
structures and names of the common cytosine analog inhibitors of DNA methylation. 
Structures were constructed using ChemSketch Version 5.12 software (Advanced Chemistry 
Development Inc., Toronto, ON, Canada). 
 64
(Constantinides et al., 1977; Jones and Taylor, 1980).  Once introduced into a 
nucleus, both nucleoside analogues are converted to the deoxynucleotide 
triphosphates and are then incorporated into replicating DNA in place of cytosine.  
As such, they are primarily active in S phase cells where they serve as powerful 
inhibitors of DNA methylation.  DNMTs get trapped on DNA containing modified 
bases such as azacytosine, 5-fluorocytosine, pseudoisocytosine and zebularine, 
resulting in the formation of heritable demethylated DNA (Jones and Taylor, 1980; 
Zhou et al., 2002b).  Of note, the covalent attachment of various DNMTs to DNA 
may well be responsible for the cytotoxicities of these agents, particularly at high 
doses (Michalowsky and Jones, 1987). 
 A disadvantage of the aza-nucleosides is their instability in aqueous 
solutions, yet this may be overcome by the use of other analogues such as 
zebularine or 5-fluoro-2’deoxycytidine, which also inhibit DNA methylation 
following incorporation into DNA.  For example, in a recent study involving tumor  
burdened mice, oral administration of zebularine, owing to its stability, was 
effective at demethylating the CDKI p16 in vivo in association with reducing tumor 
volume (Cheng et al., 2003).  Non-cytosine analogs such as procaine and the 
related compound procainamide, which are normally used to treat cardiac 
arrhythmias, are other examples of inhibitors of DNA methylation (Villar-Garea et 
al., 2003).  In addition, natural products derived from tea and sponges have shown 
DNA demethylating activity in vitro (Fang et al., 2003; Pina et al., 2003).  Clinical 
trials with antisense oligonucleotides that target the DNMT enzymes are also 
underway (Yan et al., 2003). 
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 As mentioned, inhibitors of epigenetic silencing are currently being 
evaluated in clinical trials, the most promising being 5-Aza and 5-Aza-dC in the 
treatment of hematological malignancies.  In a relatively large phase II study of 
elderly patients with intermediate or high-risk MDS, Wijermans et al. found low 
dose 5-Aza-dC to be well tolerated with the only major side effect being 
myelosuppression (Wijermans et al., 2000).  Within the treated patient population, 
20% achieved a complete remission that was associated with cytogenetic remission 
and another 28% showed significant clinical improvement (Lubbert et al., 2001).  A 
phase II study of 5-Aza-dC in CML, conducted prior to the approval of imatinib 
mesylate, also provided promising data (Kantarjian et al., 2003).  In this report 
complete hematologic responses were observed in blastic, accelerated, and chronic 
phase patients, and similar to the MDS study, the main side effect was 
myelosuppression.  Furthermore, in a very recent phase I study, Issa et al. evaluated 
low-dose prolonged exposure schedules of 5-Aza-dC in relapsed/refractory 
leukemias (Issa et al., 2004).  The drug was well tolerated in all patients, including 
those with AML/MDS, CML and ALL, and responses were seen at all dose levels.  
However, the authors report that fewer responses were seen when the dose was 
escalated or prolonged and concluded that although 5-Aza-dC is effective in 
myeloid malignancies, low doses are as or more effective than higher doses. 
 With increasing evidence of pre-clinical efficacy, the possibility of 
optimally combining 5-Aza-dC, or other DNMT inhibitors, with other drugs is 
inevitably being addressed.  Although DNMT and HDAC inhibitors act 
synergistically with respect to gene reactivation and growth inhibition in vitro, 
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clinical trials of such combinations have not yet been reported.  Furthermore, 
combination treatment including 5-Aza-dC and conventional chemotherapeutics, 
although still in development, may be effective in the treatment of various tumor 
types.  For example, 5-Aza-dC has recently been shown to act synergistically in 
vitro with imatinib mesylate in the treatment of resistant CML cell lines (La Rosee 
et al., 2004), underscoring the importance of developing novel therapy 
combinations and the difficulty in treating drug resistant tumors.  
 
1.4.4.2. Histone Deacetylase Inhibition 
 The biochemical structures of HDAC inhibitors are extremely 
heterogeneous, from simple structures, such as valproate, to more elaborate 
designs, such as the benzamide MS-275.  The very potent hydroxamic acid family, 
which includes one of the first HDAC inhibitors to be described, TSA (Fig. 1.10) 
(Yoshida et al., 1990), is the broadest class of HDAC inhibitor.  Among many other 
drugs developed in this class, one of the more common is suberoylanilide 
hydroxamic acid (SAHA) (Fig. 1.10).  Presently involved in phase I/II clinical 
trials, SAHA has recently been shown to induce the CDKI p21, like many other 
HDACs, in the human myeloma cell line ARP-1 (Gui et al., 2004).  This response 
was associated with increased histone acetylation, release of HDAC1, and 
increased DNase I sensitivity at the p21 promoter identifying, in part, a selective 
drug effect that supports cell growth inhibition.  Additional classes of HDAC 
inhibitors exist including, among others, short chain carboxylic acids, benzamides, 
and epoxides. 
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Figure 1.10 Chemical Structures of Common HDAC Inhibitors.  Illustrated are the 
chemical structures and names of some common HDAC inhibitors.  TSA and SAHA are 
hydroxamic acids and Butanoic Acid is a short chain fatty acid.  Structures were constructed 
using ChemSketch Version 5.12 software (Advanced Chemistry Development Inc., Toronto, 
ON, Canada). 
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The anticancer effects of HDAC inhibitors are believed to be mediated by 
reactivation of tumor suppressor gene expression in malignant cells.  However, 
many other secondary factors may also play an important indirect role by mediating 
differentiation, cell cycle arrest, and apoptosis (Villar-Garea and Esteller, 2004).  
As mentioned, treatment of cancer cell lines with HDAC inhibitors leads to an 
increase in global acetylated H3 and H4, which is generally associated with gene 
expression, however, several studies have revealed that the number of significantly 
repressed genes is similar to the number of upregulated transcripts (Glaser et al., 
2003), underscoring the complex relationship between chromatin structure, histone 
modification, and transcription.  Although most HDAC inhibitors act by similar 
mechanisms, blocking access of acetyl-lysine residues to the highly conserved 
HDAC catalytic pocket, these drugs have markedly different effects on the 
resulting gene expression patterns, even when treated on the same cell line (Glaser 
et al., 2003).  This behavior may be due in part to differences in drug specificity for 
the various HDACs.   
As previously mentioned, HDAC inhibitors act synergistically in vitro with 
demethylating agents, which was initially observed in colon cancer cell lines at 
hypermethylated tumor suppressor gene loci including the CDKI p16 (Cameron et 
al., 1999a), but have yet to be established together in published clinical trials.  
However, a host of HDAC inhibitors are currently undergoing phase I and II 
evaluation as monotherapy as well as in combination with other cytotoxics and 
differentiation agents (Kelly et al., 2002b).  For example, phenylbutyrate, a short 
chain fatty acid HDAC inhibitor (Fig. 1.10), has recently exhibited clinical 
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effectiveness with continuous infusion in both myeloid malignancies and solid 
tumors with the most common side effects being dyspepsia, fatigue, and nausea 
(Gilbert et al., 2001; Gore et al., 2002).   
This agent has also been examined in the M3 AML subtype APL, which 
accounts for approximately 10% of all AML patients (Table 1.1).  As mentioned, 
APL is characterized by the t(15;17) chromosomal translocation that involves the 
RARα gene on chromosome 17 and the exquisite sensitivity of APL blasts to the 
differentiating action of ATRA (Melnick and Licht, 1999).  ATRA accomplishes its 
therapeutic effect by triggering terminal differentiation of APL blasts into mature 
granulocytes, yet treatment often induces transient disease remission with 
inevitable relapse if remission is not consolidated with chemotherapy.  Based on 
the in vitro data which illustrates that the oncoprotein encoded by the fusion gene 
in APL suppresses gene transcription by the recruitment of a HDAC, APL patients 
refractory to ATRA have been treated with a combination of phenylbutyrate and 
ATRA (Warrell et al., 1998; Zhou et al., 2002a).  Phenylbutyrate induced 
accumulation of acetylated histones in the acute promyelocytic cells and restored 
ATRA sensitivity resulting in transient clinical improvement in 20% of patients 
(Zhou et al., 2002a).  Of the two phase I clinical trials using phenylbutyrate that 
have now been reported (Carducci et al., 2001; Gilbert et al., 2001), a biologically 
active dose was attained with minimal clinical and metabolic side effects and, 
although no partial or complete remissions were induced, one trial reported that 
25% of patients achieved disease stabilization for more than six months while on 
the drug (Gilbert et al., 2001). 
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Owing to the early success of HDAC inhibitors as anticancer agents, phase I 
and II studies utilizing phenylbutyrate and ATRA, phenylbutyrate and azacytidine, 
phenylbutyrate, dexamethasone and GM-CSF, plus other combinations 
incorporating other HDAC inhibitors are currently ongoing in a spectrum of human 
malignancies (Johnstone, 2002).  These drugs appear to be well tolerated at doses 
required to acetylate histones and achieve clinical outcomes, and their use in 
combination therapies is an exciting area that will likely be persued in the clinic. 
Taken together, these exciting in vitro and in vivo data illustrate the clinical 
potential of HDAC inhibitors for the treatment of leukemias and solid tumors.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 71
 
 
 
2. HYPOTHESIS AND SPECIFIC AIMS 
 
RATIONALE: Promoter hypermethylation mediated gene silencing is a frequent 
finding in many different types of human cancer (Esteller et al., 2001; Paz et al., 
2003).  The genes affected by epigenetic silencing are known to have important 
roles in cellular processes including tumor suppression, cell cycle regulation, 
apoptosis, DNA repair, and metastastic potential.  Furthermore, sites of altered 
DNA methylation constitute some of the most promising molecular markers for use 
in early cancer diagnosis, predicting cancer risk status, and monitoring prognosis. 
Understanding the mechanisms by which hypermethylation effects gene silencing 
should allow the design of future therapies that aim to improve clinical outcomes 
by restoring the expression of genes critical to cellular behavior.  It is also 
important to develop strategies to determine the spectrum of genes silenced by 
hypermethylation in specific cancer types in order to better understand the 
molecular pathogenesis of these diseases and develop improved diagnostic 
markers.  The work of several laboratories, including that of Dr. DeCoteau’s, have 
now identified a role for promoter hypermethylation in the pathogenesis of human 
leukemia and lymphoma (Scott et al., 2003; Scott et al., 2004; Toyota et al., 2001).  
The recent resurgence in the clinical use of pharmacological agents capable of 
reversing promoter methylation in the treatment of myeloid malignancies 
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underscores the importance of epigenetics to malignant myeloid biology. The 
availability of these agents also provides opportunities to manipulate relevant in 
vitro models to gain insight into the mechanisms by which hypermethylation 
mediates gene silencing and to identify the spectrum of genes silenced by this 
mechanism in these aggressively growing hematopoietic cancers.  Taken together, 
these observations constitute the basis for both the general hypotheses and specific 
aims of this thesis, which are detailed below. 
 
HYPOTHESES: In acute myeloid leukemia (AML), aberrantly methylated 
promoter alleles of tumor suppressor genes are associated with histone 
modifications that confer a transcriptionally repressive chromatin 
conformation.  For some tumor suppressor genes, pharmacological inhibition 
of DNA methylation leads to a reversal of transcriptionally repressive histone 
modifications and the restoration of gene expression. 
 
SPECIFIC AIM ONE: To investigate the relationship between aberrant promoter 
hypermethylation, histone modifications, and tumor suppressor gene silencing in a 
cell line model of relevance to the in vivo pathogenesis of AML.  (Experiments 
pertaining to this AIM are outlined in Sections 4.1 and 4.2.)   
 
SPECIFIC AIM TWO: To determine if zebularine, a novel DNA methylation 
inhibitor, can restore expression of a tumor suppressor gene by a mechanism 
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involving promoter demethylation and histone modification in a cell line model of 
AML.  (Experiments pertaining to this AIM are outlined in Section 4.3.)   
 
SPECIFIC AIM THREE: To use pharmacological inhibition of DNA methylation 
to discover novel genes silenced by promoter hypermethylation in AML.  
(Experiments pertaining to this AIM are outlined in Section 4.4.) 
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3. MATERIALS AND METHODS 
 
3.1 Reagents and Suppliers   
 The reagents used for experiments in this thesis were all molecular biology 
or reagent grade and are listed in Table 3.1.  Several of the procedures used in this 
study were performed using commercially available kits, which are listed in Table 
3.2.  Table 3.3 lists the companies from which all reagents and kits were obtained.   
 
Table 3.1 Reagents and Suppliers Used in This Study 
Reagent Supplier Name 
[3H]-thymidine (42 Ci/mmol; 1.55 TBq/mmol) Amersham Biotech 
[α32P]-dCTP (800 Ci/mmol; 29.6 TBq/mmol) Perkin Elmer 
[α32P]-UTP (3000 Ci/mmol; 111 TBq/mmol) Amersham Biotech 
β-mercaptoethanol Sigma 
5-aza-2’-deoxycytidine Sigma 
acetic acid BDH 
agarose Invitrogen Life Technologies 
ammonium acetate EMD Chemicals 
ampicillin Fisher 
aprotinin Sigma 
APS Invitrogen Life Technologies 
bacto-agar Invitrogen Life Technologies 
bacto-tryptone Difco Laboratories 
bacto-yeast extract Difco Laboratories 
borate BDH 
Bradford protein reagent Bio-Rad 
bromophenol blue BDH 
calf thymus DNA Sigma 
Coomassie Brilliant Blue R-250 Bio-Rad 
CpGenome universally methylated DNA  Chemicon 
Cyanine 3-dCTP NEN Life Science 
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Cyanine 5-dCTP NEN Life Science 
dATP Fermentas 
dCTP Fermentas 
dGTP Fermentas 
DIG Easy Hyb solution Roche 
dNTP Mix Fermentas 
DTT Invitrogen Life Technologies 
dTTP Fermentas 
EDTA EMD Chemicals 
ethidium bromide Invitrogen Life Technologies 
fetal bovine serum HyClone 
Ficoll-Paque PLUS Amersham Biotech 
formaldehyde BDH 
formamide BDH 
GeneRuler 100 bp DNA ladder Fermentas 
glycerol Invitrogen Life Technologies 
glycine EMD Chemicals 
GlycoBlue coprecipitant Ambion 
HCl EMD Chemicals 
HEPES BDH 
HotStarTaq Polymerase Qiagen 
Hybond-N+ nylon membrane Amersham Biotech  
Hybri-slips Sigma 
hydroquinone BDH 
Hyperfilm MP Amersham Biotech 
IMDM Invitrogen Life Technologies 
isopropanol EMD Chemicals 
KCl Sigma 
magnesium acetate Sigma 
methanol BDH 
MgCl2 BDH 
MOPS Sigma 
MTT Sigma 
N,N-methylene-bis-acrylamide Invitrogen Life Technologies 
NaCl BDH 
NaOH BDH 
non-fat dry milk Carnation 
NP-40 Sigma 
nuclease-free water Ambion 
penicillin/streptomycin 100X mix Invitrogen Life Technologies 
pepstatin A Sigma 
phenol:chloroform:isoamyl alcohol (25:24:1) Ambion 
PMSF Sigma 
polyacrylamide Invitrogen Life Technologies 
polyethylene glycol-8000 EMD Chemicals 
prestained protein molecular weight markers Fermentas 
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propidium iodide Sigma 
proteinase K Qiagen 
REDTaq DNA Polymerase  Sigma 
rhGM-CSF R&D Systems 
rhIL-3 R&D Systems 
RNase Worthington 
RNasin Promega 
RPMI-1640 Invitrogen Life Technologies 
rTdT Invitrogen Life Technologies 
SDS BDH 
sodium acetate BDH 
sodium azide Sigma 
sodium bicarbonate BDH 
sodium bisulfite Sigma 
sodium citrate BDH 
sodium deoxycholate Sigma 
sodium fluoride BDH 
sodium orthovanadate Sigma 
sodium pyruvate Sigma 
TEMED  EMD Chemicals 
Trans-Blot nitrocellulose Bio-Rad 
trichostatin A Sigma 
Tris EMD Chemicals 
Triton X-100 Sigma 
TRIzol Invitrogen Life Technologies 
Trypan Blue Invitrogen Life Technologies 
urea EMD Chemicals 
yeast tRNA Invitrogen Life Technologies 
zebularine Calbiochem 
 
 
 
Table 3.2 Commercially Available Kits Used in This Study 
Commercially Used Kits Company 
Chromatin Immunoprecipitation Assay kit Upstate Biotechnology 
Immun-Star HRP Chemiluminescent kit Bio-Rad 
In Vitro Transcription kit BD Biosciences 
M-MLV RT system Promega 
QIAprep Miniprep kit Qiagen 
QIAquick Gel Extraction kit Qiagen 
QIAquick PCR Purification kit Qiagen 
RNase-Free DNase set Qiagen 
RNeasy Mini kit Qiagen 
RPA kit BD Biosciences 
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Superscript RT system Invitrogen Life Technologies 
TOPO TA Cloning kit Invitrogen Life Technologies 
Wizard DNA Clean-up kit Promega 
 
 
Table 3.3 Names and Addresses of Suppliers 
Supplier Address 
Abcam Abcam Ltd., Cambridge, UK 
Ambion Ambion, Inc., Austin, Texas, USA 
Amersham Biotech Amersham Biotech, Inc., Baie d’Urfe, Canada 
BD Biosciences BD Biosciences, Mississauga, Canada 
BDH BDH Inc., Toronto, Canada 
Bio-Rad Bio-Rad Laboratories, Ltd., Mississauga, Canada 
Calbiochem EMD Biosciences, La Jolla, CA, USA 
Chemicon Serologicals Corp., Norcross, GA, USA 
Difco Laboratories Difco Laboratories, Detroit, MI, USA 
DSMZ DSMZ, Braunschweig, Germany 
EMD Chemicals EMD Biosciences, La Jolla, CA, USA 
Fermentas Fermentas Canada, Burlington, Canada 
Fisher Fisher Scientific Ltd., Nepean, Canada 
HyClone HyClone Laboratories, Logan, UT, USA 
Invitrogen Life 
Technologies Invitrogen Life Technologies, Burlington, Canada 
Millipore Millipore Ltd., Nepean, Canada 
NEN Life Science DuPont NEN Research Products, Boston, MA, USA 
Perkin Elmer Perkin Elmer Inc., Wellesley, MA, USA 
Promega Promega Corporation, Madison, WI, USA 
Qiagen Qiagen, Mississauga, Ontario, Canada 
R&D Systems R&D Systems Inc., Minneapolis, MN, USA 
Roche Diagnostics Roche, Indianapolis, IN, USA 
Santa Cruz 
Biotechnology Santa Cruz Biotechnology, Santa Cruz, CA, USA 
Sigma Sigma-Aldrich, St. Louis, MO, USA 
Upstate Biotechnology Upstate Biotechnology, Lake Placid, NY, USA 
Worthington 
Biochemical  
Worthington Biochemical Corp., Lakewood, NJ, 
USA 
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3.2 Oligonucleotides 
 Table 3.4 lists all the primers and probes used for experiments in this study 
with their optimal annealing or hybridization temperatures listed.  All 
oligonucleotides were purchased from Invitrogen.   
 
Table 3.4 Sequences and Optimal Annealing/Hybridization Temperatures of 
Primers and Probes Used in This Study 
Namea Sequenceb Temp. 
p15-RTPCR-F 5'-ATGCGCGAGGAGAACAAGGG-3' 
p15-RTPCR-R 5'-GTACCCTGCAACGTCGCGGT-3' 
63.8ºC 
Actin-RTPCR-F 5'-CCAAGGCCAACCGCGAGAAGAT-3' 
Actin-RTPCR-R 5'-TTGCTCGAAGTCCAGGGCGA-3' 
61.3ºC 
p15-MSP-U-F 5'-TGTGATGTGTTTGTATTTTGTGGTT-3' 
p15-MSP-U-R 5'-CCATACAATAACCAAACAACCAA-3' 
60.0ºC 
 
p15-MSP-M-F 5'-GCGTTCGTATTTTGCGGTT-3' 
p15-MSP-M-R 5'-CGTACAATAACCGAACGACCGA-3' 
60.0ºC 
p15-TTGE-F 5'-TGGTTTTTTATTTTGTTAGA-3' 
p15-TTGE-R 5'-[gcgcgcgcgcgc]-ACACTCTTCCCTTCTTTCCC-3' 
52.0ºC 
p15-TTGE-probe 5'-AGGGTAATGAAGTTGAGTTT-3' 40.5ºC 
p21-MSP-U-F 5'-GGTGGTGTGGTGGGTTGAGT-3' 
p21-MSP-U-R 5'-ACAAATCCACACCCAACTCC-3' 
62.0ºC 
p21-MSP-M-F 5'-TTTCGGGGAGGGCGGTTTCGGGCGGCGCGG-3' 
p21-MSP-M-R 5'-CGATACCTCGACGAATCCGC-3' 
67.0ºC 
p21-TTGE-F 5'-AAAGTTAGATTTGTGGTTTATT-3' 
p21-TTGE-R 5'-[gcgcgcgcgcgcgcgcgcgc]-CTCTCACCTCCTCTAAATACCT-3' 
51.0ºC 
p21-TTGE-probe 5'-GGGTAGTTAGGAGTTTGGGT-3' 44.0ºC 
p27-MSP-U-F 5'-GAGATTTGGTGGTTGGGTTG-3' 60.0ºC 
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p27-MSP-U-R 5'-ACACAACCACCTCTCTCACA-3' 
p27-MSP-M-F 5'-TTAGCGGAGATTCGGCGGTC-3' 
p27-MSP-M-R 5'-CGAATCTACACGACCGCCTC-3' 
58.0ºC 
p27-TTGE-F 5'-GGGTTTGTGTTTTTTGGTTT-3' 
p27-TTGE-R 5'-[gcgcgcgcgcgcgcgc]-TACAATACTTCTCCAAATCC-3' 
52.5ºC 
p27-TTGE-probe 5'-GGGAGTTTTAGTTTGGAG-3' 39.0ºC 
p15-ChIP-F 5'-GCAGGCTTCCCCGCCCTCGTGACGC-3' 
p15-ChIP-R 5'-ATTACCCTCCCGTCGTCCTTCTGC-3' 
64.6ºC 
MT1H-RTPCR-F 5'-AAATGCACCTCCTGCAAGAAGAGCTGCTG-3' 
MT1H-RTPCR-R 5'-AGGAATGTAGCAAATGAGTCGGAGTTGTAG-3' 
62.5ºC 
MT1G-RTPCR-F 5'-ACCCACTGCCTCTTCCCTT-3' 
MT1G-RTPCR-R 5'-TTGTACTTGGGAGCAGGG-3' 
57.0ºC 
SAT-RTPCR-F 5'-CACCTCCTCCTACTGTTC-3' 
SAT-RTPCR-R 5'-GATCAGAAGCACCTCTTC-3' 
52.0ºC 
MT1E-RTPCR-F 5'-CTCCTGCAAGTGCAAAGAGTGCAA-3' 
MT1E-RTPCR-R 5'-GGCACAGCTCTGTTCTGAAACCAT-3' 
55.0ºC 
IFI30-RTPCR-F 5'-CCTGGTTAAAGGCGCTTA-3' 
IFI30-RTPCR-R 5'-TGGTCAGGAAGGCTAGCT-3' 
57.0ºC 
GPX4-RTPCR-F 5'-CCTTTGCCGCCTACAGCC-3' 
GPX4-RTPCR-R 5'-TCTCTATCACCAGGGGCT-3' 
57.0ºC 
MT2A-RTPCR-F 5'-CGTGCAACCTGTCCCGACTCTA-3' 
MT2A-RTPCR-R 5'-AACGGTCACGGTCAGGGTT-3' 
58.6ºC 
MT1H-MSP-U-F 5'-TTTTGGGGTATGTGGAATGTTA-3' 
MT1H-MSP-U-R 5'-CACTAAATCCAAACCACCCACA-3' 
52.0ºC 
MT1H-MSP-M-F 5'-TTTCGGGGTACGCGGAACGTTA-3' 
MT1H-MSP-M-R 5'-CTAAATCCGAACCGCCCGCGAT-3' 
57.0ºC 
MT1G-MSP-U-F 5'-TTTGTGAGTTGGTGTGAAAGGG-3' 
MT1G-MSP-U-R 5'-AACCAAACACAAACACCCCACC-3' 
52.0ºC 
MT1G-MSP-M-F 5'-GAGTCGGTGCGAAAGGGGTCGTTT-3' 57.0ºC 
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MT1G-MSP-M-R 5'-AACGAAACCGAACGCAAACGCC-3'  
SAT-MSP-U-F 5'-GAGGTTTTATTTTATGGTTTGAGGT-3' 
SAT-MSP-U-R 5'-AAATAACAAATAAACACCAATCAAC-3' 
51.0ºC 
SAT-MSP-M-F 5'-GTTTTATTTTACGGTTCGAGGC-3' 
SAT-MSP-M-R 5'-GAATAACGAATAAACACCAATCGA-3' 
55.0ºC 
MT1E-MSP-U-F 5'-GGGTGGAGATGTTTGTGATGTT-3' 
MT1E-MSP-U-R 5'-CCACAAAAAAACCAAACACACC-3' 
52.0ºC 
MT1E-MSP-M-F 5'-GTTCGCGACGTTAAGGTTGGGGTT-3' 
MT1E-MSP-M-R 5'-ACGAAAATCGAACCGAACGCAA-3' 
57.0ºC 
IFI30-MSP-U-F 5'-TGTATTTTGTATTTGAGAGGTGT-3' 
IFI30-MSP-U-R 5'-TCACTAAAACAATAAACAAATCACT-3' 
55.0ºC 
IFI30-MSP-M-F 5'-TTCGTATTTCGTATTTGAGAGGC-3' 
IFI30-MSP-M-R 5'-GCTAAAACGATAAACAAATCGCT-3' 
55.0ºC 
GPX4-MSP-U-F 5'-AGATATAAGTGAGTATGTGTAGTTGT-3' 
GPX4-MSP-U-R 5'-TCATTAATCAAACACATCAATATTAAACAC-3' 
55.0ºC 
GPX4-MSP-M-F 5'-TAGATATAAGCGAGTATGCGTAGTC-3' 
GPX4-MSP-M-R 5'-AAACGCGTCGATATTAAACG-3' 
55.0ºC 
MT2A-MSP-U-F 5'-GTGTGTTAATGGTTTAGGTTTG-3' 
MT2A -MSP-U-R 5'-CCACACTAAATCACTTACAACT-3' 
50.0ºC 
MT2A -MSP-M-F 5'-TTCGCGCGTTAACGGTTTAGGT-3' 
MT2A -MSP-M-R 5'-GCACTAAACCGAACGCACCCGA-3' 
57.0ºC 
MT1H-ChIP-F 5'-CCAAAGGGCGGGAGTAGCAGGTAA-3' 
MT1H-ChIP-R 5'-CGCAACAGTTGGCAGCTCCTTT-3' 
57.0ºC 
 
a F: forward (sense) primers; R: reverse (antisense) primers; U: MSP primers specific for bisulfite 
modified, unmethylated DNA; M: MSP primers specific for bisulfite modified, methylated DNA. 
b MSP primer sets were designed to distinguish methylated from unmethylated DNA following 
bisulfite modification. Sequence differences between primers and unmodified DNA are in boldface 
type and potential sites of sense strand cytosine methylation within CpG dinucleotides are 
underlined.  
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3.3 Antibodies 
 Table 3.5 lists all the primary and secondary antibodies used for 
experiments in this study and the supplier from which they were purchased.   
 
Table 3.5 Antibodies Used in This Study 
Antibody  Supplier 
anti-Actin Santa Cruz 
anti-HDAC1 Upstate Biotechnology 
anti-histone H2A.X-phospho-S139 Upstate Biotechnology 
anti-histone H2B Upstate Biotechnology 
anti-histone H2B-phospho-S14 Upstate Biotechnology 
anti-histone H3 Upstate Biotechnology 
anti-histone H3-acetyl-K9/K14 Upstate Biotechnology 
anti-histone H3-acetyl-K18 Upstate Biotechnology 
anti-histone H3-acetyl-K23 Upstate Biotechnology 
anti-histone H3-dimethyl-K4 Upstate Biotechnology 
anti-histone H3-dimethyl-K9 Upstate Biotechnology 
anti-histone H3-dimethyl-R17 Upstate Biotechnology 
anti-histone H3-phospho-S10 Upstate Biotechnology 
anti-histone H4-acetyl-K5/8/12/16 Upstate Biotechnology 
anti-MeCP2 Upstate Biotechnology 
anti-SUV39h1 Upstate Biotechnology 
HRP conjugated Bovine anti-Goat IgG Santa Cruz 
HRP conjugated Goat anti-Mouse IgG Bio-Rad 
HRP conjugated Goat anti-Rabbit IgG Bio-Rad 
 
 
3.4. Patient Specimens 
AML patient and control samples were obtained from an established bank 
of marrow aspirate and peripheral blood specimens at the University of 
Saskatchewan.  Sample collection, banking and study were performed according to 
guidelines approved by the University of Saskatchewan ethics review board.  DNA 
and RNA were extracted from banked samples of marrow aspirate (n = 23) or 
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peripheral blood (n = 17) obtained from 21 adult AML patients (ages 22 - 86) at 
diagnosis (n = 36) or first relapse (n = 4).  Banked samples were prepared by 
isolating cells from fresh bone marrow aspirate or peripheral blood specimens by 
Ficoll Paque (Amersham Biosciences) density centrifugation, followed by 
cryopreservation in DMSO.  All samples were required to fulfill the following 
criteria for banking: i) the blast cell population accounted for >75% of all nucleated 
cells in the aspirate or peripheral blood sample prior to Ficoll Paque density 
centrifugation and ii) the sample contained at least 5 x 107 nucleated cells with a 
cellular viability >90% (as assessed by Trypan Blue dye exclusion) following 
Ficoll Paque separation.  The patients included the following FAB subtypes: M0 (n 
= 3), M1 (n = 10), M2 (n = 13), M4 (n = 10), M5a (n = 1), M5b (n = 1) and M6 (n 
= 2) as assessed by light microscopy, cytochemical stains and multiparameter flow 
cytometry at diagnosis.  Control DNA samples were randomly selected from a bank 
maintained at the University of Saskatchewan, Saskatoon, SK, Canada.  The source 
of these DNA samples was peripheral blood mononuclear cells from adults who 
had been investigated for Factor V Leiden and found to be negative (n = 13). 
 
3.5. Cell Lines and Tissue Culture 
3.5.1. Cell Lines and Standard Culture Conditions 
Human AML cell lines HL60, KG1, KG1A, AML193, THP1, HEL and 
K562 were purchased from the German Collection of Microorganisms and Cell 
Cultures (DSMZ) and are characterized in Table 3.6.  HL60, KG1, KG1A and 
AML193 were cultured in IMDM media and 20% (v/v) fetal bovine serum (FBS, 
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HyClone); AML193 culture was supplemented with 2 ng/ml GM-CSF and 3 
units/ml IL-3 (R&D Systems).  THP1, HEL and K562 were grown in complete 
RPMI-1640 media with 10% (v/v) FBS; THP1 and HEL cultures were 
supplemented with 1.0 mM sodium pyruvate (Sigma).  All cultures contained 1% 
(v/v) penicillin/streptomycin solution (Invitrogen) and were maintained at 37oC and 
5% CO2.  Tissue culture media was obtained from Invitrogen. 
 
Table 3.6 Cell Lines Used in This Study 
Cell Line Leukemiaa Referenceb 
HL60 AML (M2) Dalton et al., 1988. 
KG1 AML (M6) Koeffler and Golde, 1978. 
KG1A AML (M6) Koeffler et al., 1980. 
AML193 AML (M5) Lange et al., 1987. 
THP1 AML (M5) Tsuchiya et al., 1982. 
HEL AML (M6) Martin and Papayannopoulou, 1982. 
K562 CML (BP)* Lozzio et al., 1981. 
 
a Type of leukemia for each cell line is noted with FAB classification in brackets.  The asterisk (*) 
denotes blast phase (BP), a WHO classification.  
b Reference for original establishment of cell line or that which is most relevant.  
 
 
3.5.2. DNA Methylation Inhibitor Treatments 
 For DNMT inhibitor studies, cells were treated with 4 µM 5-Aza-dC 
(Sigma) in a time course assay with cell harvesting every 12 hours for four days.  
For chromatin immunoprecipitation studies, cells were typically treated with 4 µM 
5-Aza-dC for 72 hours prior to harvesting as per the chromatin 
immunoprecipitation protocol.  A zebularine (Calbiochem) dose response assay 
was performed that incorporated 2 to 500 µM of drug treated for 72 hours.  Other 
concentrations of 5-Aza-dC and zebularine treatment are noted in the appropriate 
 84
figure(s) and an equivalent volume of 1X PBS was routinely used as a vehicle 
control. 
 
3.5.3. Histone Deacetylase Inhibitor Treatments 
For HDAC inhibitor studies, cells were treated with 1 µM TSA (Sigma) for 
12 hours.  When TSA was administered in combination with DNMT inhibitors, it 
was typically treated for the final 12 hours of the 72 hour DNMT inhibition culture 
period, as noted above.  An equivalent volume of ethanol was routinely used as a 
vehicle control. 
 
3.6. General Molecular Techniques 
3.6.1. Agarose Gel Electrophoresis 
3.6.1.1. Standard Agarose Gel Electrophoresis 
Sample loading buffer consisted of 0.015% (w/v) bromophenol blue, 10% 
(v/v) glycerol, and 10 mM ethylenediamine tetra-acetic acid (EDTA).  Standard 
DNA fragment gel electrophoresis was typically performed in 2% (w/v) agarose 
gels in either 1X TAE (40 mM Tris, 20 mM acetic acid, 1 mM EDTA, pH 8.0) or 
1X TBE (90 mM Tris, 90 mM borate, 1 mM EDTA, pH 8.3) buffers containing 0.5 
µg/ml ethidium bromide and run between 90 and 110 volts for the appropriate 
amount of time required for optimal resolution.  Gels were visualized under 
ultraviolet light and either photographed or digitally captured using a gel 
documentation system (Bio-Rad).   
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3.6.1.2. Formaldehyde Agarose Gel Electrophoresis 
 Total RNA samples were routinely checked for ribosomal integrity by 
formaldehyde agarose gel electrophoresis.  Sample loading buffer consisted of 1X 
MOPS [3-(N-morpholino) propane sulfonic acid], 1.3 mM EDTA, 50% formamide, 
18% formaldehyde, 0.015% (w/v) bromophenol blue, 5% (v/v) glycerol, and 0.5 
µg/µl ethidium bromide.  Samples were prepared for electrophoresis by heating 2 
µg of total RNA in two volumes of loading buffer to 70oC for 10 min followed by 
placement on ice.  When cooled, the samples were loaded and run on 1% (w/v) 
agarose/16% (v/v) formaldehyde gels using 1X MOPS as running buffer at 
approximately 90 volts for 45 min or until the desired resolution was achieved.  
Gels were visualized under ultraviolet light and either photographed or digitally 
captured using a gel documentation system (Bio-Rad).   
 
3.6.2. Generation of 3’ End Labeled Oligonucleotide Probes   
 Terminal deoxynucleotidyl transferase (TdT) is an enzyme that catalyzes 
the repetitive addition of mononucleotides from deoxynucleotide triphosphates 
(dNTPs) to the terminal 3´-OH of a DNA initiator, accompanied by the release of 
inorganic phosphate.  End labeled probes were generated by combining 2 pmol of 
target oligonucleotide (Table 3.4.), 1X TdT buffer [200 mM potassium cacodylate, 
25 mM Tris, 0.01% (v/v) Triton X-100, 1 mM CoCl2, pH 7.2], approximately 15 
µCi (555 kBq) [α32P]-deoxycytidine-5'-triphosphate (dCTP; Perkin Elmer), and 40 
units of rTdT enzyme (Invitrogen), and incubated at 37oC for 30 min.  The reaction 
was stopped by heating at 70oC for 10 min and the radiolabeled probe was added 
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directly to hybridization solution [10% (w/v) polyethylene glycol-8000, 1% (v/v) 
sodium dodecyl sulfate (SDS), 5X sodium chloride/sodium citrate (SSC) buffer]. 
 
3.6.3. Small Scale Isolation of Plasmid DNA from Bacterial Cells 
 Isolation and purification of plasmid DNA from bacterial cells for 
sequencing was prepared using the QIAprep Miniprep kit (Qiagen).  The procedure 
was followed according to the manufacturer's instructions, which typically yielded 
approximately 5 µg of plasmid DNA per ml of bacterial culture, and samples were 
stored at -20oC until needed. 
 
3.6.4. Isolation of Total RNA from Eukaryotic Cells 
 Total RNA was isolated using TRIzol (Invitrogen) which is a modification 
of the method described by Chomczynski and Sacchi (Chomczynski and Sacchi, 
1987).  The procedure was followed according to the manufacturer’s instructions, 
which typically yielded approximately 50 µg of total RNA per 107 starting cells.  
RNA pellets were dissolved in nuclease-free water (Ambion) and concentration and 
purity was determined by standard A260/A280 spectrophotometric reading.  Samples 
were stored at -80oC until needed. 
 
3.6.5. Isolation of DNA from Eukaryotic Cells 
 Genomic DNA was isolated using TRIzol (Invitrogen) and the procedure 
was followed according to the manufacturer’s instructions, which typically yielded 
80 - 100 µg of genomic DNA per 107 starting cells.  DNA pellets were dissolved in 
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8 mM NaOH and adjusted to approximately pH 8.4 with 0.1 M HEPES (N-2-
hydroxyethylpiperazine-N'-2-ethanesulfonic acid) buffer.  Concentration and purity 
was determined by standard A260/A280 spectrophotometric reading and samples 
were stored at -20oC until needed. 
 
3.6.6. Isolation of Protein Lysates from Eukaryotic Cells 
 Protein cell lysates were harvested using radioimmunoprecipitation (RIPA) 
buffer [50 mM Tris-HCl, pH 7.4, 1% (v/v) NP-40, 0.25% (w/v) sodium 
deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride 
(PMSF), 1 µg/ml aprotinin, 1 µg/ml pepstatin A, 1 mM sodium orthovanadate, 1 
mM sodium fluoride].  Briefly, cells were washed twice in ice cold 1X PBS and 
cell pellets were resuspended in ice cold RIPA buffer (0.5 ml per 107 cells) and 
incubated on ice for 15 min.  Samples were centrifuged at 4oC for 15 min at 12000 
x g, supernatants transferred to new tubes, and protein concentration was 
determined by the Bradford assay as per the manufacturer’s instructions (Bio-Rad).  
The procedure typically yielded approximately 200 µg of protein per 107 starting 
cells and samples were stored at -80oC until needed. 
 
3.6.7. Isolation of Histone Proteins from Cultured Eukaryotic Cells 
 Protein cell lysates enriched for nuclear histones were harvested essentially 
as described elsewhere (Nguyen et al., 2002).  Briefly, cell pellets were lysed in an 
isolation buffer consisting of 10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 
0.5 mM dithiothreitol (DTT), 1.5 mM PMSF, and 0.2 M HCl (added immediately 
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prior to incubation).  Following incubation on ice for 30 min and centrifugation at 
4oC for 15 min at 12000 x g, the supernatant was buffer exchanged with twenty 
volumes of the above isolation buffer (without HCl) and concentrated using 
Amicon centrifugal filtration units with a nominal molecular weight limit of 10 
KDa (Millipore).  Protein concentration was determined by the Bradford assay as 
per the manufacturer’s instructions (Bio-Rad) and samples were stored at -80oC 
until needed. 
 
3.7. Reverse Transcriptase PCR (RTPCR) 
 Total RNA was used as a template for the synthesis of cDNA using the 
Moloney murine leukemia virus reverse transcriptase (M-MLV-RT) system 
according to the manufacturer’s instructions (Promega).  Briefly, 2 µg of total RNA 
was added to a mix containing 1X M-MLV-RT buffer (50 mM Tris-HCl, pH 8.3, 
75 mM KCl, 3 mM MgCl2), 10 mM DTT, 1.25 mM of each dNTP, 500 ng random 
hexamers (Fermentas), 20 units of RNasin (Promega), and 200 units of M-MLV-
RT in a final volume of 20 µl.  Synthesis of cDNA was completed by incubation at 
37°C for one hour and samples used immediately or stored at -20 oC. 
PCR was performed in a final volume of 30 µl containing 1.0 µl of cDNA 
template, 1x REDTaq PCR Reaction Buffer (Sigma), 2.5 mM MgCl2, 0.4 mM of 
each dNTP, 0.2 µM of each primer, and 1.5 units of REDTaq DNA Polymerase 
(Sigma). The amplification consisted of an initial denaturation step at 95°C for 3 
min followed by 30 amplification cycles (94°C for 45 sec, annealing temperature 
for 45 sec, and 72°C for 1 min) and a final incubation at 72°C for 10 min.  Primer 
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sequences and annealing temperatures are indicated in Table 3.4.  Following 
amplification, 10 µl of individual PCR products were visualized by standard 
agarose gel electrophoresis without the addition of bromophenol blue loading 
buffer.  Semiquantitation of target gene mRNA was analyzed by densitometry 
using Quantity One imaging software (Bio-Rad) of the appropriately sized RTPCR 
product normalized to that of the corresponding samples β-Actin housekeeping 
gene RTPCR product.  Differences in target gene mRNA following drug treatment 
were calculated by dividing the target genes’ drug treated normalized value by the 
untreated control normalized value and articulated numerically as ‘fold change’.   
 
3.8. RNase Protection Assay (RPA) 
 RPA was carried out with the BD RiboQuant RPA system (BD 
Biosciences) according to the manufacturer’s instructions using a probe set with 
templates of distinct length for the CDKIs p21 and p27, and for the ubiquitously 
expressed housekeeping genes L32 and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH).  Briefly, synthesis of high-specific activity [α32P]-uridine triphosphate 
(UTP; Amersham) labeled antisense RNA probes was accomplished using T7 
polymerase and the probes were hybridized in excess to 10 µg of total RNA 
isolated from patient samples and cell lines.  Following this, free probe and other 
single-stranded RNA species were digested with RNase and the remaining RNase-
protected probes were purified, resolved by denaturing polyacrylamide gel 
electrophoresis [4.75% (v/v)  acrylamide:N,N'-methylene-bis-acrylamide (19:1), 8 
M urea] in 0.5X TBE running buffer, and visualized by autoradiography using 
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Hyperfilm MP (Amersham).  The intensity of appropriately-sized, protected probe 
fragments corresponding to L32 and GAPDH gene transcripts was used to ensure 
equivalent RNA loading among the different samples. 
 
3.9. DNA Methylation Analysis 
3.9.1. Sodium Bisulfite Treatment of Genomic DNA 
 Genomic DNA was treated with sodium bisulfite reagent which converts 
unmethylated cytosine residues to uracil, and eventually thymidine following PCR, 
for downstream methylation analysis essentially as described elsewhere (Herman et 
al., 1996a; Tao et al., 2002).  Briefly, 10 µg of DNA was incubated at 37°C for 15 
min in 0.3 N NaOH.  Samples were then mixed with 2.2 M sodium bisulfite/0.5 
mM hydroquinone reagent (pH 5.0) and incubated at 55°C in the dark for 6 - 8 
hours.  Following incubation, modified DNA was purified using a Wizard DNA 
Clean-up column (Promega) as per the manufacturer’s instructions and eluted in 45 
µl of pre-warmed nuclease-free water (Ambion).  Modification was completed by 
desulfonation with 0.3 N NaOH at 37°C for 15 min and precipitation with 3 M 
ammonium acetate and overnight ethanol incubation at -20°C.  Modified DNA 
pellets were washed with 75% (v/v) ethanol, resuspended in 50 µl of water, and 
used immediately or stored at -20°C until needed. 
 
3.9.2. Methylation Specific PCR (MSP) 
 DNA methylation within promoter associated CpG islands was determined 
by MSP following sodium bisulfite treatment of genomic DNA as above.  PCR was 
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performed in a final volume of 40 µl containing 100 - 200 ng of bisulfite-treated 
DNA, 1x Qiagen PCR Buffer, 1.5 - 3.5 mM MgCl2, 0.4 mM of each dNTP, 0.2 µM 
of each primer set, and 0.2 units of HotStar Taq (Qiagen).  The amplification 
consisted of a Taq activation step at 95°C for 15 min followed by 35 amplification 
cycles (94°C for 1 min, annealing temperature for 1 min, and 72°C for 1.5 min) and 
a final incubation at 72°C for 10 min.  The 5’ CpG islands were identified using the 
online ‘CpG Island Searcher’ tool (Takai and Jones, 2003) and appropriate primers 
were designed near the target genes major transcriptional start site using Vector 
NTI software (Invitrogen) or the online ‘MethPrimer’ tool (Li and Dahiya, 2002). 
The primer sequences and optimal annealing temperatures are listed in Table 3.4.  
CpGenome universally methylated DNA (Chemicon), following bisulfite 
modification, served as the methylated MSP positive control. 
 
3.9.3. Temporal Temperature Gradient Gel Electrophoresis (TTGE) 
CpG island hypermethylation within target gene promoters was also 
determined by TTGE.  In this analysis, bisulfite-treated DNA is amplified with 
gene specific primers that amplify both unmethylated and methylated promoter 
sequences concurrently.  Differentially methylated sequences within the PCR 
product are then resolved according to differences in melting temperatures 
(Guldberg et al., 2002).  WinMelt software (Bio-Rad) was used to generate the 
melting profiles of unmethylated and methylated CpG promoter sequences.  Vector 
NTI software (Invitrogen) was used to select primers specific for bisulfite-treated 
DNA to amplify regions within the CpG islands of target genes near transcriptional 
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starting sites.  In order to minimize amplification of genomic sequences not 
converted by bisulfite treatment and to avoid biased amplification of methylated 
alleles, primers were designed to contain the maximum number of uracils 
converted from cytosines and to lack CpG dinucleotides.  5’-GC-clamps were 
attached to all reverse primers to enhance separation of unmethylated and 
methylated alleles by TTGE and primer sequences and optimal annealing 
temperatures are listed in Table 3.4.  PCR was performed in a final volume of 40 µl 
containing 100 - 200 ng of bisulfite-treated DNA, 1x Qiagen PCR Buffer, 3.5 mM 
MgCl2, 0.4 mM of each dNTP, 0.2 µM of each primer set, and 0.2 units of HotStar 
Taq (Qiagen).  The PCR reactions consisted of an initial Taq activation step of 15 
min at 95°C, followed by 35 amplification cycles (94°C for 1 min, annealing 
temperature for 1 min, and 72°C for 1.5 min) and a final incubation at 72°C for 10 
min.   
PCR products were electrophoresed in polyacrylamide gels [p15: 8%; p21: 
6%; p27: 6% (v/v) acrylamide:N,N'-methylene-bis-acrylamide (37.5:1)] containing 
urea (p15: 6 M; p21: 7 M; p27: 6 M), 1.25X TAE, and 0.1% (v/v) ammonium 
persulfate (APS).   Gels were polymerized by the addition of 0.04% (v/v) N,N,N,N-
tetramethyl-ethylenediamine (TEMED) and run at 130 volts in 1.25X TAE buffer 
over a specific temperature range (p15: 53 - 63°C; p21: 52 - 64°C; p27: 56 - 66°C) 
and at a specific temperature ramp rate (p15: 2.0°C/hour; p21: 1.5°C/hour; p27: 
1.7°C/hour) using a DCODE temperature controlling vertical gel apparatus (Bio-
Rad).  Gels were then transferred and fixed to nylon membranes (Amersham), 
hybridized overnight to [α32P]-dCTP labeled oligonucleotide probes (see Section 
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3.5.2 and Table 3.4) specific for the target gene and the resulting differentially 
methylated PCR products visualized by autoradiography using Hyperfilm MP 
(Amersham).  Plasmids containing representative unmethylated or methylated 
sequences were constructed from previously characterized hematological 
malignancy samples and their differentially methylated sequences confirmed by 
cloning and sequencing (see Section 3.9.2).  These plasmids were used as control 
PCR templates to assess TTGE migration within the unknown AML samples. 
 
3.10. DNA Sequencing 
3.10.1. Direct PCR Product Sequencing 
 PCR products were purified using a QIAquick PCR Purification kit 
(Qiagen) as per the manufacturer’s instructions.  Pure samples were quantitated by 
comparison to DNA markers (Fermentas) following standard agarose gel 
electrophoresis and automated DNA sequencing was performed with the forward 
PCR primer by Annette Kerviche at the Saskatchewan Cancer Agency DNA 
Sequencing Facility using an ABI Prism 310 Genetic Analyzer.      
 
3.10.2. TTGE Band Recovery and Sequencing 
 Cloning and sequencing of individual bands from TTGE polyacrylamide 
gels was performed by first purifying DNA fragments using a procedure adapted 
from the QIAquick Gel Extraction Protocol (Qiagen) and from Sambrook et al. 
(Sambrook et al., 1989).  Briefly, individual bands from TTGE gels were scalpel 
excised and slices were added to two volumes of diffusion buffer [0.5 M 
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ammonium acetate, 10 mM magnesium acetate, 1 mM EDTA, pH 8.0, 0.1% (v/v) 
SDS] and incubated at 50°C for 30 min.  Following 10000 x g centrifugation for 2 
min, the supernatant was removed and processed with a QIAquick Gel Extraction 
column (Qiagen) as per the manufacturer’s instructions.  DNA was eluted in 30 µl 
of elution buffer and 2 µl was inserted into a pCR2.1-TOPO vector using a TOPO 
TA cloning kit (Invitrogen) and transformed into competent Escherichia coli as per 
the manufacturer’s instructions.  Selective Luria-Bertani (LB)-agar plates for 
isolation of transformed colonies consisted of LB broth [1.0% (w/v) tryptone, 0.5% 
(w/v) yeast extract, 1.0% (w/v) NaCl, pH 7.0] with 1.5% (w/v) agar and 50 µg/ml 
ampicillin. Plates were incubated overnight upside-down at 37°C.  Isolated, 
transformed, bacterial colonies were picked from LB-ampicillin plates and 
transferred to LB-ampicillin liquid culture media and grown overnight.  Bacteria 
were then pelleted and plasmid DNA isolated as described above (Section 3.5.3.).  
Purified samples were quantitated by standard A260/A280 spectrophotometric 
reading and automated DNA sequencing was performed with the M13 Forward (-
20) primer (Invitrogen) by Annette Kerviche at the Saskatchewan Cancer Agency 
DNA Sequencing Facility using an ABI Prism 310 Genetic Analyzer.      
 
3.11. Chromatin Immunoprecipitation (ChIP) 
Following culture, formaldehyde was added directly to the cell media to a 
final concentration of 1%, and cells were incubated at room temperature for 10 min 
with agitation.  The cross-linking reaction was quenched by the addition of 125 
mM glycine and agitated for another 5 min at room temperature.  Cells were 
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washed twice in ice cold 1X PBS and lysed in 350 µL of Upstate lysis buffer 
supplemented with freshly added protease inhibitors (1 mM PMSF, 1 µg/ml 
aprotinin, 1 µg/ml pepstatin A).  Lysate genomic DNA was sheared to lengths 
between 200 and 800 bp by sonication (Branson Sonifier 450, 1.5 minutes, 1.5 
output control, 60% duty cycle).  Sheared lysates were cleared by centrifugation, 
and 50 µL was set aside as an ‘input’ PCR positive control fraction.  The remaining 
lysate was split: one half [Ab (+)] was immunoprecipitated with a specific antibody 
(anti-MeCP2: 8.0 µg; anti-SUV39h1: 10 µg; anti-HDAC1: 4.0 µg; anti-H3-acetyl-
K9/14: 4.0 µg; anti-H3-acetyl-K18: 8.0 µg; anti-H3-acetyl-K23: 8.0 µg; anti-H3-
dimethyl-K4: 4.0 µg; anti-H3-dimethyl-K9: 8.0 µg; anti-H3-dimethyl-R17: 8.0 µg; 
anti-H4-acetyl-K5/8/12/16: 4.0 µg; all from Upstate Biotechnology), and the other 
half [Ab (-)] was immunoprecipitated with pre-immune rabbit IgG.  Both fractions 
were diluted and processed with buffers and reagents supplied with the ChIP Assay 
kit according to the manufacturer’s instructions (Upstate Biotechnology).   
Following the ChIP protocol, cross-links from all samples (including the 
input fraction) were reversed by heating and genomic DNA was isolated by 
proteinase K digestion, phenol extraction, and ethanol precipitation with the 
assistance of 15 µg of GlycoBlue coprecipitant (Ambion).  DNA pellets from all 
samples were dissolved in 40 µl of water and used immediately or stored at -20°C 
until needed.  PCR amplification was performed on diluted input, Ab (-), and Ab 
(+) DNA samples in 1x Qiagen PCR Buffer, 1.5 - 2.8 mM MgCl2, 0.4 mM of each 
dNTP, 0.2 µM of each primer set, and 0.2 units of HotStar Taq (Qiagen). The 
amplification consisted of an initial Taq activation step at 95°C for 15 min followed 
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by 35 amplification cycles (94°C for 1 min, annealing temperature for 1 min, and 
72°C for 1.5 min) and a final incubation at 72°C for 10 min.  The primer sequences 
and optimal annealing temperatures are listed in Table 3.4.  Following PCR, all 
amplification products were visualized by standard agarose gel electrophoresis and 
analyzed by semi-quantitative densitometry using Quantity One imaging software 
(Bio-Rad). 
 
3.12. SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 Protein lysates, histone enriched lysates, and prestained protein molecular 
weight markers (Fermentas) were resolved on SDS-PAGE gels.  Samples were 
heated at 95°C for 5 min in equal volumes of 2X sample buffer [150 mM Tris-HCl, 
pH 6.8, 1.2% (v/v) SDS, 30% (v/v) glycerol, 15% (v/v) β-mercaptoethanol, 1.8% 
(w/v) bromophenol blue] and immediately placed on ice.  Following a brief cooling 
period, samples were loaded onto gels typically containing 15% (v/v) 
acrylamide:N,N'-methylene-bis-acrylamide (37.5:1), 380 mM Tris-HCl, pH 8.8, 
0.1% (v/v) SDS and 0.1% (v/v) APS in the resolving gel, and 3% (v/v) 
acrylamide:N,N'-methylene-bis-acrylamide (37.5:1), 125 mM Tris-HCl, pH 6.8, 
0.1% (v/v) SDS and 0.1% (v/v) APS in the stacking gel.  The percentage of 
acrylamide in the resolving gels was adjusted based on the molecular weight of the 
target protein to be resolved.  Gels were polymerized by the addition of 0.04% 
TEMED and run in buffer containing 25 mM Tris-HCl, pH 8.3, 190 mM glycine, 
and 0.1% (v/v) SDS at 175 volts at room temperature until the loading dye reached 
the end of the resolving gel.  Parallel gels were routinely stained with coomassie 
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blue staining solution [0.25% (w/v) Coomassie Brilliant Blue R-250 (Bio-Rad), 
45% (v/v) methanol, 10% (v/v) acetic acid] and destained [45% (v/v) methanol, 
10% (v/v) acetic acid] to ensure equivalent sample loading and protein resolution.   
 
3.13. Western Blotting 
Resolved proteins in SDS-PAGE gels were transferred to nitrocellulose 
membranes (Bio-Rad) using a Bio-Rad Trans-Blot SD Semi-Dry Transfer Cell run 
at 15 volts for 20 min at room temperature in transfer buffer containing 25 mM 
Tris-HCl, pH 8.3, 192 mM glycine, 20% (v/v) methanol, and 0.1% (v/v) SDS.  
Following transfer, membranes were washed in water and blocked for 20 - 60 min 
at room temperature with constant agitation in either PBS or TBS based blocking 
buffer containing non-fat dry milk (Carnation) according to the primary antibody 
manufacturer’s instructions.  After blocking, membranes were incubated with the 
primary antibody diluted appropriately in the requisite blocking buffer.  Typically, 
membranes were incubated with the primary antibody overnight at 4oC with 
constant agitation.  Membranes were then washed and incubated with the 
appropriate dilution of secondary antibody in blocking buffer.  The primary and 
secondary antibodies used in the study are listed in Table 3.5.  After incubation 
with the secondary antibody solution, membranes were washed and antibody-
protein complexes visualized using the Immun-Star HRP Chemiluminescent kit 
(Bio-Rad) and Hyperfilm MP (Amersham). 
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3.14. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] 
Assay 
Cell survival/cytotoxicity was measured by the MTT assay.  Cells were 
plated in triplicate at 2 x 104 cells per well in a 96 well plate, cultured as above, and 
treated with 1 or 4 µM 5-Aza-dC, 250 or 500 µM zebularine, or a vehicle control.  
Following the 72 hour treatment period, 1/10 culture volume of 5 mg/ml MTT 
labeling reagent (Sigma) was added to each well and cultured for an additional 4 
hours.  The resulting formazan crystals were solubilized by the addition of 100 µl 
of solubilization solution [10% (v/v) SDS, 0.01 M HCl] to each well and cultured 
overnight prior to spectrophotometric absorbance reading (570nm with 660nm 
background subtraction) using a SpectraMax microplate reader (Molecular 
Devices). 
 
3.15. Tritiated Thymidine Incorporation Assay 
Cell proliferation was measured by the tritiated [3H]-thymidine 
incorporation assay.  Cells were plated in quadruplicate at 5 x 104 cells per well in a 
96 well plate, cultured as above, and treated with 1 or 4 µM 5-Aza-dC, 250 or 500 
µM zebularine, or a vehicle control.  For the final 6 hours of the 72 hour treatment 
period 0.5 µCi (18.5 kBq) of [3H]-thymidine (Amersham) was added to each well 
of the experiment.  Cells were harvested and liquid scintillation counting was used 
to measure the [3H]-thymidine that was incorporated into newly synthesized DNA, 
directly reflecting the degree of cell proliferation. 
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3.16. Propidium Iodide (PI) Staining 
Cell cycle analysis was performed by PI staining of DNA content.  Cells 
were cultured as above, and treated with 1 or 4 µM 5-Aza-dC, 250 or 500 µM 
zebularine, or a vehicle control.  Briefly, 2 x 106 cells (in triplicate) were washed in 
ice cold 1X PBA [1X PBS, 0.1% (w/v) bovine serum albumin, 0.02% (w/v) sodium 
azide] and fixed in ice cold ethanol.  Cell pellets were reconstituted in Triton-PBA 
[0.1% (v/v) Triton X-100, 1X PBA] for 3 min, pelleted again by centrifugation, and 
incubated in 500 units/ml RNase working solution (Worthington) at 37°C for 20 
min.  Samples were stained overnight in 2 ml PI working solution (0.05 mg/ml in 
PBA; Sigma) at 4°C and filtered through 35 µM nylon mesh into glass tubes for 
flow cytometry analysis.    
 
3.17. cDNA Microarray Analysis 
 This experiment was performed in collaboration with Dr. Derek S. Pearson 
and Matthew N. Bainbridge at the University of Saskatchewan.  Dr. Pearson 
participated in the experiment by repeating the human 1.7K arrays using previously 
harvested RNA samples as described above, and an indirect labeling reverse 
transcriptase methodology essentially as described by the University Health 
Network Microarray Centre (http://www.microarray.ca/).  Mr. Bainbridge assisted 
in the experiment by combining the data sets from each array labeling methodology 
(direct and indirect) and analyzing the data using Acuity 3.1 bioinformatics 
software (Molecular Devices). 
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3.17.1. Sample Preparation 
 Total RNA from each culture condition was isolated as described above and 
20 - 30 µg was purified using the RNase-Free DNase and RNeasy Mini kits as per 
the manufacturer’s instructions (Qiagen).  Samples were eluted with the supplied 
RNase-free water and concentration and purity was determined by standard 
A260/A280 spectrophotometric reading.  Samples were used immediately or stored at 
-80oC until needed. 
 
3.17.2. Direct Labeling with Cyanine 3- and Cyanine 5-dCTP 
 Purified RNA samples from each culture condition were reverse transcribed 
using fluorescent Cyanine-labeled dCTP as follows.  Briefly, 15 µg of total RNA 
was combined with 1X Superscript First Strand reaction buffer (Invitrogen), 10 
mM DTT, 0.5 mM each of dATP, dGTP and dTTP, 0.05 mM dCTP, 150 pmol 
Oligo-dT12-18 primer (Invitrogen), 5.0 ng control Arabidopsis thaliana RNA, and 25 
µM of either Cyanine 3- or Cyanine 5-dCTP (NEN Life Sciences) in a final volume 
of 40 µl.  The control and experimental labeling reactions were incubated at 65°C 
for 5 min and 42°C for 5 min in the dark prior to the direct addition of SuperScript 
II reverse transcriptase (400 units; Invitrogen) and RNasin (40 units; Promega).  
Labeling proceeded at 42°C for 3 hours in the dark and was stopped by placement 
on ice, the addition of 4 µl of 50 mM EDTA (pH 8.0) and 2 µl of 10 N NaOH, and 
incubation at 65°C for 20 min.  Following an addition of 4 µl of 5 M acetic acid, 
the control and experimental samples were combined and precipitated at -20°C for 
30 min with 100 µl isopropanol.  Samples were centrifuged for 10 min at 14000 
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rpm at 4°C and pellets were washed in 70% ethanol.  Pellets containing both 
control and experimental cDNA were briefly dried at room temperature and 
resuspended in 10 µl 1X TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0).  
Samples were then mixed with 40 µl of hybridization solution [1X DIG Easy Hyb 
solution (Roche), 50% (w/v) yeast tRNA (Invitrogen), 50% (w/v) calf thymus DNA 
(Sigma), heated at 65°C for 2 min and cooled to room temperature] and incubated 
at 65°C for 2 min and cooled to room temperature. 
 
3.17.3. Probe Hybridization 
 Hybridization mixtures (50 µl) were directly pipetted onto 22 x 40 mm 
Hybri-slips (Sigma) followed by careful placement, array side down, of human 
1.7K arrays (Microarray Centre) containing 1718 known ESTs.  Slides were 
carefully enclosed in a hybridization chamber (Genetix) containing a small volume 
(approximately 2 ml) of DIG Easy hybridization solution and incubated on a level 
surface at 37°C for approximately 18 hours. 
 
3.17.4. Microarray Washing 
 Following hybridization, Hybri-slips were removed by slide immersion in 
1X SSC and washed for three sets of 15 min each in 50°C pre-warmed 1X 
SSC/0.1% (v/v) SDS with occasional gentle agitation.  Slides were then rinsed 
briefly in 1X SSC and 0.1X SSC and carefully spun dry at 600 rpm for 5 min.  
Arrays were scanned immediately or stored at room temperature in the dark until 
needed. 
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3.17.5. Microarray Scanning 
 Microarray slides were scanned using GenePix Pro 4.1 software and an 
Axon 4000B scanner (Molecular Devices).  Individual 16-bit TIFF images were 
obtained by scanning each of the two fluors and an overlay image of the two 
images was created and quantified using GenePix Pro 4.1 software. 
 
3.17.6. Data Analysis 
 Scanned images and the associated quantification data files were entered 
into a GeneTraffic Microarray Database and Analysis System (Iobion Informatics) 
as well as Acuity 3.1 bioinformatics software (Molecular Devices).  Individual 
array spots from each of the three hybridizations had to pass a number of quality 
criteria to be included in the data analysis and each array dataset was normalized 
using LOWESS (locally weighted regression scatter plot smoothing) subarray 
normalization (Quackenbush, 2002).  Resultant normalized log2 ratios were used 
for statistical analysis. 
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4. RESULTS AND DISCUSSION 
 
4.1. METHYLATION STATUS OF CDKI GENES IN HUMAN AML 
 
4.1.1. CDKI Expression in Human AML Cell Lines and Patient Samples  
Cyclins, CDKs, and CDKIs are frequently deregulated in cancer.  As such, 
absent or reduced CDKI expression is a characteristic of many different tumors 
including some human leukemias and lymphomas (Drexler, 1998; Tsihlias et al., 
1999).  Moreover, disruption of the TGF-β1 pathway has been implicated in the 
pathogenesis of hematological malignancies (DeCoteau et al., 1997; Lowsky et al., 
2000) and the CDKIs p15, p21 and p27 are downstream effectors of TGF-β1 
signaling (Robson et al., 1999).  In order to evaluate CDKI expression in human 
AML, RTPCR and RPA assays were employed to measure p15, p21, and p27 
mRNA in AML cell lines and patient samples.     
The p15 gene was evaluated by RTPCR using primers specific for the 
gene’s coding sequence.  Interestingly, the assay failed to detect p15 mRNA in 6/7 
(86%) AML cell lines (Fig. 4.1A), only being detected in the cell line HL60.  This 
data is consistent with other studies that have analyzed HL60 p15 mRNA by 
RTPCR (Cameron et al., 1999b; Herman et al., 1996b).  Extending this analysis to 
AML patient material, p15 mRNA was absent in 25/32 (78%) cases (Fig. 4.1B),  
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Figure 4.1 CDKI Expression in Human AML.  A) and B) Representative p15 RTPCR data 
from AML cell lines (A) and patient samples (B).  Included in each amplification is a PCR 
positive control (PCR +), and water and reverse transcriptase negative controls (dH2O and RT 
-).  The housekeeping gene β-Actin was amplified in all cell lines and patient samples to 
ensure RNA integrity and equivalent cDNA template quantity between samples.  Note the 
presence of detectable p15 mRNA in the cell line HL60 and patients AML8 and AML38.  C)
and D) Representative p21 and p27 RPA data from AML cell lines (C) and patient samples 
(D).  The RPA template probe set used in this study allowed the simultaneous analysis of p21 
and p27, and the housekeeping gene GAPDH within the same reaction ensuring RNA integrity 
and equivalent RNA loading between samples.  Note the presence of detectable p21 mRNA in 
the cell line THP1 and patients AML11, AML24, AML25 and AML37, and detectable p27 in 
all cell lines and patients tested. 
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suggesting the possibility of p15 transcriptional silencing in the molecular 
pathogenesis of the disease.  As a control for cDNA integrity and equivalent 
RTPCR template quantity, the housekeeping gene β-Actin was amplified in all cell 
lines and patients analyzed. 
The CDKIs p21 and p27 were evaluated by RPA, a sensitive detection 
method that unlike standard RTPCR methods does not employ an amplification 
step and therefore provides linear mRNA signals over a broad input range.  
Another advantage of RPA is its capacity to simultaneously quantify several 
mRNA species in a single sample of total RNA, which permitted the comparison of 
p21 with the expression of its CIP/KIP family member p27.  Furthermore, 
incorporating a probe for the housekeeping gene GAPDH allowed comparison of 
individual CDKI mRNAs between samples.  By RPA, p21 and p27 mRNA was 
absent in 6/7 (86%; only detectable in THP1) and 0/7 (0%) AML cell lines, 
respectively (Fig. 4.1C).  Due to limited RNA availability, RPA analysis was 
performed on 24 AML patients and p21 and p27 mRNA were absent in 6/24 (25%) 
and 0/24 (0%) cases, respectively (Fig. 4.1D), suggesting the possibility of p21 
transcriptional silencing, and not that of p27, in the molecular pathogenesis of the 
disease.  Combining the AML cell line and patient data, p15, p21, and p27 mRNA 
were absent in 31/39 (79%), 12/31 (39%), and 0/31 (0%) of cases, respectively.  
 
4.1.2. p15 Promoter Hypermethylation in Human AML  
 Previous work in our lab has established a correlation between p15 
promoter hypermethylation and a lack of detectable p15 mRNA in T-cell 
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lymphoblastic lymphoma/leukemia (Scott et al., 2004) and others have reported 
similar findings in a variety of hematological malignancies, including myeloid 
leukemias (Cameron et al., 1999b; Herman et al., 1997; Toyota et al., 2001).  As 
p15 mRNA was absent in 79% of the AML samples analyzed in this study, the 
possibility of promoter hypermethylation induced p15 transcriptional silencing was 
therefore investigated.  Two techniques were employed to analyze the degree of 
p15 promoter methylation: standard MSP and a novel method that resolves 
differentially methylated promoter alleles on denaturing polyacrylamide gels 
known as TTGE.  Primers and probes for these techniques were designed to be 
located within the p15 promoter associated CpG island and near the major 
transcriptional start site (GenBank Accession Number S75756) as illustrated in 
Figure 4.2A. 
 MSP analysis of the p15 promoter region in the AML cell lines using 
previously defined unmethylated and methylated specific primers (Herman et al., 
1996a) detected the presence of methylated alleles in KG1, KG1A, and AML193 
cells when compared to the methylated positive control (Fig. 4.3A).  Unmethylated 
alleles were detected in HL60 and KG1 cells and neither the unmethylated nor the 
methylated MSP reactions successfully amplified in THP1, HEL, and K562 cells.  
The lack of p15 promoter region MSP amplification in THP1, HEL, and K562 
cells, although not conclusive, is indicative of gene deletion at this locus, a genetic 
abnormality known to occur in a small percentage of hematological cancers 
(Drexler, 1998).  The identification of p15 promoter hypermethylation by MSP in 
KG1 and KG1A cells has been reported previously (Dodge et al., 2001; Herman 
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Figure 4.2 p15, p21, and p27 MSP, TTGE, and ChIP PCR Product Locations.  Illustrated 
are the CpG island associated promoter regions of the p15 (A), p21 (B), and p27 (C) genes and 
the locations of amplification products (labeled horizontal black bars) used in this study. 
Arrow heads represent the location of the major transcriptional start sites, vertical black lines 
represent CpG dinucleotides, and asterisks (*) denote the location of TTGE methylation-
independent probe oligonucleotide binding sites.  STAT: Signal Transducer and Activator of 
Transcription. 
 
 108
 
   
 
 
 
Figure 4.3 p15 Methylation in Human AML.  A) MSP analysis of bisulfite modified AML 
cell line DNA.  Commercially available universally methylated bisulfite modified DNA was 
used as a methylated positive control (METH +) and water as a negative reagent control 
(dH2O).  B) TTGE analysis of 30 CpG sites within the p15 promoter in AML cell lines. 
Differentially methylated sequences within the p15 amplicons were resolved according to 
differences in melting temperature and compared to the known controls (UNMETH + and 
METH +).  C) MSP analysis of bisulfite modified AML patient sample DNA.  D)
Representative MSP product sequences from both the unmethylated and methylated PCR 
reactions.  U: unmethylated MSP reaction; M: methylated MSP reaction. 
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et al., 1996b), yet this is the first study to our knowledge to report p15 promoter 
hypermethylation in AML193 cells. 
 To confirm the p15 MSP cell line data, TTGE analysis was performed 
incorporating known p15 unmethylated and methylated positive controls.  As 
illustrated in Figure 4.3B, TTGE analysis corroborated the MSP data whereby 
HL60 cells amplified only unmethylated p15 alleles, KG1 cells amplified both 
unmethylated and methylated alleles, and KG1A and AML193 cells amplified 
strictly methylated p15 alleles.  Of note, all successful TTGE PCR reactions 
amplify products of equal size, regardless of methylation status, as visualized by 
standard agarose gel electrophoresis, and only following TTGE do the differentially 
methylated products become detectable.   Again, similar to the MSP data, this locus 
was unable to amplify with TTGE PCR primers in THP1, HEL, and K562 cells.   
Bisulfite treated DNA from the 32 AML patients that were analyzed for p15 
mRNA expression and that from another 8 AML samples was available for MSP 
analysis and altogether 36/40 (90%) cases had detectable p15 promoter 
hypermethylation (Fig. 4.3C).  Of note, no methylation of the p15 gene was 
detected in the DNA of 13 non-leukemic controls (data not shown).  To ensure that 
the amplification of bisulfite treated DNA was specific for each MSP primer set, 
representative samples from both the unmethylated and methylated reactions were 
directly sequenced using the appropriate forward primer (Fig. 4.3D).  Importantly, 
the sequences confirm that no methylation is present within the amplification 
product of the unmethylated specific MSP primers and that CpG dinucleotides, 
representing 5-methyl-CpG in the native DNA, are present within the amplification 
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product of the methylated specific MSP primers.  Taken together, p15 promoter 
hypermethylation was identified in 39/47 (83%) AML cell lines and patient 
samples. 
 
4.1.3. p21 Promoter Hypermethylation in Human AML 
 Mutations and deletions of p21 occur only rarely in human cancer but the 
gene is frequently repressed by epigenetic mechanisms (Ying et al., 2004).  
However, investigation of hematological malignancies and solid tumors for p21 
promoter hypermethylation, an important mechanism of epigenetic silencing, have 
shown variable, and in some cases, discrepant results (Roman-Gomez et al., 2002; 
Shen et al., 2002; Ying et al., 2004).  As p21 mRNA was absent in 39% of the 
AML samples analyzed in this study, the possibility of promoter hypermethylation 
induced p21 transcriptional silencing was therefore investigated.  Two techniques 
were employed to analyze the degree of p21 promoter methylation: standard MSP 
and TTGE.  Primers and probes for these techniques were designed to be located 
within the p21 promoter associated CpG island and near the major transcriptional 
start site (GenBank Accession Number U24170) as illustrated in Figure 4.2B. 
 MSP analysis of the p21 promoter region did not detect methylated alleles 
in any of the AML cell lines when compared to the methylated positive control 
(Fig. 4.4A).  In contrast, unmethylated alleles were detected in all of the cell lines 
tested despite the fact that only the cell line THP1 had detectable mRNA by RPA.  
These results were confirmed by TTGE, as shown in Figure 4.4B, whereby all 
AML cell line TTGE PCR products migrate parallel to the unmethylated control. 
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Figure 4.4 p21 Methylation in Human AML.  A) MSP analysis of bisulfite modified AML 
cell line DNA.  Commercially available universally methylated bisulfite modified DNA was 
used as a methylated positive control (METH +) and water as a negative reagent control 
(dH2O).  B) TTGE analysis of 35 CpG sites within the p21 promoter in AML cell lines. 
Differentially methylated sequences within the p21 amplicons are resolved according to 
differences in melting temperature and compared to the known controls (UNMETH + and 
METH +).  C) MSP analysis of bisulfite modified AML patient sample DNA.  D)
Representative MSP product sequences from both the unmethylated and methylated PCR 
reactions.  U: unmethylated MSP reaction; M: methylated MSP reaction. 
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Bisulfite treated DNA from the 24 AML patients that were analyzed for p21 
mRNA expression and that from another 16 AML samples was available for MSP 
analysis and altogether 0/40 (0%) cases had detectable p21 promoter 
hypermethylation (Fig. 4.4C).  Moreover, no methylation of the p21 gene was 
detected in the DNA of 13 non-leukemic controls (data not shown).  To ensure that 
the amplification of bisulfite treated DNA was specific for each MSP primer set, 
representative samples from both the unmethylated and methylated reactions were 
directly sequenced using the appropriate forward primer (Fig. 4.4D).  Importantly, 
the sequences confirm that no methylation is present within the amplification 
product of the unmethylated specific MSP primers and that CpG dinucleotides, 
representing 5-methyl-CpG in the native DNA, are present within the amplification 
product of the methylated specific MSP primers.  Taken together, p21 promoter 
hypermethylation was identified in 0/47 (0%) AML cell lines and patient samples.  
 
4.1.4. p27 Promoter Hypermethylation in Human AML  
p27 promoter hypermethylation has been reported in some subtypes of 
hematological malignancies, with lymphoma cases reported to be positive for p27 
methylation in association with absent p27 protein (Go, 2003; Kibel et al., 2001; 
Nakatsuka et al., 2003).  Although all samples analyzed in this study had detectable 
p27 mRNA by RPA, the presence of p27 promoter hypermethylation was 
investigated as a control.  As per the analyses of p15 and p21 methylation, all MSP 
and TTGE primers and probes for p27 were designed to be located within the 
promoter associated CpG island and near the major transcriptional start site 
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(GenBank Accession Numbers AB005590 and S76986) as illustrated in Figure 
4.2C. 
Consistent with the finding that p27 mRNA was strongly expressed in all 
AML cell lines and patients, including those samples that lacked p15 and/or p21 
mRNA, no p27 promoter hypermethylation in 47 of 47 samples available for 
analysis was observed using either MSP or TTGE (Fig. 4.5).  This included all 
AML cell lines (n = 7) and patient samples (n = 24) analyzed by RPA as well as the 
16 patient samples for which expression data was not available.  Moreover, no 
methylation of the p27 gene was detected in the DNA of 13 non-leukemic controls.  
The specificity of p27 MSP, like that of p15 and p21, was confirmed by sequencing 
methylated PCR products generated from the universally methylated positive 
control and unmethylated PCR products from individual AML cases (Fig. 4.5D).   
     
4.1.4. DISCUSSION 
 Most genetic alterations that have been characterized in hematopoietic 
malignancies concern oncogene activation, yet recently, a large body of evidence 
has suggested that the loss of tumor suppressor gene activity is an important event 
in the development of such cancers.  Examples of potential tumor suppressors are 
the CDKI small regulatory proteins which exert a negative control on the cell cycle 
by inhibiting the kinase activity of CDKs.  Previous studies implicating CDKI 
genes in human leukemogenesis (Drexler, 1998; Tsihlias et al., 1999) and the 
critical role epigenetic silencing plays in neoplasia (Verma and Srivastava, 2002) 
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Figure 4.5 p27 Methylation in Human AML.  A) MSP analysis of bisulfite modified AML 
cell line DNA.  Commercially available universally methylated bisulfite modified DNA was 
used as a methylated positive control (METH +) and water as a negative reagent control 
(dH2O).  B) TTGE analysis of 22 CpG sites within the p27 promoter in AML cell lines. 
Differentially methylated sequences within the p27 amplicons are resolved according to 
differences in melting temperature and compared to the known methylated control (METH +). 
C) MSP analysis of bisulfite modified AML patient sample DNA.  D) Representative MSP 
product sequences from both the unmethylated and methylated PCR reactions.  U: 
unmethylated MSP reaction; M: methylated MSP reaction. 
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prompted the investigation of mRNA levels and promoter methylation status of the 
p15, p21, and p27 CDKI genes in human AML. 
Hypermethylation of the p15 promoter and associated transcriptional 
silencing has been previously reported in a host of hematological malignancies 
including Burkitt’s lymphoma, ALL, CML, MDS and AML (Herman et al., 1997; 
Nguyen et al., 2000; Quesnel et al., 1998).  The frequency of p15 hypermethylation 
presented in this study (83%) is consistent with previously reported AML data 
(Herman et al., 1997; Melki et al., 1999) and further implicates p15 promoter 
hypermethylation in the molecular pathogenesis of human AML.  Importantly, p15 
mRNA was absent in 79% of cell lines and patient samples and was absent in all 
testable cases harboring p15 promoter hypermethylation, even though 
unmethylated p15 alleles were often detected in the patient samples by MSP.  The 
presence of unmethylated alleles within the patient samples harboring p15 
hypermethylation could be a result of a small percentage of contaminating normal 
cells in the initial bone marrow or peripheral blood sample.  However, if this is the 
case, they did not have a significant effect on p15 mRNA status.  Another 
possibility is that p15 promoter hypermethylation in AML is monoallelic, yet this is 
unlikely as other studies using bisulfite sequencing have shown heterogeneous 
biallelic p15 promoter hypermethylation, varying greatly in methylation density 
and not limited to a single allele (Cameron et al., 1999b).  This is consistent with 
the TTGE data of the present study and the denaturing gradient gel electrophoresis 
(DGGE) data previously published (Aggerholm et al., 1999), which reveal a high 
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degree of both intra- and interindividual heterogeneity of p15 promoter 
hypermethylation in AML patients. 
As mentioned, p15 is normally upregulated by TGF-β1, possibly mediating 
the cell cycle arrest and reduced phosphorylation of RB seen following TGF-β1 
treatment (Laiho et al., 1990).  Furthermore, TGF-β1 is a potent growth inhibitor of 
hematopoietic stem cells and early progenitor cells, which are considered the 
putative cells of origin in AML.  For these normal cells, TGF-β1 inhibits 
proliferation despite the presence of mitogenic stimuli (Hooper, 1991).  Thus, 
ablation of p15 function, by either genetic or epigenetic means, could lead to 
escape from normal growth suppression.  Although this attractive hypothesis has 
yet to be confirmed, evidence to support this notion has been offered by Dodge et 
al. who reported p15 protein induction and G1 arrest in HL60, but not KG1 or 
KG1A cells, following treatment with the differentiating agent phorbol 12-
myristate 13-acetate (PMA) (Dodge et al., 2001).  The authors, similar to the data 
presented herein, also report partial p15 hypermethylation in the KG1 cell line and 
complete p15 promoter hypermethylation in the KG1A cell line as detected by 
MSP.  Furthermore, the upregulation of p15 following TGF-β1 treatment has been 
shown to be exerted at the level of transcription through promoter associated GC-
rich Sp1 consensus sites (Li et al., 1995).  As such, it is very tempting to 
hypothesize that p15 promoter hypermethylation in AML blocks normal p15 
transcriptional induction by interfering with growth factor signaling at the 
promoter.   
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Similar to p15, a high frequency of AML samples lacked p21 mRNA 
(39%).  However, unlike p15, the absence of p21 mRNA was not associated with 
promoter hypermethylation.  Analysis of p21 methylation status in hematological 
malignancies and solid tumors have shown variable, and in some cases discrepant 
results (Roman-Gomez et al., 2002; Shen et al., 2002; Ying et al., 2004).  A 
recently reported large study of primary lymphoma and carcinoma tumors and cell 
lines found p21 hypermethylation by MSP in only 5 of 245 (2.0%) samples (Ying 
et al., 2004).  A summary of all pertinent literature by this group found p21 
hypermethylation to be rare in tumors in general, especially when analyzed by 
bisulfite-based methods such as MSP (Ying et al., 2004).  They also noted that both 
studies employing restriction enzyme based assays, which analyze the methylation 
status of very few CpG sites, detected methylation at high frequencies, including 
normal tissues in some instances (Chen et al., 2000; Roman-Gomez et al., 2002; 
Ying et al., 2004).  This observation may be pertinent, as recently Roman-Gomez et 
al., reported the presence of p21 promoter hypermethylation in 51 of 124 (41%) 
ALL patients using a restriction enzyme based assay (Roman-Gomez et al., 2002), 
whereas, Shen et al., found no methylation of the p21 promoter in a group of 31 
ALL patients using bisulfite-based methods (Shen et al., 2002).  Consistent with the 
data from Shen et al., our lab recently reported the absence of p21 promoter 
hypermethylation in 28 T-cell lymphoblastic lymphoma/leukemia cell lines and 
patient samples using both MSP and TTGE assays (Scott et al., 2004).  
As MSP is the technique most widely used to assess methylation status, it 
was employed for evaluation of the AML samples in the present study.  The 
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absence of p21 promoter hypermethylation reported herein was confirmed by 
TTGE, which allows the analysis of multiple CpGs within the p21 promoter and 
limits the influence of primer amplification bias on the assessment of methylation 
status.  Thus, the data presented herein is the first to analyze p21 promoter 
hypermethylation in AML, concurs with the analysis of ALL by Shen et al., and 
argues against a role for p21 promoter hypermethylation in the molecular 
pathogenesis of AML.  However, other epigenetic mechanisms of p21 silencing 
independent of promoter methylation, such as histone deacetylation, can not be 
ruled out. 
Interestingly, a restriction based study by Chen et al., found CpG 
methylation of a distal STAT binding site within the p21 promoter (Fig. 4.2B) to be 
associated with decreased constitutive p21 mRNA expression in 
rhabdomyosarcoma (Chen et al., 2000).   Thus, while gene silencing as a 
consequence of methylation is most often associated with dense methylation within 
promoter CpG islands (Cameron et al., 1999b), future studies of distal CpG sites in 
AML may also be of interest. 
 Similar to the CIP/KIP CDKI family member p21, mutations and deletions 
of p27 are rare in human cancer (Ponce-Castaneda et al., 1995), prompting 
investigation into alternative mechanisms of p27 inactivation, including promoter 
hypermethylation (Go, 2003; Kibel et al., 2001; Nakamura et al., 2001; Nakatsuka 
et al., 2003; Worm et al., 2000).  Data from malignant melanoma has suggested that 
DNA methylation may cause monoallelic p27 silencing (Worm et al., 2000).  Given 
the paucity of p27 mutations or deletions, this melanoma study supports a role for 
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p27 haploinsufficiency in human cancer.  However, melanoma cell lines harboring 
one methylated and one wild-type p27 allele showed reduced p27 mRNA 
expression.  In contrast, the presented AML data reveal strong p27 mRNA 
expression in all samples arguing against epigenetic silencing of p27 as an 
important mechanism in the pathogenesis of human AML.  Consistent with the 
expression data, no evidence of p27 hypermethylation was found in any of the 47 
AML samples analyzed.  The absence of p27 hypermethylation observed in AML 
is in contrast to studies of predominantly nodal based B-cell lymphomas and nasal 
cavity NK/T-cell lymphomas (Nakatsuka et al., 2003) and primary central nervous 
system B-cell lymphomas (Nakamura et al., 2001) but consistent with analysis of 
primary gastrointestinal B-cell lymphomas (Go, 2003).  The differing frequencies 
of p27 promoter hypermethylation suggest that the importance of p27 inactivation 
may vary among subtypes of hematological malignancies.  Alternatively, p27 
disruption in those hematological malignancies lacking promoter methylation may 
occur by other mechanisms, for example increased proteasome mediated protein 
degradation (Loda et al., 1997). 
 In summary, the results indicate that p15 and p21 mRNA is absent in 
human AML cell lines and patient material at a high frequency, whereas, p27 
mRNA levels are not reduced.  Thus, these findings implicate the ablation of 
certain TGF-β1 pathway CDKI genes (p15 and p21) but not others (p27) in the 
pathogenesis of this disease.  The findings that p15 mRNA absence is frequently 
accompanied by promoter hypermethylation in AML, whereas, reduced p21 
expression occurs independently of promoter hypermethylation are consistent with 
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the literature and suggest that within the same tumor, epigenetic silencing of CDKI 
genes may involve methylation dependent or independent mechanisms depending 
on the target gene. 
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4.2. DEMETHYLATION AND RE-EXPRESSION OF p15 BY 5-Aza-dC IS 
ASSOCIATED WITH H3 MODIFICATIONS AND RELEASE OF MeCP2 
AND SUV39h1 AT THE PROMOTER 
 
4.2.1. 5-Aza-dC Demethylates and Induces p15 in AML193 Cells 
 As mentioned, p15 promoter hypermethylation and associated 
transcriptional silencing has been reported in various hematological malignancies 
(Herman et al., 1997; Melki et al., 1999; Nguyen et al., 2000; Quesnel et al., 1998; 
Scott et al., 2004), and is consistent with our previous investigation of CDKIs in 
human AML.  While p15 promoter hypermethylation occurs frequently in AML, 
little is known about the components of repressor complexes that effect epigenetic 
silencing of densely methylated p15 promoter alleles or their relationship to 
covalent histone modifications.  Moreover, 5-Aza-dC has recently been shown to 
have both methylation dependent and independent activities depending on the cell 
type and methylation status of the target gene (Schmelz et al., 2005).  Given the 
identification of AML cell lines harboring complete p15 promoter 
hypermethylation in the previous study, AML193 cells were used in combination 
with the DNMT inhibitor 5-Aza-dC (Fig. 1.8) to confirm the involvement of CpG 
island hypermethylation in p15 transcriptional silencing and to investigate the 
mechanism of p15 gene silencing in human AML. 
 To determine if 5-Aza-dC can demethylate the p15 promoter and 
reconstitute p15 mRNA in AML193 cells, a time course experiment was designed 
with 4 µM 5-Aza-dC treated over a period of four days with both DNA and RNA 
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harvested every 12 hours (Fig. 4.6).  A dose response experiment was initially done 
to determine optimal 5-Aza-dC dosage (data not shown), which was consistent with 
previous studies that have reported robust DNA demethylation with acceptable 
toxicity in the low micromolar dose range (Covey and Zaharko, 1984; Davis et al., 
1989; Issa, 2003; Issa et al., 2004; Momparler and Laliberte, 1990).  As expected, 
at the zero time point the p15 promoter was completely methylated (Fig. 4.6A) and 
mRNA was undetectable (Fig. 4.6B) as determined by TTGE and RTPCR, 
respectively.  However, after approximately 60 hours of 5-Aza-dC treatment, 
unmethylated p15 alleles were detectable by TTGE in association with detectable 
mRNA (Fig. 4.6).  Importantly, no change in p15 methylation status or mRNA was 
detected following treatment with a PBS vehicle control throughout the same time 
period and as a control for cDNA integrity and equivalent RTPCR template 
quantity, the housekeeping gene β-Actin was amplified in all time point samples.  
This data provides further evidence for the central role that aberrant promoter 
hypermethylation plays in p15 gene silencing and is consistent with previous 
reports that used 5-Aza-dC to induce p15 mRNA in KG1A cells (Herman et al., 
1996b), and those that used 5-Aza-dC to demethylate and reactivate the 
neighboring p16 gene in colon cancer cell lines (Herman et al., 1995). 
 
4.2.2. 5-Aza-dC Mediated Induction of p15 is Associated with MeCP2 and 
SUV39h1 Release at the Promoter 
 A direct relationship between DNA hypermethylation mediated 
transcriptional silencing and the modification of regional chromatin was established  
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Figure 4.6 Demethylation and Re-expression of p15 by 5-Aza-dC Treatment in AML193 
Cells.  A) TTGE analysis of bisulfite modified DNA from a 5-Aza-dC time course assay in 
AML193 cells.  DNA was harvested every 12 hours for four days from cells treated with either 
a vehicle control or 5-Aza-dC.  Differentially methylated sequences within the p15 amplicons 
were resolved by TTGE according to differences in melting temperature and compared to the 
migration of controls (UNMETH + and METH +).  Water was used as a PCR reagent control 
(dH2O).  B) RTPCR analysis of the p15 gene using RNA harvested from the same 5-Aza-dC 
time course assay described in (A).  Included in each amplification is a PCR positive control 
(PCR +), and water and reverse transcriptase negative controls (dH2O and RT -).  The 
housekeeping gene β-Actin was amplified in all cell lines to ensure RNA integrity and 
equivalent cDNA template quantity between samples.  Note the presence of detectable p15 
mRNA by RTPCR in concordance with promoter demethylation by TTGE following 60 to 72 
hours of 5-Aza-dC treatment.   
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in 1998 by the observation that methylated DNA associates with a repressive 
protein assembly that includes members of the MBD family and HDAC activity 
(Jones et al., 1998).  As mentioned, since then MBD proteins have been determined 
by ChIP assays to be physically associated with hypermethylated promoters in 
hepatocellular carcinoma (Bakker et al., 2002), colon cancer (Magdinier and 
Wolffe, 2001), bladder cancer (Nguyen et al., 2002), and T-cell leukemia cell lines 
(El-Osta et al., 2002).  Moreover, the MBD MeCP2 has recently been shown to not 
only colocalize with HDAC activity, but also that of H3 lysine 9 methyltransferase 
activity (Fuks et al., 2003b), implying that MeCP2 acts as a bridge between DNA 
methylation and chromatin remodeling.  As such, in order to examine if MBDs, 
HMTs, and HDACs are present at the hypermethylated p15 promoter in AML193 
cells, ChIP assays were employed with antibodies specific for MeCP2, SUV39h1 
and HDAC1, and PCR primers specific for the p15 promoter region (Fig. 4.2).    
 Similar to the methylated p16 promoter reported in bladder cancer (Nguyen 
et al., 2002) and the methylated MDR1 promoter in T-cell leukemia (El-Osta et al., 
2002), MeCP2 was found to be associated with the hypermethylated p15 promoter 
region in AML193 cells and was reduced by almost 9 fold following treatment with 
4 µM 5-Aza-dC (Fig. 4.7A), a dosage consistent with p15 promoter demethylation 
and re-expression of the gene.  Along with MeCP2, the p15 promoter region also 
harbored the H3 lysine 9 specific methyltransferase SUV39h1, which was reduced 
4 fold following 5-Aza-dC treatment (Fig. 4.7B).  However, a ChIP assay for 
HDAC1 was unable to immunoprecipitate p15 promoter region DNA fragments in 
the absence or presence of 5-Aza-dC (Fig. 4.7C).  Although repressive complexes  
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Figure 4.7 Epigenetic Proteins at the p15 Promoter in AML193 Cells.  Illustrated is the 
ethidium bromide staining of ChIP PCR products from input positive controls (Input), no-
antibody negative controls [Ab (-)], and specific antibody immunoprecipitates [Ab (+)].  Each 
experiment was performed in the absence and presence of 5-Aza-dC and included in each PCR 
is a water negative reagent control (dH2O).  Lower panels graphically represent semi-
quantitation of the ChIP assay using densitometry of the PCR products from 
immunoprecipitated samples normalized to their input counterparts and expressed numerically 
in brackets as fold change following 5-Aza-dC treatment.  ChIP was performed with antibodies 
for MeCP2 [α-MeCP2; (A)], SUV39h1 [α-SUV39h1; (B)], and HDAC1 [α-HDAC1; (C)]. 
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that contain MeCP2 are known to harbor HDAC activity it is important to note that 
to date, many members of the mammalian HDAC superfamily have been identified 
and therefore other HDACs beyond that of HDAC1 could be involved at the 
hypermethylated p15 locus.  Future ChIP assays are required to define exactly 
which HDAC, if any, is present at the p15 promoter. 
 
4.2.3. 5-Aza-dC Mediated Induction of p15 is Associated with Changes in H3 
Acetylation 
Although HDAC1 was not found to be associated with the p15 promoter in 
AML193 cells, hypermethylated CpG islands are typically associated with an 
inaccessible chromatin conformation and deacetylated histones (Bachman et al., 
2003; Nguyen et al., 2001).  Increased acetylation of histones by pharmacological 
inhibition of HDACs causes an increase in DNA accessibility through chromatin 
remodeling (Gui et al., 2004; Richon et al., 2000), which presumably assists 
transcription by allowing the RNA polymerase machinery access to important 
enhancer elements and transcriptional start sites.  Interestingly, evidence also exists 
supporting a role for 5-Aza-dC induced enrichment of histone acetylation at 
promoter regions previously silenced by CpG island hypermethylation (Coombes et 
al., 2003; Fahrner et al., 2002; Nguyen et al., 2002).  Given the induction of p15 
mRNA and release of repressive components at the p15 promoter following 5-Aza-
dC treatment and the previous studies looking at 5-Aza-dC induced histone 
acetylation in other genes and cell types, ChIP assays were employed to test if H3 
acetylation is affected following demethylation of the p15 promoter in AML193 
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cells.  If MeCP2 recruits HDAC activity to aid in the silencing of p15 in AML193 
cells, then diminished levels of histone acetylation should be associated with this 
gene.  Indeed, H3 acetylation at lysine residues 9 and 14 was found to be absent at 
the hypermethylated p15 promoter region in AML193 cells, yet was enriched by 
approximately 16 fold following treatment with 4 µM 5-Aza-dC (Fig. 4.8A).  To 
examine acetylation at additional sites of H3, ChIP assays were performed with 
antibodies specific for single H3 acetylated lysine residues 18 and 23.  An increase 
in H3 acetylation was observed at the lysine 18 residue, where 5-Aza-dC treatment 
caused a 2 fold enrichment (Fig. 4.8B), however the ChIP assay for acetylated H3 
lysine 23 was unable to immunoprecipitate p15 promoter region DNA fragments in 
the absence or presence of 5-Aza-dC (Fig. 4.8C).  Taken together, similar to the 
neighboring p16 gene in bladder cancer (Nguyen et al., 2002) and head and neck 
squamous cell carcinoma (HNSCC) (Coombes et al., 2003), 5-Aza-dC induced 
demethylation and re-expression of the p15 gene in AML193 cells is associated 
with a regional enrichment of H3 acetylation, in this case specifically at lysine 
residues 9, 14, and 18.  
 
4.2.4. 5-Aza-dC Mediated Induction of p15 is Associated with Changes in H3 
Methylation  
Unlike histone acetylation, regional histone methylation is not always 
associated with either a strictly active or inactive transcriptional state.  In fact, as 
mentioned previously, methylation of specific histone amino acids correlates with 
differing states of transcriptional activity depending on which lysine or arginine 
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Figure 4.8 H3 Acetylation at the p15 Promoter in AML193 Cells.  Illustrated are ChIP 
experiments as described in Figure 4.7 with antibodies for acetylated H3 lysine 9 and 14 [α-
H3-AcK9/14; (A)], acetylated H3 lysine 18 [α-H3-AcK18; (B)], and acetylated H3 lysine 23 
[α-H3-AcK23; (C)]. 
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residue is modified (Lachner and Jenuwein, 2002).  The best characterized are 
those of H3 lysine 4 and 9, where methylation of lysine 4 consistently correlates 
with transcriptionally active chromatin and methylation of lysine 9 consistently 
correlates with transcriptionally inactive chromatin (Kondo et al., 2003).  Given the 
association between H3 lysine 4 methylation and transcriptionally active chromatin 
regions in higher eukaryotes (Schneider et al., 2004; Strahl et al., 1999), one would 
expect this modification to be enriched at the p15 gene in AML193 cells following 
5-Aza-dC treatment.  In contrast, H3 lysine 9 methylation is reported to be involved 
in chromatin compaction through a repressive complex that associates with DNA 
hypermethylation.  Interestingly, it has recently been shown that DNMT1 and 
DNMT3a associate with the H3 lysine 9 specific methyltransferase SUV39h1 
(Fuks et al., 2003a), which is most likely linked by MeCP2 (Fuks et al., 2003b), 
substantiating the connection between DNA and histone methylation.  Given our 
previous data showing occupation of the p15 promoter region by both MeCP2 and 
SUV39h1 in AML193 cells, one would expect H3 lysine 9 methylation to be 
enriched at this locus prior to 5-Aza-dC treatment.  Thus, to test for the presence or 
absence of H3 lysine 4 and 9 methylation at the hypermethylated p15 promoter 
region, ChIP assays were employed in the absence and presence of 5-Aza-dC in 
AML193 cells.  To examine the methylation status of arginine H3 residues, ChIP 
assays were performed with an antibody specific to H3 dimethylated arginine 17. 
As shown in Figure 4.9A, demethylation and re-expression of p15 by 5-
Aza-dC resulted in an almost 5 fold enrichment of dimethylated H3 lysine 4 at the 
p15 promoter region, which is consistent with the hypothesis that H3 lysine 4 
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methylation plays a role in transcriptionally active chromatin.  In contrast, the p15 
promoter region was associated with dimethylated H3 lysine 9 at high levels prior 
to drug administration yet was reduced by almost 3 fold following treatment with 
5-Aza-dC (Fig. 4.9B), suggesting an inverse correlation between the methylation of 
lysines 4 and 9 on H3.  Similar to the MeCP2 and H3 acetylation data, these 
findings are consistent with aforementioned reports on the p16 gene in bladder 
cancer (Nguyen et al., 2002) and HNSCC (Coombes et al., 2003). 
Acetylation of H3, a modification traditionally associated with 
transcriptionally active chromatin, has recently been shown to tether the 
aforementioned arginine HMT CARM1 to the H3 amino-terminal in vivo (Daujat et 
al., 2002) and methylation of H3 arginine 17, the major target of CARM1 
methylation, has been shown to be associated with gene activation (Bauer et al., 
2002).  Hence, it stands to reason that induction of the p15 gene in AML193 cells 
by 5-Aza-dC would be marked by H3 arginine 17 methylation enrichment, and as 
shown in Figure 4.9C, 5-Aza-dC induces this modification almost 4 fold.  To our 
knowledge, this is the first study to describe an inverse correlation between DNA 
hypermethylation and H3 arginine methylation. 
 
4.2.5. 5-Aza-dC Mediated Changes in H3 Modifications are Gene Specific 
It is important to note that the H3 modification observations from the 
previous ChIP assays could be the result of global changes in the cellular levels of 
modified H3.  To confirm that the changes observed by ChIP analysis before and  
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Figure 4.9 H3 Methylation at the p15 Promoter in AML193 Cells.  Illustrated are ChIP 
experiments as described in Figure 4.7 with antibodies for dimethylated H3 lysine 4 [α-H3-
dimK4; (A)], dimethylated H3 lysine 9 [α-H3-dimK9;(B)], and dimethylated H3 arginine 17 
[α-H3-dimR17; (C)]. 
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after 5-Aza-dC treatment are gene specific observations, western blots were 
performed to measure the total protein levels of modified H3. 
Figure 4.10 shows that the overall levels of H3 acetylation (lysines 9/14, 18, 
and 23) and H3 methylation (lysines 4 and 9, and arginine 17) do not dramatically 
change after 5-Aza-dC treatment of AML193 cells (Fig. 4.10), suggesting that the 
chromatin remodeling detected by ChIP analysis at the p15 promoter region are 
gene specific events rather than a reflection of global changes in histone 
modification.  The experiment was performed on two types of total protein, one 
which was extracted by standard methods, and another which was extracted using a 
protocol that enriches for the histone fraction.  In both cases, no major changes in 
histone protein level were observed when compared to the levels of total 
unmodified H3.   
 
4.2.6. 5-Aza-dC and TSA Combinatorial Treatment Synergistically Induces 
p15 in AML193 Cells 
As mentioned, previous reports have shown that combinatorial inhibition of both 
DNMT and HDAC activities can synergistically reactivate epigenetically silenced 
genes in vitro (Cameron et al., 1999a) and the potential for combinatorial treatment 
as a cancer therapy is currently being evaluated (Shaker et al., 2003; Zhu and 
Otterson, 2003).  Therefore, to test for synergistic induction of p15 by 
pharmacologic inhibition of DNMT and HDAC in AML193 cells, RTPCR was 
employed following treatment with both 5-Aza-dC and the well known HDAC 
inhibitor TSA.  As shown in Figure 4.11A, treatment of AML193 cells with 5-Aza- 
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Figure 4.10 Effects of 5-Aza-dC on Global H3 Modifications in AML193 Cells.  A)
Coomassie stained SDS-PAGE gel showing resolution of total cellular proteins. B)  Western 
blot analysis of modified histones with antibodies used for the previous ChIP assays and an 
antibody for total unmodified H3 (α-H3).  Protein was extracted using two separate protocols 
as described in the Materials and Methods; a standard cell lysate protocol (Cell Lysate) and a 
protocol that enriches for the histone fraction (Acid Extract.), both in the absence and presence 
of 5-Aza-dC.   
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dC, similar to the experiment in Figure 4.6, resulted in re-expression of detectable 
p15 mRNA.  Inhibition of HDAC activity by treatment of AML193 cells with TSA 
alone for 12 hours had no effect on p15 induction, implying that DNA 
hypermethylation is a dominant process over histone deacetylation at this locus.  
However, treatment of AML193 cells with TSA for the final 12 hours of a three 
day 5-Aza-dC treatment synergistically induced detectable p15 mRNA.  This 
pattern of mRNA induction has been shown in other systems following DNMT 
and/or HDAC inhibition and is emblematic of a gene which is silenced by promoter 
hypermethylation.  For example, similar mRNA induction patterns have been 
reported for the MLH1, TIMP3 and p16 genes in colon cancer (Cameron et al., 
1999a) and the ERα gene in breast cancer (Yang et al., 2001), and the results 
suggest that for genes silenced by promoter hypermethylation, DNA demethylation 
is a prerequisite to induce transcription by inhibiting HDAC activity. 
To assess the levels of histone acetylation at the p15 promoter following 
treatment with 5-Aza-dC and/or TSA, ChIP assays were employed using α-H3-
AcK9/14 (Fig. 4.11B).  Similar to the previous experiment illustrated in Figure 4.8, 
5-Aza-dC induced H3 acetylation in concert with re-expression of p15 mRNA.  In 
contrast, treatment with TSA alone was unable to induce regional H3 acetylation, 
reflecting its inability to induce transcription of this gene (Fig. 4.11A).  Yet, when 
TSA was treated in combination with 5-Aza-dC, synergistic induction of p15 
mRNA was observed in association with an increase in H3 acetylation at the p15 
promoter region.  Although a synergistic enrichment of H3 acetylation was not 
observed following combinatorial treatment, a trend towards a greater induction of  
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Figure 4.11 Effects of 5-Aza-dC and TSA Combinatorial Treatment in AML193 Cells.
A) p15 RTPCR following treatment with vehicle controls, 5-Aza-dC, TSA, and combinatorial 
treatment with 5-Aza-dC and TSA.  Included in each RTPCR amplification is a PCR positive 
control (PCR +) and water and reverse transcriptase negative controls (dH2O and RT -).  The 
housekeeping gene β-Actin is amplified in all samples to ensure RNA integrity and equivalent 
cDNA template quantity between samples.  B) Illustrated is a ChIP experiment as described in 
Figure 4.7 immunoprecipitated with α-H3-AcK9/14 and tested following the same treatment 
conditions as in (A).  C) Western blot analysis using α-H3-AcK9/14 and α-H3 on protein 
lysates harvested as described in 4.10, following the same treatment conditions as in (A).   
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H3 acetylation was consistently detected in AML193 cells.  To test the effect of 5-
Aza-dC and/or TSA treatment on global cellular levels of acetylated H3 in 
AML193 cells, western blots were performed utilizing α-H3-AcK9/14 on cell 
lysates and enriched histone protein fractions (Fig. 4.11C).  Similar to the 
experiment illustrated in Figure 4.10, 5-Aza-dC failed to significantly alter the 
levels of acetylated H3 when treated alone, however TSA – a well known inhibitor 
of HDAC activity – greatly induced global acetylation of H3 when treated as a 
single agent and when treated in combination with 5-Aza-dC.  This is of interest as 
even though global acetylation is induced by TSA, the ChIP data reveals that the 
p15 promoter retains deacetylated histones following TSA treatment.  This again 
suggests that DNA methylation preserves DNA:histone complexes in a 
transcriptionally inert conformation and that hypermethylated genes require 
promoter demethylation prior to pharmacologic HDAC inhibition to induce 
transcription. 
 
4.2.7. DISCUSSION  
Taken together, the 5-Aza-dC time course experiment illustrated in Figure 
4.6 and the ChIP data summarized in Figure 4.12 demonstrate that the p15 gene is 
in a transcriptionally inactive state when its promoter associated CpG island is 
hypermethylated in AML193 cells.  Histones, the key protein components of 
chromatin, located near the p15 transcriptional start site and within the CpG island 
are marked by H3 amino-terminal deacetylation, enriched lysine 9 methylation, 
diminished lysine 4 and arginine 17 methylation and presumably an inaccessible  
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Figure 4.12 Summary of ChIP Data Before and After 5-Aza-dC Treatment.  Illustrated is 
a hypothetical schematic representation of the p15 promoter region in AML193 cells before 
and after treatment with 5-Aza-dC.  DNA: black lines; histone octamers: cylinders; protruding 
histone amino tails: gray lines; methyl moieties: red circles; acetyl moieties: green rectangles. 
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chromatin conformation.  Furthermore, p15 demethylation by 5-Aza-dC reverses 
local covalent histone modifications without altering their global levels and results 
in p15 induction.  Global HDAC inhibition by TSA treatment is insufficient to 
reactivate methylated p15 alleles and requires 5-Aza-dC pretreatment in order to 
synergistically enhance p15 mRNA production.  This data corroborates previous 
reports on both p15 (Cameron et al., 1999a) and p16 (Coombes et al., 2003; Kondo 
et al., 2003; Nguyen et al., 2002) induction and supports the hypothesis that 
promoter hypermethylation is the dominant epigenetic process over histone 
deacetylation.  Similar to the experiments with DNMT and HDAC inhibitors, it 
would be interesting to study the effects of a pharmacologic inhibitor of histone 
methylation, specifically H3 lysine 9 methylation; however such a compound does 
not yet exist. 
MeCP2 is a chromosomal protein that preferentially binds to DNA that 
contains a single symmetrically methylated CpG (Nan et al., 1996) and has been 
shown in several solid tumor cell lines to localize to hypermethylated tumor 
suppressor gene promoters (Nguyen et al., 2001; Nguyen et al., 2002).  Our data 
involving the hypermethylated p15 gene supports this concept and extends the 
current body of MeCP2 literature to include a role for this MBD in hematologic 
malignancy tumor suppressor gene silencing.  The co-localization of SUV39h1 at 
this same region is also consistent with the literature as MeCP2 has recently been 
shown to harbor a protein complex containing H3 lysine 9 methyltransferase 
activity (Fuks et al., 2003b).  As SUV39h1 is an H3 lysine 9 specific HMT, our 
data would suggest that the HMT activity observed in the MeCP2 complex reported 
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by Fuks et al. would be that of SUV39h1, yet it should be noted that other 
mammalian lysine 9 specific HMTs do exist.   
As previously mentioned, methylated H3 lysine 9 is consistently associated 
with silent heterochromatic regions yet the exact role this modification plays in this 
epigenetic process is not fully understood.  The prevailing dogma involves the 
heterochromatic adaptor protein HP1, which has been implicated in both gene 
silencing and supra-nucleosomal chromatin structure.  Methylated H3 lysine 9 is a 
binding site for the chromodomain of HP1 (Bannister et al., 2001; Lachner et al., 
2001), which is known to mediate gene silencing and repress transcription (Li et 
al., 2002a).  Furthermore, HP1 and SUV39h1 have been shown to directly interact 
(Yamamoto and Sonoda, 2003), as has SUV39h1 and the DNMTs (Fuks et al., 
2003a), which supports the hypothesis that the epigenetic machinery located at 
hypermethylated promoters propagates a self-reinforcing transcriptionally inert 
heterochromatic subdomain.  Further ChIP experiments using antibodies for the 
three human HP1 isoforms are necessary to confirm the presence or absence of this 
epigenetic regulator at the hypermethylated p15 promoter region in AML cells. 
The ability of 5-Aza-dC to reduce H3 lysine 9 methylation at tumor 
suppressor gene loci is interesting and warrants further investigation as the 
mechanism behind this is not known.  It is possible that cytosine methylation is 
required to maintain histone methylation, but given the vast potential methylation 
marks within the histone amino-terminals, it is difficult to envision 5-Aza-dC 
having the ability to specifically downregulate the methylation of certain amino 
acids (such as H3 lysine 9) and upregulate or not effect others.  Given the fact that 
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DNMTs have recently been shown to associate with a complex that includes 
HDAC activity and SUV39h1 (Fuks et al., 2003a; Vaute et al., 2002), it is tempting 
to hypothesize that DNMT depletion induced by 5-Aza-dC leads to H3 lysine 9 
demethylation via disruption of the epigenetic silencing complex.  In the same 
manner, this disruption could also facilitate the local enrichment of acetylated 
histones which is supported by the data presented herein and by studies on the 
hypermethylated p16 gene (Coombes et al., 2003; Kondo et al., 2003; Nguyen et 
al., 2002) and MLH1 gene (Fahrner et al., 2002) in solid tumor cell lines.  
However, this hypothesis is complicated by the fact that 5-Aza-dC treatment has 
also been shown to augment the expression and chromatin remodeling of a small 
number of unmethylated genes in vitro (Coombes et al., 2003; Lavelle et al., 2003; 
Nguyen et al., 2002), suggesting that it may have effects which are independent of 
cytosine demethylation.  
In contrast to H3 lysine 9 methylation, H3 lysine 4 methylation was 
associated with a transcriptionally active p15 gene in AML193 cells.  Although this 
finding is consistent with the literature (Santos-Rosa et al., 2002; Strahl et al., 
1999), the exact function that this epigenetic mark has with respect to the 
transcriptional machinery is largely unknown.  One possibility could arise from the 
fact that H3 lysine 4 methylation has recently been shown to block the binding of 
the aforementioned NuRD transcriptional repressor complex, which normally binds 
H3 amino-terminals facilitating repressive chromatin remodeling (Zegerman et al., 
2002).  Moreover, the authors of this study report that the H3 lysine 4 modification 
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is unique as methylation at H3 lysine 9 failed to prevent NuRD binding to the H3 
amino-terminal, and therefore failed to inhibit NuRD mediated silencing. 
Similarly, methylation of arginine residues has been shown to be associated 
with transcriptionally active chromatin which is supported by our finding of 
enriched H3 arginine 17 methylation at the p15 promoter following 5-Aza-dC 
treatment.  Although proteins that harbor domains which specifically bind such a 
modification have yet to be defined, evidence does exist supporting a role for the 
arginine specific HMT CARM1 in transcriptional activation (Bauer et al., 2002) 
and histone acetylation (Daujat et al., 2002).  Furthermore, deimination of the H3 
amino-terminal, the process of converting histone arginine to citrulline and 
therefore inhibiting arginine methylation, has recently been reported to antagonize 
transcriptional induction of the pS2 estrogen-regulated promoter (Cuthbert et al., 
2004), further supporting an in vivo role for arginine methylation in transcriptional 
activation. 
Epigenetic mechanisms involving promoter hypermethylation and covalent 
histone modifications are clearly linked but many questions involving gene 
silencing remain unanswered.  For example, how do cellular mechanisms target 
certain CpG islands for hypermethylation while others remain unaffected or is it 
merely a stochastic process?  One possible explanation is the recently discovered 
ability of short interfering RNAs to induce DNA methylation and gene silencing in 
human cells (Kawasaki and Taira, 2004; Morris et al., 2004).  Although known for 
some time in plants, the recent identification of this process in mammalian cells is 
of great interest as it provides a rationale as to how specific tumor suppressor genes 
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are targeted for DNA and H3 lysine 9 methylation and others are not.  Furthermore, 
does DNA methylation direct histone modification or is the reverse true?  As 
mentioned, evidence in Neurospora crassa exists supporting the notion that histone 
methylation directs DNA methylation to specific genomic regions (Tamaru and 
Selker, 2001), but the data presented herein suggests that the process is more 
complicated in mammalian cells and that most likely DNA methylation is the 
dominant process. 
Drugs that affect the epigenetic machinery, including HDAC and DNMT 
inhibitors, are becoming increasingly more common as cancer therapeutics, 
particularly in leukemias.  Given their inherent lack of specificity on not only cell 
type but target gene of interest, it is important to better understand their actions and 
consequences at a molecular level and to identify pharmacologic agents with 
acceptable toxicity profiles.  Microarray analysis has revealed the significant effect 
that 5-Aza-dC and TSA have on gene expression in various solid tumor cell types 
(Suzuki et al., 2002; Yamashita et al., 2002), yet the correlation of gene expression 
with chromatin conformation and epigenetic modifiers are only beginning to be 
defined.  Further ChIP assays would be useful to assist in the identification of other 
histone modifications and chromatin remodeling enzymes that are associated with 
hypermethylated p15 promoter alleles.  Thus, understanding how 5-Aza-dC 
influences these covalent modifications in connection with transcriptional 
activation and chromatin accessibility will yield interesting insights into how these 
events become altered in disease states and perhaps how they can be addressed in 
therapy.   
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4.3. ZEBULARINE INHIBITS HUMAN AML GROWTH AND p15 
PROMOTER HYPERMETHYLATION 
 
4.3.1. Zebularine Induces and Demethylates p15 in AML193 Cells 
Along with 5-Aza and 5-Aza-dC, other pharmacologic inhibitors of 
cytosine methylation exist, including but not limited to 5-fluoro-cytosine (Santi et 
al., 1983), 5,6-dihydro-5-azacytidine (Sheikhnejad et al., 1999), 4’-thio-2’-
deoxycytidine (Kumar et al., 1997), and procaine (Villar-Garea et al., 2003).  
Although many have proven useful in vitro, their utility as in vivo anti-cancer 
therapeutics has been inhibited by toxicity and chemical stability concerns.  The 
cytidine analog zebularine, originally developed as an inhibitor of cytidine 
deaminase (Driscoll et al., 1991; Kim et al., 1986), has recently demonstrated in 
vitro and in vivo DNMT inhibition and stable antitumor properties (Cheng et al., 
2003; Cheng et al., 2004a; Cheng et al., 2004b).  Given the previous studies 
investigating 5-Aza-dC mediated DNMT inhibition, the recently reported stability 
and minimal toxicity of zebularine, and the large collection of data involving p15 
promoter hypermethylation in human leukemia, we evaluated the DNA 
demethylation and anti-proliferative effects of zebularine on the methylated p15 
cell line AML193.  
 Previous studies using zebularine have reported that higher doses, when 
compared to common 5-Aza-dC treatments, are required for efficient cytosine 
demethylation and reconstitution of mRNA expression (Cheng et al., 2003; Cheng 
et al., 2004a).  Thus, a dose response experiment encompassing 2 to 500 µM 
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zebularine was performed on AML193 cells followed by p15 RTPCR.  As shown 
in Figure 4.13A, p15 mRNA is detectable following 100 and 500 µM zebularine 
treatment when compared to the 5-Aza-dC treated and HL60 positive controls.  To 
confirm that the zebularine mediated induction of p15 mRNA was associated with 
promoter demethylation, MSP of the p15 promoter region was performed.  As 
shown in Figure 4.13B, the vehicle control confirms complete hypermethylation of 
the p15 promoter in AML193 cells when compared to the unmethylated control cell 
line HL60 and the methylated positive control DNA.  Interestingly, treatment with 
zebularine resulted in minor p15 promoter demethylation at dosages in the 10 to 
50 µM range and substantial demethylation at 100 and 500 µM, yet only the higher 
doses were associated with detectable p15 mRNA.  Taken together, the data 
suggests that higher doses of zebularine, when compared to 5-Aza-dC, are required 
to demethylate p15 promoter alleles in vitro and induce expression in AML193 
cells. 
 As mentioned, previous reports have shown that combinatorial inhibition of 
both DNMT and HDAC activity can synergistically reactivate methylated genes 
(Cameron et al., 1999a).  To determine if zebularine, like 5-Aza-dC, can also be 
effective in conjunction with HDAC inhibitors, AML193 cells were treated with 
zebularine and TSA and assayed for p15 mRNA and promoter hypermethylation 
(Fig. 4.13C and D).  Treatment of AML193 cells with TSA for the final 12 hours of 
a three day zebularine treatment synergistically induced detectable p15 mRNA by 
7.1 fold when compared to the vehicle control.  As expected, all conditions that 
included zebularine induced demethylation of the p15 promoter as detected by 
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Figure 4.13 Zebularine Treatment in AML193 Cells.  A) p15 RTPCR following a 
zebularine dose response.  B) p15 MSP of the zebularine dose response shown in (A).  C) p15 
RTPCR following combinatorial drug treatments as labeled.  D) p15 MSP of the combinatorial 
drug treatments shown in (C).  Included in each RTPCR amplification [(A) and (C)] is a PCR 
positive control (HL60) and water and reverse transcriptase negative controls (dH2O and RT -) 
The housekeeping gene β-Actin is amplified in all samples to ensure RNA integrity and 
equivalent cDNA template quantity between samples.  Relative fold-induction of p15 mRNA 
following drug treatment, as defined in the Materials and Methods, are depicted below their 
respective lanes.  Included in each MSP assay [(B) and (D)] are unmethylated (HL60) and 
methylated (METH+) positive controls and water negative controls (dH2O).  
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MSP.  Of note, consistent with previously published data (Cameron et al., 1999a), 
TSA treatment alone failed to induce p15 expression and promoter demethylation 
as illustrated previously in Figure 4.11.  To our knowledge, this is the first study to 
combine HDAC inhibitors with zebularine treatment. 
 
4.3.2. Zebularine Mediated Induction of p15 is Associated with Regional 
Histone Acetylation Enrichment 
 Previous work on the hypermethylated MLH1 gene in RKO human colon 
cancer cells has shown that following demethylation by 5-Aza-dC various histone 
modifications, including H3 acetylation, become enriched at the MLH1 promoter 
region (Fahrner et al., 2002) and similar results have been reported involving the 
hypermethylated p16 gene in T24 bladder cancer cells (Nguyen et al., 2002).  
Based on the literature concerning solid tumor promoter demethylation and 
regional chromatin remodeling and given our previous data involving 5-Aza-dC 
induced demethylation of p15 in AML193 cells in association with local 
enrichment of H3 acetylation, ChIP assays were employed to test if p15 
demethylation by zebularine treatment is also associated with local enrichment of 
acetylated histones.  
 Using the previously established zebularine dose and treatment time, a ChIP 
assay was performed on AML193 cells using antibodies for acetylated H3 at 
lysines 9 and 14, and H4 at lysines 5, 8, 12, and 16 (Fig. 4.14).  When the 
immunoprecipitated DNA was amplified with PCR primers specific for the p15  
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Figure 4.14 ChIP Analysis of H3 and H4 Acetylation Following Zebularine Treatment in 
AML193 Cells.  Illustrated is the ethidium bromide staining of ChIP PCR products from input 
positive controls (Input), no-antibody negative controls [Ab (-)], acetylated H3 
immunoprecipitates (α-H3-AcK9/14), and acetylated H4 immunoprecipitates (α-H4-
AcK5/8/12/16).  The experiment was performed in the absence and presence of zebularine and 
included in each PCR is a water negative reagent control (dH2O).  The lower panel graphically 
represents semi-quantitation of the data using densitometry of the PCR products from 
immunoprecipitated samples normalized to their input counterparts and expressed numerically 
in brackets as fold change following zebularine treatment.  
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promoter region (Fig. 4.2) a 3.5 fold enrichment of acetylated H3 and a 6.5 fold 
enrichment of acetylated H4 was observed following zebularine treatment.  These 
results suggest that like 5-Aza-dC, zebularine also has the ability to affect regional 
chromatin remodeling, specifically histone acetylation, in association with p15 
promoter demethylation.   
 
4.3.3. Zebularine is Cytotoxic and Inhibits AML193 Proliferation 
 To assess the biological effects of zebularine on cellular toxicity and 
proliferation, MTT and tritiated thymidine assays were performed.  The MTT assay 
is useful for the quantitation of toxicity and chemosensitivity by measuring 
mitochondrial metabolism based on the reduction of the MTT tetrazolium salt as a 
reflection of viable cell number.  As previous reports have shown that 5-Aza-dC is 
most effective at lower doses (Cameron et al., 1999a; Herman et al., 1996b; Issa et 
al., 2004) and our RTPCR, MSP and ChIP data suggest that zebularine effectively 
demethylates DNA at dosages in the 100 to 500 µM range (Cheng et al., 2003; 
Zhou et al., 2002b) we chose 1 and 4 µM 5-Aza-dC and 250 and 500 µM 
zebularine for MTT analysis.  Both 5-Aza-dC and zebularine treatment of AML193 
cells greatly reduced the spectrophotometric absorbance in a dose dependent 
manner when compared to the vehicle control cells (Fig. 4.15A).  5-Aza-dC 
treatment at 1 and 4 µM resulted in a 69.8% and 76.6% mean reduction in viable 
cells, respectively, and zebularine treatment at 250 and 500 µM resulted in an 
85.2% and 86.6% mean reduction in viable cells, respectively. 
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Figure 4.15 MTT and Tritiated Thymidine Assays Following Zebularine Treatment in 
AML193 Cells.  A) MTT assay of AML193 cells following pharmacologic DNMT inhibition. 
At standard demethylating doses, both 5-Aza-dC and zebularine strongly reduce cell viability. 
B) Tritiated thymidine assay of AML193 cells following pharmacologic DNMT inhibition.  At 
standard demethylating doses, both 5-Aza-dC and zebularine greatly inhibit cellular 
proliferation.   
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The tritiated thymidine uptake assay is useful for the quantitation of cellular 
proliferation by measuring the incorporation of [3H]-labeled thymidine into newly 
synthesized DNA.  Employing the same dosages as used in the MTT assay we 
found that both 5-Aza-dC and zebularine treatment of AML193 cells resulted in a 
dramatic reduction in cellular proliferation in a dose dependent manner when 
compared to the vehicle control cells (Fig. 4.15B).  5-Aza-dC treatment at 1 and 4 
µM resulted in a 97.2% and 98.6% mean reduction in cell proliferation, 
respectively, and zebularine treatment at 250 and 500 µM resulted in a 97.5% and 
99.5% mean reduction in cell proliferation, respectively.  Taken together, these 
results show that the cytosine analogs 5-Aza-dC and zebularine, when treated at 
standard demethylating doses, impart very strong growth inhibitory effects onto 
AML cells in vitro resulting in a decrease in both cell viability and proliferation.   
 
4.3.4. Zebularine Induces Apoptosis and Halts AML193 Cells at G2/M 
To test the effects of both 5-Aza-dC and zebularine treatment on the cell 
cycle, PI DNA staining of AML193 cells was employed.  Using the same dosages 
as the MTT and tritiated thymidine assays we found that both 5-Aza-dC and 
zebularine treatment of AML193 cells resulted in an increase in the percentage of 
cells undergoing apoptosis and those arrested in G2/M of the cell cycle (Fig. 4.16).  
When compared to the vehicle control cells, 1 and 4 µM 5-Aza-dC resulted in a 
7.7% and 7.8% increase in apoptotic cells, respectively, while 250 and 500 µM 
zebularine resulted in a dramatic 16.6% and 25.3% increase in apoptotic cells, 
respectively.  Regarding the G2/M halt, when compared to the vehicle control cells, 
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Figure 4.16 Effects of Zebularine on the Cell Cycle in AML193 Cells.  A)  Histograms of 
PI stained DNA from AML193 cells before and after pharmacologic DNMT inhibition.  B) 
The percentages of cells in the various stages of the cell cycle (see legend) were quantitated 
from the graphs shown in (A) as determined by histogram deconvolution.  At standard 
demethylating doses, both 5-Aza-dC and zebularine increased the number of cells undergoing 
apoptosis and those halted at G2/M.  All results are an average of three independent 
experiments and error bars represent the standard deviation. 
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1 and 4 µM 5-Aza-dC resulted in a 3.2% and 10.0% increase in G2/M phase cells, 
respectively, while 250 and 500 µM zebularine resulted in a 17.1% and 9.1% 
increase in G2/M phase cells, respectively.  The minor increase in G2/M phase 
cells following 500 µM zebularine (9.1%) when compared to the lower dosage of 
250 µM (17.1%) could be a result of the high percentage of cells undergoing 
apoptosis.   
Consistent with the increases in apoptotic and G2/M phase cells, concurrent 
decreases in the percentage of cells in G0/G1 and S phase were also observed 
following both 5-Aza-dC and zebularine treatment.  The decrease in S phase cells is 
consistent with the dramatic reduction in cellular proliferation following drug 
treatment as previously shown by the tritiated thymidine uptake assays.  Taken 
together, these results show that the cytosine analogs 5-Aza-dC and zebularine, 
when treated at standard demethylating doses, induce apoptosis and G2/M arrest in 
AML193 cells.      
 
4.3.5. Zebularine Induces Global Histone Phosphorylation in AML193 Cells 
As mentioned, the histone code hypothesis has been expanded upon to 
incorporate such cellular processes as DNA double-strand break repair (Morrison et 
al., 2004) and apoptosis (Cheung et al., 2003) in addition to the previously 
hypothesized roles in gene transcription, DNA replication, and chromosome 
segregation (Jenuwein and Allis, 2001; Strahl and Allis, 2000).  Both the extrinsic 
and the intrinsic pathways of apoptosis result in many molecular events including 
cleavage of PARP, chromatin condensation, inter-nucleosomal degradation of 
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DNA, and packaging of the cell into apoptotic bodies.  Recently defined histone 
modifications are also believed to be involved in apoptosis and include the 
phosphorylation of H2A.X at serine 139 and H2B at serine 14 (Cheung et al., 2003; 
Rogakou et al., 2000) (Fig. 1.7).  H2A.X is rapidly phosphorylated in response to 
ionizing radiation and other agents that cause DNA double-strand breaks (Rogakou 
et al., 1998) and is also induced by apoptotic DNA fragmentation (Rogakou et al., 
2000).  H2B serine 14 phosphorylation has been correlated with cells undergoing 
programmed cell death (Cheung et al., 2003) and DNA double-strand breakage 
(Fernandez-Capetillo et al., 2004).  Furthermore, although phosphorylation of H3 at 
serine 10 has traditionally been associated with the induction of mitosis (Prigent 
and Dimitrov, 2003), evidence does exist for an association with gliotoxin-
mediated apoptosis (Waring et al., 1997).  As a result of the recent interest in 
histone phosphorylation as a marker of apoptosis and given the dramatic increase in 
AML193 cells that undergo apoptosis following zebularine treatment (Fig. 4.16), 
western blots were employed with antibodies specific for phosphorylated histones 
following 5-Aza-dC and zebularine time course treatments. 
As shown in Figure 4.17, following zebularine treatment, AML193 cells 
strongly induce global phosphorylation of H3 at serine 10 that is observed as early 
as two days following initial drug treatment.  Phosphorylated serine residues 139 
and 14 of H2A.X and H2B, respectively, are also markedly induced in AML193 
cells following two days of zebularine treatment that is sustained and enhanced 
through day six (Fig. 4.17).  In comparison to zebularine, minimal induction of H3, 
H2A.X and H2B phosphorylation is observed following 5-Aza-dC treatment, which  
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Figure 4.17 Zebularine Induces Global Histone Phosphorylation in AML193 Cells.  Time 
course western blot analysis of phosphorylated and total histone protein levels following 
treatment with either 5-Aza-dC or zebularine for up to six days.  Note the increase in histone 
and histone variant serine phosphorylation following zebularine treatment when compared to 
total histone H2B.  Parallel gels were stained with Coomassie blue to ensure equivalent sample 
loading. 
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correlates with the smaller percentage of cells undergoing apoptosis following 5-
Aza-dC treatment illustrated in Figure 4.16.  Importantly, the increases in 
phosphorylated histones are specific and not a reflection of increases in total 
unmodified histones as confirmed by the equivalent protein bands when the time 
course assay blot was probed with an antibody for total H2B (Fig. 4.17).  Taken 
together, these results implicate histone phosphorylation of serine residues as a 
marker of cells undergoing zebularine mediated apoptosis of AML cells in vitro 
and provide further evidence for a potential apoptotic histone code. 
 
4.3.6 DISCUSSION  
Hypermethylation of promoter CpG islands, an epigenetic event, represents 
an alternative mechanism to genomic deletions or mutations in the inactivation of 
tumor suppressor genes and this frequent alteration in human cancer can potentially 
lead to the abnormal and uncontrolled growth of cancer cells.   Examples of genes 
that are commonly methylated in cancer include the GSTP1 gene in carcinoma of 
the prostate (Zhou et al., 2004), the MLH1 gene in colon cancer (Ricciardiello et 
al., 2003), the RB gene in neuroblastoma (Sakai et al., 1991), the E-cadherin gene 
in esophageal adenocarcinoma (Corn et al., 2001), and the aforementioned p15 
gene in leukemia (Herman et al., 1996b).  This type of alteration is of importance to 
the field of cancer therapeutics as promoter hypermethylation is a reversible 
process and, consequently, pharmacologic inhibitors of DNA methylation are 
currently being tested in clinical trials (Egger et al., 2004; Issa, 2003).  Several 
known pharmacological inhibitors exist yet for some their utility as in vivo anti-
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cancer therapeutics has been limited by toxicity and chemical stability concerns 
(Beisler, 1978).  Previous pre-clinical studies utilizing the novel methylation 
inhibitor zebularine in solid tumor cell lines and the large collection of data 
involving p15 promoter hypermethylation in leukemia prompted our investigation 
of the DNA demethylation and anti-proliferative effects of zebularine in human 
AML.  
Originally developed as an inhibitor of cytidine deaminase (Driscoll et al., 
1991; Kim et al., 1986), zebularine contains a 2-(1H)-pyrimidinone ring (Fig. 1.9) 
and has displayed both antitumor and DNA demethylating properties (Cheng et al., 
2003; Cheng et al., 2004a; Cheng et al., 2004b; Zhou et al., 2002b).  For example, 
oligonucleotides containing zebularine have been shown to form tight complexes 
with bacterial methyltransferases that leads to a potent inhibition of DNA 
methylation (Hurd et al., 1999; Zhou et al., 2002b) and recently Cheng et al. 
reported a depletion of DNMT1 following zebularine treatment in human T24 
bladder cancer cells (Cheng et al., 2004a).  In another study by Cheng et al., 
zebularine was administered orally to EJ6 human bladder cancer-bearing mice and, 
owing to its stability, was able to significantly reduce tumor growth with minimal 
toxicity in association with demethylation and re-expression of the p16 gene 
(Cheng et al., 2003).  Our findings of zebularine mediated in vitro demethylation 
and re-expression of the p15 tumor suppressor gene in AML are consistent with the 
reported data in solid tumor systems and substantiate zebularine as a viable DNA 
methylation inhibitor in hematological malignancies.  Furthermore, this is the first 
study to our knowledge that has combined zebularine treatment with the HDAC 
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inhibitor TSA, and like 5-Aza-dC and TSA combinatorial treatment (Cameron et 
al., 1999a), synergistic induction of p15 mRNA was observed. 
As mentioned, the tumor suppressor gene p16, silenced by promoter 
hypermethylation in T24 bladder cancer cells, has been shown to be reactivated by 
5-Aza-dC treatment (Nguyen et al., 2002).  Importantly, the authors from this study 
report that 5-Aza-dC treatment also induced regional chromatin remodeling at this 
locus, including a release of MeCP2, a reduction in H3 lysine 9 methylation, and 
enrichment in H3 acetylation and H3 lysine 4 methylation.  These results are 
consistent with our finding that zebularine treatment in AML cells induces p15 
mRNA in association with local histone H3 and H4 acetylation, modifications 
consistent with a chromatin conformation which is accessible to the transcriptional 
machinery (Agalioti et al., 2002; Morales and Richard-Foy, 2000).  Further ChIP 
assays are necessary to define other proteins and histone modifications that are 
modulated at this gene locus by zebularine treatment. 
Administration of zebularine to AML193 cells caused many anti-
proliferative effects including decreased cell viability and proliferation, an increase 
in the proportion of cells undergoing apoptosis and arrested in G2/M, and a 
decreased proportion of cells in G0/G1 and S phases of the cell cycle.  These 
results were comparable to 5-Aza-dC yet were often more dramatic, possibly as a 
result of the higher dosages required to efficiently demethylate DNA and 
reconstitute p15 expression.  A recent study using bile duct cancer cells also found 
5-Aza-dC to be cytotoxic with an increase in apoptotic cells, yet found the cells to 
be halted in the G0/G1 phase of the cell cycle (Tang et al., 2004).  Similarly, Yang 
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et al. reported 5-Aza-dC mediated growth inhibition in breast cancer cells with an 
increase in G0/G1, not G2/M, phase cells (Yang et al., 2002).  However, a very 
early study of 5-Aza-dC in HL60 human leukemic cells found, similar to the data 
presented herein, that 5-Aza-dC administration resulted in an increased proportion 
of cells in G2/M rather than G0/G1 (Levva et al., 1986).  This implies that cell 
cycle responses to DNA methylation inhibition may be cell type specific.  The 
difference in cellular response to DNMT inhibition is understandable as different 
genes will be induced in different cell types following 5-Aza-dC and/or zebularine 
treatment depending on which genes are silenced by promoter hypermethylation.  
Global gene expression arrays would be useful to test this hypothesis. 
To this end a microarray study using zebularine in the KAS-6/1 multiple 
myeloma cell line has recently revealed a number of genes to be demethylated and 
re-expressed following drug treatment which have the potential to significantly 
contribute to myeloma cell growth and survival (Pompeia et al., 2004).  
Furthermore, the preference of zebularine incorporation into cancer cells, as 
opposed to normal fibroblasts, has recently been reported in a microarray study by 
Cheng et al. which showed considerably more affected genes in bladder, colon, and 
pancreatic carcinoma cells then the normal fibroblasts (Cheng et al., 2004b).  This 
study also reported a decrease in detectable DNMT1 protein following zebularine 
administration similar to the aforementioned study that used bladder cancer cells 
(Cheng et al., 2004a) and has also been reported following 5-Aza-dC treatment 
(Velicescu et al., 2002).   This is presumably a result of the ‘quenching’ effect that 
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the cytosine analogs have on DNMTs when incorporated into newly synthesized 
DNA (Bouchard and Momparler, 1983; Santi et al., 1983; Santi et al., 1984).   
Outside of the DNMTs, no other global protein levels have been analyzed to 
date following in vitro zebularine administration.  The growing interest in the 
histone code, its relation to DNA hypermethylation (Fahrner et al., 2002), and the 
hypothesis that an apoptotic histone code exists (Cheung et al., 2003) prompted our 
analysis of global protein levels of phosphorylated histones, specifically H3-
phosphoserine 10, H2A.X-phosphoserine 139, and H2B-phosphoserine 14, 
following zebularine treatment.  Consistent with the increases observed in the 
percentage of cells undergoing apoptosis following zebularine treatment, global 
induction of histone phosphorylation was detected in AML cells within two days of 
drug administration.  The role of histone phosphorylation during apoptosis is still 
unresolved yet it is attractive to hypothesize that histone modifications, such as 
serine phosphorylation, play functional roles in promoting the drastic changes that 
occur in DNA integrity and chromatin compaction during apoptosis.  Whether 
these modifications have functional consequences regarding apoptotic chromatin 
condensation or are merely DNA damage markers remains to be determined.    
Taken together, our findings indicate that zebularine is an effective inhibitor 
of p15 promoter hypermethylation and cell growth in human AML in vitro.  By 
expanding the spectrum of zebularine antitumor effects to include hematological 
malignancies, our study also provides further support for the clinical potential of 
this agent as a cancer therapy, alone, or in combination with other drugs such as 5-
Aza-dC and HDAC inhibitors. 
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4.4. cDNA MICROARRAY ANALYSIS OF GENES UPREGULATED BY 
TREATMENT WITH 5-Aza-dC IN COMBINATION WITH TSA 
IDENTIFIES ABERRANT MT1H PROMOTER HYPERMETHYLATION 
AT A HIGH FREQUENCY IN HUMAN AML 
 
4.4.1. cDNA Microarray Analysis of AML193 Cells Following DNMT and 
HDAC Inhibition 
 As mentioned, it is well documented that a common occurrence in cancer 
cells is the aberrant hypermethylation of CpG islands in gene promoters with 
accompanying loss of transcription (Baylin and Herman, 2000).  Although many 
genes have been identified which are frequently affected by promoter 
hypermethylation in specific types of cancer, numerous experimental strategies 
have been utilized in the hope of discovering novel genes affected by aberrant 
epigenetic silencing.  One strategy that has been employed for this purpose 
combines high throughput gene expression analysis with pharmalogical inhibition 
of the epigenetic silencing machinery.  Based on the recent success of this approach 
in colorectal cancer (Suzuki et al., 2002), esophageal squamous cell carcinoma 
(Yamashita et al., 2002), pancreatic carcinoma (Sato et al., 2003a), and multiple 
myeloma (Pompeia et al., 2004), and given the fact that multiple genes have been 
shown to be concurrently hypermethylated in human cancer including AML 
(Esteller et al., 2001; Melki et al., 1999; Paz et al., 2003), cDNA microarray 
analysis was performed on AML193 cells following treatment with 5-Aza-dC and 
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TSA in order to identify novel genes aberrantly silenced by promoter 
hypermethylation in AML. 
 As the previous work with this drug combination successfully demethylated 
and synergistically upregulated the CDKI p15 in AML193 cells, the same drug 
dosages and incubation times were employed to screen for novel genes silenced by 
promoter hypermethylation.  Following microarray analysis, genes with a log2 ratio 
greater than 1 in all three microarrays following treatment with 5-Aza-dC and TSA 
were considered upregulated and are listed in Table 4.1.  Seven genes were found 
to be consistently upregulated by cDNA microarray analysis and all have known 
chromosomal locations and transcriptional start sites as defined by public genome 
databases.  Of the 1718 genes spotted on the 1.7K human microarrays, 978 were 
used in the data analysis based on their conforming to the filtering criteria between 
each of the three microarrays.  Criteria to incorporate specific microarray genes 
into the analysis included, but was not limited to, spot morphology, minimum 
intensity values, and consistency between each of the three microarray experiments.  
The seven genes that were successfully identified by the microarray screen were 
analyzed by semi-quantitative RTPCR in cells subjected to vehicle treatment, 5-
Aza-dC alone, TSA alone, or a combination of the two drugs (Fig. 4.17).   
The upregulation of metallothionein 1H (MT1H), metallothionein 1G 
(MT1G), spermidine/spermine N1-acetyltransferase (SAT), metallothionein 1E 
(MT1E), interferon-gamma inducible protein 30 (IFI30), glutathione peroxidase 4 
(GPX4), and metallothionein 2A (MT2A), as detected by microarray, following 
combinatorial drug treatment was confirmed by RTPCR in all cases.  Interestingly, 
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Table 4.1 Genes Upregulated by 5-Aza-dC and TSA Treatment in AML193 Cells 
Accession 
No.a Gene Name Symbol Location 
CpG 
Islandb Meth.
c 
R93527 Metallothionein 1H MT1H 16q13 yes yes 
NM_005950 Metallothionein 1G MT1G 16q13 yes yes 
AA056280 Spermidine/Spermine N1-Acetyltransferase SAT Xp22.1 yes partial 
H93255 Metallothionein 1E MT1E 16q13 yes partial 
W24688 Interferon-Gamma Inducible Protein 30 IFI30 19p13.1 yes no 
N31188 Glutathione Peroxidase 4 GPX4 19p13.3 yes no 
H91613 Metallothionein 2A MT2A 16q13 yes no 
 
a GenBank accession number. 
b yes: CpG island located near presumed transcription start site or 5’ upstream region; no: no CpG 
island located near presumed transcription start site or 5’ upstream region. 
c yes: fully methylated; partial: partially methylated; no: no methylation detected. 
 
 
 
 
 
 
 
 
 163
 
 
 
 
 
 
Figure 4.18 Semi-quantitative RTPCR of Candidate Genes Identified by cDNA 
Microarrays.  The seven genes identified by microarray analysis and the housekeeping gene 
β-Actin were subjected to RTPCR analysis following control, individual, and combinatorial 
drug treatments.  The fold change in target gene mRNA, as compared to the vehicle control, is 
represented numerically in brackets below individual sample gel lanes.   
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the degree of transcriptional upregulation following individual drug treatment 
varied and in some cases (SAT, MT1E, IFI30, GPX4, MT2A) basal mRNA was 
detected in the vehicle treated cells.  However, in almost all cases, treatment with 
5-Aza-dC alone resulted in an induction of detectable candidate gene mRNA, 
implying the possibility of promoter hypermethylation mediated silencing at these 
loci.  Moreover, the gene MT1G displayed a classic synergistic upregulation 
pattern following drug treatments, similar to the previously studied CDKI p15, 
further reinforcing the rationale for downstream methylation analysis. 
 
4.4.2. Methylation Analysis of Candidate Genes in AML193 Cells 
All seven genes upregulated by treatment with 5-Aza-dC and TSA harbored 
CpG islands, as defined by Takai and Jones (Takai and Jones, 2002), within their 5’ 
promoter regions.  Given the availability of the 5’ promoter sequence of all seven 
candidate genes, MSP primers were designed to test for the presence of CpG island 
hypermethylation.  Limiting the analysis to AML193 cells, out of the seven 
candidate genes, four harbored methylated promoter alleles (MT1H, MT1G, SAT, 
MT1E) and the remaining three genes (IFI30, GPX4, MT2A) amplified strictly 
unmethylated alleles (Fig. 4.18).  Interestingly, SAT and MT1E displayed a partial 
methylation pattern as they harbored both unmethylated and methylated alleles 
(Fig. 4.18B).  Importantly, the two genes with complete promoter hypermethylation 
(MT1H, MT1G) were partially demethylated following a 72 hour treatment with 5-
Aza-dC (4.18A).  This timeframe is consistent with 5-Aza-dC induced 
demethylation of p15 and provides further evidence of promoter hypermethylation 
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Figure 4.19 MSP of Candidate Genes Following Treatment with 5-Aza-dC.  A) MSP 
analysis of Group 1 genes (MT1H, MT1G) harboring completely methylated alleles.  Note the 
reconstitution of unmethylated alleles following 72 hours of 5-Aza-dC treatment.    B) MSP 
analysis of Group 2 genes (SAT, MT1E) harboring partially methylated alleles.  C) MSP 
analysis of Group 3 genes (IFI30, GPX4, MT2A) harboring completely unmethylated alleles. 
Commercially available universally methylated bisulfite modified DNA was used as a 
methylated positive control (METH +) and water as a negative reagent control (dH2O) for all 
reactions. 
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mediated gene silencing at these loci.  Taken together, the seven candidate genes 
were categorized into three groups based on their promoter methylation patterns in 
AML193 cells: Group 1 genes harbored completely methylated promoter alleles 
(MT1H, MT1G); Group 2 genes harbored partially methylated promoter alleles 
(SAT, MT1E); and Group 3 genes harbored completely unmethylated promoter 
alleles (IFI30, GPX4, MT2A) (Fig. 4.18 and Table 4.1). 
 
4.4.3. Methylation Analysis of Metallothionein Genes in AML 
 The most striking finding from the microarray analysis was that of the 
seven candidate genes, four (MT1H, MT1G, MT1E, MT2A) are members of the 
metallothionein family of cysteine-rich small molecular weight proteins.  The 
majority of this gene family is located on chromosome 16q13 (West et al., 1990) 
(Fig. 4.20), and although their function has yet to be fully realized, they are induced 
by toxic heavy metals, UV irradiation, and reactive oxygen species and are 
considered to be important mediators of cellular detoxification (Palmiter, 1998).  
Many of the metallothioneins at this locus have promoter region CpG islands and, 
interestingly, MT1G promoter hypermethylation has recently been implicated in 
the pathogenesis of sporadic papillary thyroid carcinoma (Huang et al., 2003).  As 
such, the metallothionein genes that were identified by microarray analysis of 
AML193 cells (MT1H, MT1G, MT1E, MT2A) were subsequently analyzed for 
promoter hypermethylation in a panel of AML cell lines.  
Including AML193 cells, promoter hypermethylation was detected in 
MT1H, MT1G, MT1E and MT2A in 5/7 (71%), 2/7 (29%), 2/7 (29%), and 0/7 
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Figure 4.20 16q13 Locus and Metallothionein Amino Acid Alignment.  A) Schematic of 
metallothionein genes located at 16q13.  Arrows represent gene location and orientation and 
red circles represent known CpG islands.  B) The amino acid sequences of known 
metallothioneins are aligned revealing both the high degree of homology and the cysteine-rich 
alpha and beta clusters (represented by black bars above sequence).  Alignments were 
generated using the ‘ClustalW’ amino acid sequence alignment algorithm and the ‘prettyplot’ 
diagram tool available from EMBOSS.   
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(0%) AML cell lines, respectively (Fig. 4.21A).  Interestingly, promoter 
hypermethylation was detected in three of the candidate genes (MT1H, MT1G, 
MT1E) in KG1A and AML193 cells, which also both harbor complete p15 
promoter hypermethylation (Fig. 4.3), implying the possibility of a common 
abnormality in the DNA methylation machinery of these cell lines.  To investigate 
for the occurrence of MT1H, MT1G and MT1E promoter hypermethylation in 
human AML in vivo, AML patient blasts (n = 39) and non-leukemic controls (n = 
13) were analyzed by MSP.  MT1H, MT1G and MT1E methylation was detected in 
20/39 (51%), 1/37 (3%) and 0/37 (0%) AML patient samples (Fig. 4.20B), 
respectively, and there was no methylation of any of these genes in control samples 
(Fig. 4.20C).  Taken together, MT1H, MT1G and MT1E promoter 
hypermethylation was identified in 27/46 (54%), 3/44 (7%) and 2/44 (5%) AML 
cell lines and patient samples, respectively. 
 
4.4.4. 5-Aza-dC Mediated Induction of MT1H is Associated with Changes in 
H3 Methylation and Acetylation 
 To further address our hypothesis, we chose to investigate the MT1H 
promoter for changes in histone modifications following 5-Aza-dC mediated 
promoter demethylation.  Given our previous analysis of the methylated p15 
promoter in AML193 cells which identified deacetylated histones in association 
with specific H3 lysine methylation, ChIP assays were employed to determine if 
similar patterns of H3 amino-terminal modifications were present at the 
hypermethylated MT1H promoter region in AML193 cells.  As illustrated in Figure 
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Figure 4.21 Metallothionein Promoter Hypermethylation.  A) MSP analysis of bisulfite 
modified DNA from AML cell lines.  B) Representative MSP analysis of bisulfite modified 
DNA from AML patient samples.  C) Representative MSP analysis of bisulfite modified DNA 
from non-leukemic control samples.  Commercially available universally methylated bisulfite 
modified DNA was used as a methylated positive control (METH +) and water as a negative 
reagent control (dH2O) for all reactions. U: unmethylated MSP reaction; M: methylated MSP 
reaction. 
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4.22, the MT1H promoter is associated with methylated H3 lysine 9 and 
deacetylated H3 at lysines 9 and 14 in AML193 cells and, like p15, following 5-
Aza-dC mediated demethylation, both modifications are reversed.  This finding is 
consistent with our model of promoter hypermethylation mediated p15 gene 
silencing and further implicates specific histone modification patterns in the 
remodeling of chromatin to affect epigenetic gene silencing.  Importantly, similar 
H3 modifications have been observed at the hypermethylated metallothionein I 
promoter in rat lymphosarcoma cells which were also reversible following 
treatment with 5-Aza (Ghoshal et al., 2002).  Further ChIP assays are warranted to 
investigate which other histone modifications are associated with the methylated 
MT1H promoter in AML. 
 
4.4.5. DISCUSSION  
 Since the discovery that DNMT and HDAC inhibitors synergistically 
induce transcription of genes silenced by promoter hypermethylation in vitro 
(Cameron et al., 1999a), numerous groups have exploited this model to further 
understand the mechanism behind epigenetic silencing.  As a result, it is now 
commonplace to reactivate epigenetically silenced tumor suppressor genes in vitro 
with pharmacological inhibitors of both the DNMT and HDAC machineries and 
this combination of drugs is currently being tested in a clinical setting (Shaker et 
al., 2003).  Recently, DNMT inhibitors such as 5-Aza and 5-Aza-dC have been 
utilized in the clinic for the treatment of hematological malignancies (Lyons et al., 
2003) and solid tumors (Aparicio et al., 2003) with varying outcomes.  A phase I  
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Figure 4.22 MT1H ChIP Analysis of H3 Lysine 9 Methylation and Acetylation.  Illustrated 
is the ethidium bromide staining of ChIP PCR products from input positive controls (Input), 
no-antibody negative controls [Ab (-)], methylated H3 immunoprecipitates (α-H3-dimK9), and 
acetylated H3 immunoprecipitates (α-H3-AcK9/14).  The experiment was performed in the 
absence and presence of 5-Aza-dC and included in each PCR is a water negative reagent 
control (dH2O).  The lower panel graphically represents semi-quantitation of the data using 
densitometry of the PCR products from immunoprecipitated samples normalized to their input 
counterparts and expressed numerically in brackets as fold change following 5-Aza-dC 
treatment.  
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study involving solid tumors reported no objective responses in patients with 
metastatic disease yet 5-Aza-dC was well tolerated and changes in gene 
methylation were observed (Aparicio et al., 2003).  In a recent phase I trial 
analyzing the efficacy of 5-Aza-dC in the treatment of multiple hematological 
cancers, the drug was well tolerated and appeared to be more effective at low, not 
high, doses (Issa et al., 2004).  Based on the recent resurgence of interest in DNMT 
inhibitors in the treatment of cancer and given that in diseases such as AML, 
promoter hypermethylation is most often not limited to a single gene, but rather a 
number of genes concurrently (Melki et al., 1999), a microarray study was designed 
to identify novel genes aberrantly silenced by promoter hypermethylation in human 
AML. 
 Other research groups have identified novel genes silenced by promoter 
hypermethylation in diverse cancer types using a number of different experimental 
strategies.  The present study employed cDNA microarray expression analysis 
following pharmacological inhibition of both the DNMT and HDAC machineries 
in the human cell line AML193 and out of 978 genes analyzed, seven (MT1H, 
MT1G, SAT, MT1E, IFI30, GPX4, MT2A) were found to be consistently 
upregulated.  The percentage of genes upregulated in the present study (0.7%) is 
comparable to the previous studies that utilized a similar methodology.  Following 
combinatorial drug treatment, the colorectal cancer study (Suzuki et al., 2002), 
esophageal squamous cell carcinoma study (Yamashita et al., 2002), and the 
pancreatic carcinoma study (Sato et al., 2003a) identified upregulation in 0.7%, 
~0.5%, and ~1.6%, of the total genes analyzed, respectively.   
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All genes identified by the microarray screen in the present study were 
confirmed by RTPCR and subsequent MSP analysis revealed promoter 
hypermethylation in four of the seven genes identified (MT1H, MT1G, SAT, 
MT1E).  Importantly, following treatment with 5-Aza-dC the two genes that 
harbored fully methylated alleles (MT1H, MT1G) reconstituted unmethylated 
alleles in association with the induction of detectable mRNA.  The three genes that 
did not harbor promoter hypermethylation (IFI30, GPX4, MT2A) may have been 
upregulated at the mRNA level as a secondary effect from an upstream 
epigenetically regulated gene.  Or, in the case of MT2A, the high degree of 
nucleotide homology between it and its metallothionein family members may be 
responsible for triggering a false positive result.  Moreover, a number of 
unmethylated genes have been previously reported to be induced by DNMT 
inhibition in other microarray studies and more detailed investigation regarding the 
methylation independent activities of 5-Aza-dC has been put forward regarding the 
unmethylated CDKIs p19 (Zhu et al., 2001) and p21 (Lavelle et al., 2003).   
Strikingly, of the seven candidate genes identified by microarray, four are 
members of the metallothionein family of cysteine-rich small molecules located at 
16q13 and three of the four (MT1H, MT1G, MT1E) were shown to harbor 
promoter hypermethylation in the AML193 cell line.  Many isoforms of human 
metallothioneins exist, including non-functional pseudogenes (Stennard et al., 
1994; West et al., 1990), rendering them difficult to study due to their high degree 
of conservation at both the amino acid and nucleotide level.  Although the function 
of metallothioneins likely involves both metal ion homeostasis and metal ion 
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chaperoning for the synthesis of other metalloproteins, their role in cancer is largely 
unknown (Theocharis et al., 2004). 
 Based on the ability of metallothioneins to neutralize free radicals, it has 
been suggested that these proteins may play a role in the suppression of the toxic 
effects of mutagens and anticancer agents by protecting the DNA from alkylation 
(Waalkes et al., 1996).  This is further evidenced by the fact that transcriptional 
upregulation of metallothioneins following irinotecan treatment, a 
chemotherapeutic DNA topoisomerase I inhibitor, is associated with drug 
resistance in a small set of gastric cancer patients (Chun et al., 2004).  Furthermore, 
there is direct evidence that certain tumors have enhanced levels of metallothionein 
proteins and that induction of these metalloproteins is often associated with rapidly 
proliferating cells (Cherian et al., 1993).  Examples of tumors that have shown 
elevated metallothionein expression by immunohistochemistry include thyroid 
carcinoma (Nartey et al., 1987), testicular germ cell tumors (Chin et al., 1993), and 
bladder transitional cell carcinoma (Bahnson et al., 1991).  Given that the majority 
of metallothionein expression data originates from early studies on solid tumors, 
the exact role metallothioneins may play in hematological malignancies is as yet 
unknown.   
Although previous studies emphasize upregulation and overexpression of 
metallothioneins in association with malignancy, compelling evidence from recent 
reports implicates metallothionein transcriptional inactivation and associated 
promoter hypermethylation in mouse lymphosarcoma (Ghoshal et al., 2002), rat 
hepatoma (Ghoshal et al., 2000; Majumder et al., 2002), human gastric cancer 
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(Deng et al., 2003), and papillary thyroid carcinoma cells (Huang et al., 2003).  
These reports, and the data presented herein, suggest that the absence of 
metallothionein protein(s) may be associated with tumorigenesis.  For example, 
Deng et al. report metallothionein 3 (MT3) 5’ CpG island hypermethylation in 
gastric cancer cell lines in association with undetectable mRNA that is reversed 
following treatment with 5-Aza (Deng et al., 2003).  Furthermore, the authors 
found a significantly higher degree of MT3 hypermethylation in primary tumor 
samples when compared to non-malignant gastric epithelial tissues.  Huang et al. 
recently reported MT1G promoter hypermethylation in association with low 
mRNA expression in papillary thyroid cell lines and patient samples (Huang et al., 
2003) and using dosages similar to the present study, the authors report marked 
MT1G induction following treatment with 5-Aza-dC and TSA.  Of note, MT1G 
promoter hypermethylation was also identified in 29% of our AML cell lines and, 
interestingly, was consistently detected in conjunction with neighboring MT1H 
promoter hypermethylation.  As the two genes are orientated in opposite directions 
with CpG islands separated by a mere kilobase (Fig. 4.19A), it is attractive to 
hypothesize that a methylation ‘hotspot’ exists at this locus.  
 Further evidence of methylation mediated metallothionein inactivation in 
cancer cells comes from two previous studies involving cDNA microarray analysis 
following pharmacological DNMT inhibition.  The esophageal squamous cell 
carcinoma study by Yamashita et al. also identified MT1G promoter 
hypermethylation (Yamashita et al., 2002) and a recent microarray study by 
Schuster et al. identified MT1B and MT1L mRNA upregulation following 5-Aza-
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dC treatment in both breast and liver carcinoma cell lines (Schuster et al., 2003).  
Importantly, in the latter study, the authors also reported 5-Aza-dC induced mRNA 
upregulation of SAT in a glioblastoma cell line and IFI30 upregulation in prostate 
and breast carcinoma cell lines.  Although these genes were also found to be 
upregulated in our microarray dataset, it should be noted that no confirmation of 
DNA methylation was performed in the solid tumor cell line study.  As such, the 
induction of IFI30, as evidenced in our study, may not be a direct result of 
promoter demethylation but rather a secondary effect.   
The finding of SAT partial methylation in our data is not completely 
surprising as the gene is located near the pseudoautosomal region of the X 
chromosome and, like most X-linked genes in females, is imprinted, only actively 
transcribing one allele (Mank-Seymour et al., 1998).  Partial methylation of the 
SAT gene in our data could be indicative of monoallelic methylation, a hallmark of 
X chromosome inactivation.  Furthermore, the cells used in the aforementioned 
study (U-87 glioblastoma cells) and those used in the present study (AML193 cells) 
are both derived from females and therefore could be normally regulated by DNA 
methylation mediated imprinting.  Further SAT methylation studies with germline 
female DNA controls are required to confirm these observations. 
 Taken together, the current base of scientific literature reinforces our 
findings of MT1H promoter hypermethylation in AML and suggests that repression 
of metallothionein transcription may play a role in promoting tumor cell growth in 
specific cell types.  Further studies are required to elucidate the exact role these 
proteins play in cellular transformation and to what effect metallothionein 
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repression has on heavy metal cellular homeostasis.  Our findings implicate MT1H 
promoter hypermethylation in the pathogenesis of human AML and suggest that the 
use of cDNA microarray technology following pharmacological manipulation is a 
useful approach for identifying novel epigenetically silenced genes in this disease. 
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5. CONCLUSIONS AND FUTURE STUDIES  
 
 The etiology of human AML for any individual patient is unknown.  In 
some cases it is a disease secondary to an underlying bone marrow disorder, either 
congenital or acquired, and in the remaining patients the disease arises 
spontaneously.  To address this, a substantial effort has been put forward to 
assemble a better understanding of AML pathogenesis and the increasing body of 
knowledge regarding the genetic components of AML is beginning to direct a 
promising array of targeted therapies, many of which are in clinical development.  
Yet, despite such optimism, the majority of AML patients will die of their disease.  
As such, a major component of the research compiled in this thesis revolves around 
the need to better understand the epigenetic components involved in the 
pathogenesis of AML.  The specific aims of this project were defined with the goal 
of studying epigenetically silenced genes potentially involved in AML 
pathogenesis and the cytosine analogs currently used to inhibit or reverse this 
process. 
A major finding of the work presented in this thesis is the high frequency of 
p15 promoter hypermethylation in association with absent p15 mRNA in AML 
patients and cell lines.  Importantly, the CDKI methylation data in this study was 
evaluated using not only conventional MSP, but also a novel technique known as 
 179
TTGE.  This technique has previously been used for mutation detection yet 
technical modifications designed in our laboratory have allowed for the detailed 
analysis of DNA methylation (Scott et al., 2003; Scott et al., 2004).  The technique 
enables visualization of promoter hypermethylation heterogeneity and was adapted 
from a similar study which used DGGE (Aggerholm et al., 1999).  To the best of 
our knowledge, our lab is the first to utilize TTGE for the analysis of DNA 
methylation. 
 The CDKI genes analyzed in this study are all downstream mediators of the 
TGF-β1 pathway.  The TGF-β1 cytokine is important as it can trigger a diverse set 
of responses, including inhibition of cell cycle progression, facilitation of 
differentiation, induction of apoptosis, and regulation of cell adhesion and 
extracellular matrix production, depending on the genetic makeup and environment 
of the target cell (Blobe et al., 2000; Massague, 2000).  A natural extension from 
the studies presented in this thesis would therefore be to investigate other non-
TGF-β1 pathway members of both the CIP/KIP and INK4 families of CDKIs for 
promoter hypermethylation and transcriptional silencing.  For example, the 
CIP/KIP candidate tumor suppressor gene p57 has recently been implicated in 
promoter hypermethylation mediated gene silencing in a number of tumor types 
(Kikuchi et al., 2002; Li et al., 2002b; Shen et al., 2003) and could therefore be 
quickly analyzed in our panel of AML samples.  Furthermore, the other INK4 
genes p16, p18, and p19 have all been associated with epigenetic silencing in other 
cancers and could also be candidates for aberrant silencing in AML.  Of note, 
preliminary data on the p16 promoter associated CpG island in our sample set has 
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revealed p16 methylation mediated silencing in only a small percentage of AML 
patients and cell lines (data not shown). 
 Importantly, no promoter hypermethylation was detected in the CpG island 
of the CDKI p21 in any of the AML samples used in this study, even those that 
lacked detectable p21 mRNA.  Given the paucity of mutations reported in this gene 
and the growing body of literature implicating histone deacetylation as the primary 
cause of aberrant p21 gene silencing in cancer (Gui et al., 2004; Richon et al., 
2000), further work is warranted to characterize the mechanism behind p21 
methylation independent silencing in human AML and its potential as a target for 
epigenetic therapy.  To this end, work in our lab is ongoing.  Recent data supports 
the hypothesis that the demethylating agent 5-Aza-dC has methylation independent 
activity as we have found that 5-Aza-dC relieves p21 repression in AML cell lines 
by a mechanism involving release of HDAC1 and enrichment of local H3 
acetylation (manuscript submitted for publication).  We also found that combined 
5-Aza-dC and HDAC inhibitor treatment enhances chromatin remodeling and 
reactivation of the unmethylated p21 tumor suppressor gene.  This latter finding is 
of relevance to the clinical use of these agents in AML due to the fact that the p21 
promoter is unmethylated in vivo.  
 The burgeoning relationship between promoter hypermethylation and 
histone amino-terminal modifications is also worth pursuing.  Our finding of a 
repressor complex that includes MeCP2, SUV39h1, deacetylated H3, methylated 
H3 lysine 9, and depleted H3 lysine 4 and arginine 17 methylation in association 
with p15 promoter hypermethylation is novel and it would be interesting to identify 
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which other proteins are involved at this region (HDACs, HP1, other chromatin 
remodeling factors, etc.) and which other histone modifications are consistent with 
transcriptional inactivity, including those on H4.   Further ChIP assays, given the 
availability of high quality antibodies, are required to address these types of 
questions.  Moreover, unknown transcription factors and epigenetic repressors 
could also be identified by combining ChIP assays with modern mass spectrometry 
techniques.  Although this latter methodology would not be able to identify proteins 
at specific genomic loci, such as promoter regulatory regions, it could assist in the 
identification of unknown protein complexes involved in epigenetic transcriptional 
repression. 
 It is important to emphasize the ability of 5-Aza-dC in our data to not only 
demethylate promoter regions and relieve transcriptional repression, but also its 
ability to facilitate the release of MBD proteins and reverse the H3 modifications 
normally associated with gene silencing.  5-Aza-dC is becoming increasingly 
attractive as a therapeutic option for patients with hematological malignancies 
(Daskalakis et al., 2002; Issa et al., 2004; Kantarjian et al., 2003) and it is 
imperative to have a full understanding as to the mechanisms behind its tumor 
suppressive and gene inducing activities.  Future work is required to identify the 
target genes of this agent, both methylation dependent and independent, and to 
increase the tumor cell specificity of this global acting drug.  Moreover, the 
identification of other less toxic DNMT inhibiting agents and their evaluation both 
in vitro and in vivo will be of great value.   
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To address this issue, a significant portion of the work reported in this thesis 
was devoted to the study of a relatively new DNMT inhibitor, zebularine, using 
AML193 cells as a model system.  Zebularine was able to demethylate the p15 
promoter and induce transcription with local enrichment of histone acetylation, but 
only at significantly higher doses than those required for 5-Aza-dC mediated p15 
induction.  However, owing to the in vivo stability and activity of zebularine 
(Cheng et al., 2003) and given the conflicting reports on the ability of 5-Aza-dC to 
demethylate p15 in vivo (Daskalakis et al., 2002; Issa et al., 2004), it will be 
interesting to follow the pre-clinical evaluation of zebularine as it becomes a more 
utilized DNMT inhibitor in hematological malignancies, both in vitro and in vivo. 
 The ability of pharmacological agents to reactivate epigenetically silenced 
genes was exploited in this study in order to identify novel genes silenced by 
aberrant promoter hypermethylation in AML.  Using cDNA microarrays seven 
genes were found to be consistently upregulated following treatment with 5-Aza-
dC and TSA in AML193 cells.  Of these candidate genes, detailed MSP analysis 
identified a high frequency of promoter hypermethylation in a number of 
metallothionein genes in AML cell lines and further experimentation identified one 
gene, MT1H, to be hypermethylated at a high frequency in AML patient samples.  
Remarkably, metallothionein induction following 5-Aza-dC treatment was 
recognized in rat liver cells almost twenty years ago prior to the identification of 
promoter methylation mediated metallothionein transcriptional silencing (Waalkes 
et al., 1988).   
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However, although the microarray approach was very successful in 
identifying genes silenced by promoter hypermethylation, the exact role that these 
genes play in AML pathogenesis, if any, is unknown.  Given that similar 
approaches in other cell types have also identified aberrant metallothionein 
methylation (Schuster et al., 2003; Yamashita et al., 2002), it would be of value to 
extend these studies further to determine if metallothioneins are bona fide tumor 
suppressor genes in AML.  Studies in our lab are currently underway to test the 
effects of promoter hypermethylation on MT1H induction following treatment with 
cadmium, a heavy metal known to rapidly induce metallothionein expression 
(Ghoshal et al., 1998; Majumder et al., 1999).  As such, we hypothesize that 
promoter hypermethylation will inhibit cadmium mediated induction of the MT1H 
gene in AML cells and that 5-Aza-dC pretreatment, and therefore MT1H 
demethylation, will re-enable cadmium induced MT1H expression. 
 Another approach to identifying novel genes silenced by promoter 
hypermethylation combines ChIP assays with commercially available CpG island 
microarrays.  This technique has been previously used to identify specific 
transcription factor targets (Weinmann et al., 2002) and genes associated with 
specific histone modifications, notably H3 lysine 9 acetylation and methylation 
(Kondo et al., 2004).  By immunoprecipitating with high quality antibodies for 
mammalian DNMTs, either DNMT1 and/or DNMT3b, one could identify CpG 
islands associated with the DNA methylation machinery, therefore most likely 
identifying hypermethylated promoter loci.  Confirmation of candidate genes could 
be accomplished by standard bisulfite-based techniques and gene expression 
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correlation by RTPCR.  It would be interesting to perform this type of experiment 
in AML193 cells as it could potentially provide valuable confirmation to the 
presented cDNA microarray data. 
 In conclusion, the findings presented within this thesis provide new insights 
into aberrant epigenetics in the molecular pathogenesis of human AML and build 
on the current base of related scientific literature.  The scope of the work put 
forward touches on many important aspects of translational research, including an 
in vivo analysis of AML patient material, mechanistic studies using an AML cell 
line model system, detailed evaluation of pharmacological agents with therapeutic 
potential, and a high-throughput genomics approach for the identification of novel 
genes aberrantly silenced in this disease.  In addition, these studies will provide a 
concept and framework for future research involving aberrant epigenetics in other 
hematological malignancies and solid tumors. 
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